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ABSTRACT 
Background: Health-related Quality of Life (QoL) pertains to how medical conditions affect the 
lives of people suffering from those respective conditions, and QoL measurements therefore help 
to define the everyday impacts of the conditions; understanding these impacts can lead to 
improvements in the healthcare provisions for patients with each condition. There is yet to be a 
large-sample Study that compares QoL across different stages of Chronic Kidney Disease (CKD) 
while (i) utilizing a predominantly North American adult population, and (ii) factoring in 
commonly-associated co-morbidities (i.e. Diabetes and Heart Disease). 
Methods: A Retrolective Cross-sectional Observational Study utilizing historical baseline data 
from 1135 anonymous adult CKD patients was performed; CKD Stages 3 and 5 were 
predominant, and every selected patient had answered to a comparable version of the Short Form 
36 (SF-36) Health Survey, having had CKD with/without a co-morbidity at baseline. SF-36 
Domain and Summary scores were compared, across the stages of CKD (in terms of medians, as 
distributions were skewed); similar comparisons were also performed with co-morbidities and 
demographic factors as respective grouping variables. Regression models were subsequently 
built to analyse the associations between relevant SF-36 scores and each of these independent 
variables – Stage of CKD, Diabetes, Heart Disease, Age, and Gender. 
Results: The Physical Component Summary (PCS) score was significantly (p < 0.05) lowest 
among patients with Stage 5 CKD, while patients with Stage 4 CKD, in turn, exhibited 
significantly lower PCS scores than patients with Stage 3 CKD; Stage 5 CKD patients - who 
were all on Hemodialysis therapy - also scored lowest (significantly) on five of the eight SF-36 
Domains. Coexisting Diabetes and Heart Disease were each associated with further significant 
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decreases in the PCS score and three physical health-related Domain scores. Compared to 
females, males scored significantly higher on the PCS measure and on four Domains. Patients’ 
Age did not impact QoL, definitively - while the Mental Component Summary (MCS) score and 
mental health-related Domain scores were seen to gradually but inconsistently increase with Age, 
physical health-related QoL was generally unaffected by Age. Regression models, by and large, 
confirmed the findings from the comparisons of medians. 
Conclusions: Greater negative impacts on physical health appear to occur, as CKD progresses 
from stage to stage, but the effects of CKD progression on mental health seem to be negligible. 
Among CKD patients, Diabetes and Heart Disease appear to further reduce patient perceptions of 
physical health. Male patients with CKD appear to have more favourable perceptions of their 
overall health status, as compared to female patients with CKD. 
Recommendations: Regarding future research - a prospective longitudinal study that 
periodically assesses QoL across a cohort with CKD would be advisable (in order to further 
assess the impact of CKD progression on QoL, and to overcome the issues of “missing” data that 
were encountered during this Study). Regarding the clinical perspective - considerable efforts 
should be made to prevent (or slow) the progression of CKD towards the final stage of the 
disease, while enabling patient education, too. 
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I. AN INTRODUCTION 
With regards to the Study Design, this Study was – a Retrolective Cross-sectional Observational 
Study. 
The ultimate objective of this particular project was to ascertain if there are significant 
differences in health-related Quality of Life (QoL) between predominantly Canadian adult 
patients who have different stages of Chronic Kidney Disease (CKD); additionally, another 
major objective was to ascertain if the presence of coexisting conditions (specifically - Diabetes 
Mellitus and/or symptomatic Heart Disease) in these CKD patients would lead to them 
experiencing a significantly different QoL, as compared to the QoL of CKD patients without 
those coexisting conditions (i.e. co-morbidities). In case significant differences in patients’ QoL 
would be shown to exist, modifications in Patient Care could then be suggested, based on which 
particular stage of CKD (and/or which associated co-morbidity) a patient is known to have. 
Prior to any data analysis, an exhaustive search of the literature concerning this Research 
Question was performed, in order to ascertain – (a) any similarities/differences between this 
Study and related studies from the past, (b) the advantages and disadvantages of this Study, as 
compared to related studies from the past, and (c) the best methods for analysing the available 
data. A search of the literature was also performed, in order to understand the relative 
strengths/weaknesses of the QoL-measuring instrument being used (i.e. the SF-36 Health 
Survey). Finally, there was a brief perusal of published papers and/or drafts that arose out of the 
analyses of the three previously-compiled datasets (note - each of those datasets from the past 
contributed data that was used during this particular Study, and it was necessary to understand 
the definition of each variable within each of those three “source” datasets). 
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As a result of the available data, the final dataset used for analysis comprised patients who were 
known to have had Stage 2, Stage 3, Stage 4, or Stage 5 of CKD, at baseline (i.e. at the time of 
first measurement of QoL); these patients had no personal identifiers (just as in the “source” 
datasets), and were all pooled from those three already-existing datasets. It should be noted that 
the “source” datasets each arose out of separate multi-centre studies that were conducted at 
different time periods. The majority of patients in the final dataset had been on Hemodialysis 
therapy at baseline, as a result of suffering from Stage 5 CKD (i.e. “end-stage” Kidney Disease); 
the bulk of the remaining patients had been suffering from Stage 3 CKD at baseline, while those 
who had had Stage 4 CKD or Stage 2 CKD constituted a small minority. Some of the patients in 
the final dataset had one or both of the co-morbidities of interest (Diabetes Mellitus and 
symptomatic Heart Disease), as well. 
With a very few exceptions, all of the patients in the final dataset had answered to a QoL-
measuring Health Survey (in its entirety), at the time of their first entry into the respective 
original Study that they were a part of, and the Health Survey was either the Short Form 36 (SF-
36) instrument or the Kidney Disease Quality Of Life (KDQOL) instrument (note – all of the 
questions in the former instrument are included within the latter one, too). Since only SF-36 
information was common across the three “source” datasets, only SF-36 answers were 
subsequently utilized for the analyses during this particular Study. In addition, except when 
impossible in certain cases, the answers of each patient to the various questions in the SF-36 
instrument were combined into two “Summary” scores (representing overall physical and overall 
mental perceptions of health, respectively); this was performed for individual patients before 
final analyses (i.e. Comparisons of Means/Medians and Multiple Linear Regression modelling) 
were carried out. As per the characteristics of the available data, primary analyses were 
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performed to look for significant differences in QoL between the following groups of patients – 
(a) Hemodialysis (i.e. Stage 5 CKD) patients and non-Hemodialysis (i.e. Stage 2/3/4 CKD) 
patients, (b) CKD patients with Diabetes and CKD patients without Diabetes, and (c) CKD 
patients with symptomatic Heart Disease and CKD patients without symptomatic Heart Disease. 
In addition, any QoL trends that were based on the respective variables of “Stage of CKD”, 
“Age”, and “Gender” were also looked for.   
Prior to statistical analyses, the three “source” datasets were deemed to be comparable, after 
ensuring that the definitions of the relevant variables (e.g. the definition of symptomatic Heart 
Disease) were, as far as practically possible, the same across all of the datasets. In addition, as far 
as possible, all necessary calculations (e.g. calculations to recode, transform and aggregate the 
“raw” QoL scores) were performed in exactly the same way across all three datasets. 
All of the statistical analyses were carried out, using Statistical Product and Service Solutions 
(SPSS) software (note – this software used to be known as Statistical Package for the Social 
Sciences, but with the same acronym). After obtaining the relevant Descriptive Statistics, final 
statistical analyses were performed, and these included – (a) Comparisons of Means/Medians 
between groups (accomplished by either parametric tests or non-parametric tests, based on 
whether the distributions of data points were normal, or not), and (b) Multiple Linear Regression 
modelling. It may be mentioned that performing both the Comparisons of Means/Medians and 
the Multiple Linear Regression ought to assist in verifying the results from each respective form 
of analysis. 
At the end of all of the analyses, an understanding of the findings would lead to – (a) definitions 
of trends, based on significant differences in SF-36 (Domain/Summary) scores between the 
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relevant groups, (b) interpretation of the observed trends, based on the available data, (c) 
comparisons of the results with results from related past studies, and (d) suggestions for further 
research on this topic, and (where applicable) suggestions for improved care of patients who may 
have one or more of the conditions that were compared, here.  
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II. CHRONIC KIDNEY DISEASE AND POSSIBLE ASSOCIATED CO-
MORBIDITIES 
II.1 CHRONIC KIDNEY DISEASE 
Definition 
Chronic Kidney Disease (CKD) is a loss of kidney function over a period of time, which can 
range from months to years (note – while progression does occur at some point, progression may 
have ceased by the time of diagnosis). A lower than normal Glomerular Filtration Rate (GFR) 
occurs in patients with CKD - this means that the capability of the kidneys to excrete waste 
products is decreased, and this reduced capability is classified into different stages that will be 
described in due course. 
Prevalence 
In Canada, 1.9 to 2.3 million people are estimated to suffer from CKD.
1
 According to a progress 
report (that is periodically updated, following initiation in 2009) from the Canadian Institute for 
Health Information (CIHI), the number of patients with Stage 5 CKD (i.e. Kidney Failure) in 
Canada steadily increased for 20 years before stabilizing at about 40000 patients, from 2009 
onwards; the largest increase occurred in patients aged 75 and above who account for about 20% 
of all Stage 5 CKD patients. The CIHI also reported that, in 2009, out of the total number of 
Stage 5 CKD patients, approximately 60% were on Dialysis (with about 80% of these being 
treated with Hemodialysis), and approximately 8% were waiting for a Kidney Transplant. As 
elsewhere, CKD in Canada is mostly a disease of the elderly with no notable gender-based 
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differences (note – these CKD patients include those on Dialysis, those who have Kidney 
Transplants, and those who are waiting for either Dialysis or Kidney Transplantation). 
Causes 
The causes of CKD can be classified, as follows (based largely on which particular part of the 
renal anatomy is involved) – 
 Vascular (i.e. a large or small blood vessel supplying or draining the kidney is affected). 
 Glomerular (i.e. the glomeruli are involved) – this can be primary (e.g. focal 
glomerulosclerosis), or secondary due to other diseases (e.g. Diabetes, certain 
autoimmune disorders, etc.). 
 Tubular or tubulointerstitial (i.e. the tubules and interstitium of the kidney are affected by 
toxins, polycystic disease, etc.). 
 Obstructive (i.e. drainage from the kidney is impaired - by kidney stones, for example). 
 Infections. 
(Note: The most common specific causes of CKD have been shown to be – Diabetes, 
Hypertension, and Glomerulonephritis
2
). 
Signs 
Laboratory and clinical tests may indicate the following (with the frequency and severity of each 
sign being influenced by both the stage of CKD and the underlying etiology) – 
 Increased serum Creatinine. 
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 Proteinuria, or an increased amount of Protein in the urine (this is prognostically 
important during all of the stages of CKD). 
 Increased blood Urea, which can lead to the more serious conditions of Azotemia, and 
Uremia. 
 Hyperkalemia (i.e. an increase in blood Potassium). 
 Hyperphosphatemia (i.e. an increase in blood Phosphates). 
 Hypocalcemia (i.e. a reduction in blood Calcium). 
 Fluid overload in the body. 
 Decreased amounts of Erythropoietin, which leads to Anemia. 
 Metabolic acidosis. 
 Hypertension. 
Symptoms 
Symptoms are uncommon during the early stages of CKD, and the non-specific nature of several 
symptoms can lead to even patients with advanced CKD being unaware of their condition. 
However, any symptoms experienced may relate to the issues that are listed, above. The 
commoner symptoms include the following – 
 Lethargy, reduced appetite, and general malaise. 
 Symptoms of high blood pressure, such as headaches. 
 Fatigue (due to Anemia, among other reasons). 
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 Nausea. 
 Weight loss. 
 Itching. 
 Bone pain. 
 Edema. 
Complications 
Several complications (often impacting the heart) can develop, as a consequence of even the 
initial effects of CKD; the more serious complications include – 
 Congestive Heart Failure. 
 Pericarditis. 
 Cardiac Arrhythmias. 
 Ischemic Heart Disease (often leading to “heart attacks”), as a result of increased 
Atherosclerosis. 
 Pulmonary Edema. 
 Encephalopathy. 
 Secondary Hyperparathyroidism and Renal Osteodystrophy. 
 Bleeding from the gastro-intestinal tract. 
 Liver damage/failure. 
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 Infertility/miscarriages. 
 Increased risk for cancer, according to certain studies.3 
Diagnostic Tests 
In the few patients who develop CKD without any prior kidney disease (or any CKD-
precipitating disorder), it may be necessary to perform diagnostic tests. It is also important to 
differentiate CKD from Acute Renal Failure (ARF) because the latter is potentially reversible. 
Some of the common tests that are used to diagnose CKD (when necessary) are, as follows – 
 Measurement of serum Creatinine levels (with gradually increasing levels over 
months/years being suggestive of CKD). 
 Urine analysis for protein, along with measurement of the Albumin to Creatinine ratio in 
urine (progressive loss of protein indicates worsening of CKD, as well as an increasing 
risk for Cardiovascular Disease). 
 Measurement of blood Urea Nitrogen levels. 
 Measurement of serum Electrolyte levels. 
 Abdominal ultrasound or Computed Tomography - to check for kidney size and structure. 
 Nuclear Imaging (i.e. radio-isotope) scans - to check for kidney function. 
Stages of CKD 
Individuals who have a Glomerular Filtration Rate (GFR) <60 mL/min/1.73m
2
 for, at least, 3 
months and/or clear kidney damage are classified as having CKD. These patients are thereby at a 
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higher risk for total loss of kidney function, along with cardiovascular complications and earlier 
death. 
TABLE II.1: Summary of the main differentiating features of the various stages of CKD 
 Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 
Amount of 
kidney function 
remaining 
More than 
90% 
60 to 89% 30 to 59% 15 to 29% Less than 15% 
Description Early kidney 
damage with 
normal or 
even 
increased 
function 
Worse kidney 
damage with 
reduced 
function 
Even worse 
kidney damage 
with less 
function than 
during the 
preceding stage 
Severe kidney 
damage with 
poor function 
that is barely 
enough to 
keep the 
patient alive 
End-Stage Kidney 
Disease with kidney 
function that is 
insufficient to keep the 
patient alive 
Symptoms No symptoms 
observed; 
Urea and 
Creatinine 
levels are 
normal 
(although 
other markers 
of kidney 
damage are 
seen) 
No symptoms 
observed; Urea 
and Creatinine 
levels are 
normal, or 
mildly 
elevated 
Early symptoms 
(e.g. lethargy, 
itching, and poor 
appetite) appear; 
Creatinine level 
rises, Urea level 
is high, and 
Anemia may 
begin to appear 
Symptoms 
(e.g. lethargy, 
itching, and 
poor appetite) 
may worsen 
Symptoms include – 
poor sleep, difficulty 
breathing, severe 
itchiness, and frequent 
vomiting; Creatinine 
and Urea levels are 
very high 
GFR level 
(mL/min/1.73m
2
) 
90 or more 60 to 89 30 to 59 15 to 29 Less than 15 
Treatment 
options 
Identify cause 
and try to 
reverse it 
Monitor 
Creatinine, 
blood pressure, 
and general 
health; try to 
stop/slow the 
worsening 
kidney 
function 
Continue to try 
to stop/slow the 
worsening 
kidney function; 
educate patient 
about disease / 
treatment 
options 
Plan and 
create access 
site for 
Dialysis; 
receive 
assessment 
for possible 
Transplant 
Commence Renal 
Replacement Therapy 
(Dialysis or 
Transplantation) 
 
[*Table is courtesy of – “Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, 
classification and stratification”; American Journal of Kidney Disease (2002); 39 (Supplement 
Number 1): S19]. 
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It may be noted that individuals with Stages 1-4 CKD are also sometimes said to have Non-
Dialysis Dependent CKD, while those with Stage 5 CKD (who require Dialysis or Renal 
Transplantation) are said to have End-Stage Kidney Disease. 
Management and Prognosis 
There is no true cure for CKD, at present. However, patients with Stages 1–4 CKD require the 
progression of their disease to Stage 5 to be slowed or halted, and they need to be protected from 
potential Cardiovascular Disease, too. Some of the common treatments advocated for Stages 1–4 
CKD patients (inclusive of treatment for common coexisting conditions, such as Hyperlipidemia 
and Hypertension) are, as follows – 
 Lifestyle changes, such as - dietary modifications, regular exercise, cessation of smoking, 
control of blood sugar levels, etc. 
 Anti-Hypertensive drugs (commonly - Angiotensin Converting Enzyme Inhibitors, or 
Angiotensin II Receptor Antagonists). 
 Erythropoietin Replacement Therapy. 
 Calcitriol Replacement Therapy. 
 Phosphate Binders. 
 Supplementation of certain Vitamins (e.g. Vitamin D) and minerals (e.g. Iron). 
However, these medications rarely slow the progression of CKD into Stage 5, for which the only 
possible treatment is one of these two forms of Renal Replacement Therapy – 
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 Dialysis (the usual forms of which are – (a) Conventional Hemodialysis, which is 
performed in a hospital setting for 3-4 hours, three times a week, (b) Daily Hemodialysis, 
which is usually performed at home for 2 hours on six days per week, (c) Nocturnal 
Hemodialysis, which is usually performed during sleep in a home or hospital setting for 
6-10 hours on three to six days per week, and (d) Peritoneal Dialysis, which is carried out 
at home by the patient, but which usually requires 4-5 repetitions per day). 
 Renal Transplantation (which involves a compatible donor providing a well-functioning 
kidney). 
The prognosis is not good for CKD patients. It has been shown that mortality increases as kidney 
function decreases, with Cardiovascular Disease being the leading cause of death.
4
 While forms 
of Renal Replacement Therapy (especially Renal Transplantation) significantly prolong the life 
of Stage 5 CKD patients, they are known to also negatively affect the patients’ QoL (especially in 
the short term, after the particular therapy).
5
 However, high intensity “Home Hemodialysis” is 
reported to both increase survival and provide a better QoL, as compared to other forms of 
Dialysis.
6
 
Risk and Screening 
Studies have shown a higher prevalence of CKD among African-Americans, which could be 
explained by a higher prevalence of Hypertension in this group; treating Hypertension in those 
African-Americans who are afflicted with CKD does not appear to slow the progression of the 
CKD, and this is different from what generally occurs in Caucasians.
7,8
 Another pointer to a 
genetic basis is the higher risk of CKD in individuals who have had close relatives suffer from 
CKD, too.
8
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Screening for CKD is suggested for people who have the following risk factors – 
 Hypertension. 
 History of Cardiovascular Disease. 
 Diabetes. 
 Obesity. 
 Age >60 years. 
 Certain ethnic groups (African-Americans, First Nations communities, etc.). 
 History of past Kidney Disease. 
 Close relatives with a history of Kidney Disease. 
A referral to a nephrologist would be especially advisable, if the following signs (among others) 
are present – 
 Low and/or progressively decreasing GFR, which is estimated from the serum Creatinine 
level. 
 High Albumin to Creatinine ratio, in the urine. 
 Hematuria. 
 Uncontrollable high blood pressure.  
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II.2 CO-MORBIDITIES THAT ARE FREQUENTLY ASSOCIATED WITH 
CHRONIC KIDNEY DISEASE 
Diabetes Mellitus 
Definition: Diabetes Mellitus (simply referred to as – Diabetes) is a metabolic disorder that is 
characterized by high blood sugar levels, in the affected individual. This occurs due to either 
insufficiency of the hormone called Insulin, or non-responsiveness of body cells to the effects of 
Insulin. 
Prevalence: 285 million people are estimated to be affected by Diabetes, worldwide, with 
approximately 9 million people in Canada being affected.
9
 Type 2 Diabetes in particular is seeing 
a major increase in industrialized countries, with further great increases envisaged in Asia and 
Africa.
9
 
Types: There are three main forms of the disease, plus miscellaneous variants. The types of 
Diabetes are summarized, as follows – 
 Type 1 Diabetes occurs due to insufficient production of Insulin from the pancreas, has a 
strong genetic basis, is often diagnosed during childhood, and is the type seen in 
approximately 10% of patients with Diabetes. 
 Type 2 Diabetes occurs when the body’s cells fail to respond to Insulin, usually manifests 
itself in older age groups, is often due to lifestyle-related issues like unhealthy diets, and 
accounts for approximately 90% of all Diabetes cases.   
 Gestational Diabetes occurs in women during pregnancy, is often transient, can lead to 
fetal complications/anomalies, and is reported to occur in 2 to 10% of all pregnancies, 
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with 5 to 10% of women with Gestational Diabetes being shown to have Type 2 Diabetes, 
post-pregnancy.
10
 
 Other forms of Diabetes include - (a) Latent Autoimmune Diabetes of Adults (LADA), 
and (b) Prediabetes (which often precedes the manifestation of Type 2 Diabetes). 
Prognosis: The Canadian Diabetes Association reports that approximately 80% of people with 
Diabetes will die due to Heart Disease or Stroke, and that Diabetes is a contributing factor in the 
deaths of about 41,500 Canadians, each year. The life expectancy of people with Diabetes may 
be shortened by 5 to 15 years, with the greatest reductions in individual life expectancies 
occurring due to Type 1 (rather than Type 2) Diabetes.
9
 
Effects of Diabetes on the kidneys: It is estimated that approximately 30% of patients with 
Type 1 Diabetes will eventually develop Stage 5 CKD, while about 10-40% of patients with Type 
2 Diabetes will do so.
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Diabetes can affect the kidneys (and other components of the urinary 
tract) in the following ways –  
 Diabetic Nephropathy: The small blood vessels in the kidneys are damaged, which leads 
to salt and water retention in the body, as well as to Proteinuria and decreased excretion 
of waste products. 
 Diabetic Neuropathy: The nerve damage caused by Diabetes can lead to inadequate 
emptying of urine from the urinary bladder, which can then lead onto kidney damage 
(due to the back pressure of the urine, and also due to the retrograde infections that may 
be precipitated by the urinary stasis). 
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Signs of Kidney Disease in patients with Diabetes: When patients with Diabetes develop 
Kidney Disease, they may exhibit the following signs – 
 Albumin and other proteins in the urine (this is usually an early sign of coexistence of 
both conditions). 
 High blood pressure (this is usually an early sign of coexistence of both conditions). 
 Edema. 
 Increased Urea in blood and increased Creatinine in serum (these are usually late signs of 
coexistence of both conditions). 
 Anemia (this is usually a late sign of coexistence of both conditions). 
Symptoms of Kidney Disease in patients with Diabetes: When patients with Diabetes develop 
Kidney Disease, they may experience the following symptoms – 
 Swelling and cramps. 
 Nocturnal polyuria. 
 Nausea and vomiting. 
 Weakness, paleness, and itching. 
 Lesser need for anti-Diabetic medications. 
Management of patients who have both CKD and Diabetes: The management of patients 
with both CKD and Diabetes usually involves the following – 
 Anti-Diabetic medication (e.g. Insulin, Metformin, etc.). 
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 Anti-Hypertensive medication (e.g. Angiotensin Converting Enzyme Inhibitors). 
 Specific treatments for any disorders of the urinary tract (such as – infections). 
 Following a healthy diet (e.g. restricting the intake of protein, and sugars). 
 Ensuring home monitoring (and general awareness) of blood glucose levels and blood 
pressure. 
 Avoidance of any potentially nephrotoxic drugs. 
 Renal Replacement Therapy for those patients who have both Diabetes and Stage 5 CKD 
(Steroid therapy is required, post-transplant, and a higher dose of Insulin is required by 
some of those who receive donor kidneys, too). 
 Pancreatic Transplantation (although rare, this can be done in conjunction with Kidney 
Transplantation). 
Heart Disease 
While Heart Disease actually includes a large number of different sub-divisions, only those 
specific conditions that come under the heading of “symptomatic Heart Disease” and that could 
be accurately utilized as variables during this Study will be described in detail. This is advisable 
because only those CKD patients who have active Heart Disease at the time when their QoL is 
measured can definitely be said to have both CKD and the co-morbidity of Heart Disease 
(however, the form of Heart Disease cannot be truly acute because patients will not be expected 
to have their QoL measured during medical emergencies). The conditions in focus are – Ischemic 
Heart Disease and Heart Failure, which together are estimated to affect 5% of all Canadians aged 
greater than 12 years (based on prior cross-sectional self-reporting).
12
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Ischemic Heart Disease 
Definition: Ischemic Heart Disease (IHD) is characterized by a reduction in the blood flow to 
the muscle of the heart. This reduced blood flow is due to spasm or obstruction of the coronary 
arteries that supply the muscle of the heart. 
Prevalence: Based on cross-sectional self-reporting in Canada, it was once estimated that 
(among Canadians of 12 years of age, and older) 2.1% had had a Myocardial Infarction, with 
1.9% having Angina Pectoris.
12
 The incidence of IHD increases as age increases, and IHD is 
commoner in males, overall (however the incidence rates in males and females become similar, 
after menopause). 
Manifestations: IHD can lead to – (a) Angina Pectoris, which can range in severity from the 
stable form to the unstable form, and which basically is chest pain due to ischemia of the heart 
muscle (breathlessness, nausea, and sweating may be associated with this chest pain, too) and/or 
(b) Acute conditions (which are medical emergencies), with Myocardial Infarction being the 
most serious of these because it involves death of part of the heart muscle, and often precipitates 
the following symptoms – severe radiating chest pain, breathlessness, palpitations, sweating, 
nausea, and even loss of consciousness that may be followed by death (however, non-
symptomatic Myocardial Infarctions are known to occur, as well
13
). 
Prognosis: The prognosis varies according to the symptoms of the individual patient, as well as 
the presence/absence of various risk factors. General prognostic trends include – 
 Angina Pectoris is often the presenting symptom of IHD (especially in women); the 
mortality rate at 5 years, post-onset of Angina is approximately 5%, and men with Angina 
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are at a greater risk (compared to women with Angina) for Myocardial Infarction and 
IHD-related death.
14
 
 The prognosis after a Myocardial Infarction varies. Predictive prognostic value is 
assigned to factors like - age, hemodynamic parameters (systolic blood pressure, left 
ventricular ejection fraction, etc.), ST-segment changes on the Electrocardiogram, 
elevated cardiac markers, and a few others.
15
 The mortality rate after Myocardial 
Infarctions has decreased over time, but it is estimated that just over 12% of all annual 
deaths (worldwide) are due to Myocardial Infarctions, with it being the leading cause of 
death in “high/middle income” countries.16 In the United States, median mortality at 30 
days after a Myocardial Infarction ranges from 10 to 25%.
17
 In Canada, it is estimated 
that there are 70000 Myocardial Infarctions per year, with 16000 Canadians dying each 
year, as a result of that (the majority of deaths are out of hospital).
18
 
Globally, approximately 7 million people suffer IHD-related acute events, each year,
19
 and it is 
predicted that Disability Adjusted Life Years (DALYs) lost to IHD will account for 5.5% of total 
DALYs in 2030 (making IHD the second leading cause of disability, and the leading cause of 
death, at that time).
16
 In total, slightly more women than men die of IHD due to women generally 
living for longer, as compared to men.
20
 
 
Heart Failure 
Definition: Heart Failure (also known as - Congestive Heart Failure) refers to a serious condition 
in which the heart is unable to pump out sufficient amounts of blood to meet the body’s 
requirements. 
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Prevalence: It is estimated that about 500000 Canadians are living with Heart Failure, with 
50000 being newly diagnosed with the condition, each year.
18
 Based on cross-sectional self-
reporting in Canada, it was once estimated that (among Canadians of 12 years of age, and older) 
1% were living with Heart Failure.
12
 The prevalence rate is much higher in those over 65 years 
of age, and certain ethnic groups (e.g. African-Americans) have higher prevalence rates, too. 
Types: Based on anatomy, there are two types of Heart Failure, which are the following – 
 Right-sided Failure, in which the heart cannot pump out sufficient blood to the lungs for 
the purpose of getting oxygenated (this is often due to incomplete filling up of the heart 
with blood). 
 Left-sided Failure, in which the heart cannot pump out sufficient oxygenated blood to the 
rest of the body. 
Prognosis: The prognosis for patients with Heart Failure is generally not good. The following 
statistics from the Canadian Cardiovascular Society would support the preceding statement
18
 – 
 The average annual mortality rate for Heart Failure is 10% per year. 
 The five-year survival rate for Heart Failure is 50%. 
 Severity of presenting symptoms, level of heart dysfunction, age, and some other factors 
all help to determine the prognosis for individual patients, but up to 50% of patients with 
Heart Failure will die within 5 years of the diagnosis. 
Relationship between CKD and Heart Disease: It has been shown that chronic dysfunction of 
the kidneys is closely associated with the following disorders that (i) affect the vasculature, and 
(ii) can lead to serious heart-related conditions – 
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 Atherosclerosis (i.e. thickening of the walls of arteries due to the formation of “plaques”, 
which are accumulations of cholesterol plus other fatty substances and calcium) – this 
can lead to a compromise in the arterial blood supply to the heart muscle. 
 Hypertension (i.e. increased pressure required to propel the blood within arteries) – this 
can weaken the walls of arteries, and also compromise the arterial blood supply to the 
heart muscle. 
(It should be mentioned that certain less-conspicuous abnormalities that are associated with CKD 
can also increase the risk of developing Heart Disease, and these abnormalities are – (a) 
Dyslipidemia; as a result of lipoprotein metabolism being altered during CKD, increases of fatty 
substances like Cholesterol can occur within the blood, and those increases can subsequently 
lead to Atherosclerosis and IHD, and (b) Inflammation; as a result of certain metabolic pathways 
being altered during CKD, inflammatory changes that affect the arterial walls can follow, thereby 
potentially leading to arterial damage and IHD, in due course).  
Specific complications of CKD that have an impact on the heart: CKD can lead to certain 
complications (which can indirectly impact the workings of the heart); the notable complications 
are explained, as follows – 
 Hypertension – A hormone called Renin is produced by the kidneys, and Renin is part of 
a hormone chain that acts to increase blood pressure whenever necessary; however, 
impaired kidneys can over-secrete Renin, leading to unnecessarily high blood pressure 
(this can then cause IHD, Heart Failure, Strokes, and even reduce arterial blood perfusion 
to the kidneys in a round-about way). 
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 Anemia – A hormone called Erythropoietin is produced in the kidneys, and is responsible 
for stimulating the production of Red Blood Cells from the bone marrow, but impaired 
production of Erythropoietin due to dysfunctional kidneys can ultimately lead to a 
deficiency of Red Blood Cells and Hemoglobin; thus, the heart muscle may receive 
insufficient oxygen, while parts of the heart muscle may also hypertrophy when the heart 
attempts to compensate for the systemic oxygen deficit by pumping out more blood (note 
- IHD can result from the impaired oxygenation of the heart muscle, while Heart Failure 
can result from the hypertrophy of the heart muscle). 
 Hyperglycemia: If Diabetes already exists in a patient with CKD, the increased blood 
sugar can result in damage to the arteries that supply the heart (as well as the kidneys, and 
other organs); this can lead on to IHD, and potentially to Heart Failure, after that.  
 Mineral imbalance: High levels of Calcium and Phosphorous in the blood have been 
linked to Atherosclerosis of the coronary arteries (and even to bone formation within the 
walls of said arteries);
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therefore, when improperly-functioning kidneys are unable to 
excrete excess amounts of Calcium and Phosphorus, IHD could result. 
 Homocysteine imbalance: Excess levels of an amino-acid called Homocysteine have been 
linked to Atherosclerosis and clot formation because high levels of this amino-acid can 
lead to both the build-up of “plaques” on the walls of arteries, and the damage of the 
arterial walls;
22
 as dysfunctional kidneys cannot adequately regulate the amounts of 
Homocysteine in the blood, IHD (including Myocardial Infarctions) and Strokes could 
result when CKD is associated with high Homocysteine levels. 
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Management of patients who have both CKD and Heart Disease: The management of 
patients who have both CKD and Heart Disease usually includes the following guidelines, 
irrespective of how each of the conditions are caused - 
 Regular monitoring of – (a) Renal parameters (primarily - Urea and Creatinine levels), 
(b) Heart function, (c) Serum electrolytes, and (d) Blood pressure. 
 A prescribed regimen of exercise and diet (usually designed with the help of a dietician). 
 Medications for any complications (such as - Hypertension, Diabetes, 
Hypercholesterolemia, etc.). 
 Renal Replacement Therapy when the kidneys go into “failure” mode (i.e. Stage 5 CKD). 
 Treatments for IHD can vary from anti-Angina medications (e.g. Nitroglycerin and other 
Vasodilators, Calcium Channel Blockers, Beta Blockers, etc.) to immediate treatments for 
Myocardial Infarctions (e.g. Fibrinolysis, and even interventional procedures to remove 
coronary artery clots), while Heart Failure is usually treated with medications (e.g. 
Angiotensin Converting Enzyme Inhibitors, Diuretics, Vasodilators, etc.). 
Other Cardiovascular conditions (associated with Chronic Kidney Disease) that can be 
analysed 
Based on the available data, the Cardiovascular conditions of Stroke and Peripheral Vascular 
Disease could also be used as independent variables to predict respective aspects of the QoL of 
CKD patients. It ought to be mentioned that both Stroke and Peripheral Vascular Disease 
(particularly when the latter involves arteries) are often due to Atherosclerosis, Hypertension, 
and Hypercholesterolemia (which are all associated with CKD); as a result, just as CKD patients 
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are at an increased risk for Heart Disease, they are also at an increased risk for other forms of 
Cardiovascular Disease, such as Stroke and Peripheral Vascular Disease. The hemostatic 
imbalances associated with CKD and the reduced amounts of physical activity that is associated 
with any chronic disorder could also lead to venous conditions, which are part of the Peripheral 
Vascular Disease spectrum.  
Stroke 
A Stroke occurs when the blood supply to a part of the brain ceases, leading to death of the brain 
cells in that area of supply. Strokes are medical emergencies. 
There are approximately 50000 Strokes in Canada, every year, and about 315000 Canadians are 
living with the effects of Strokes.
18
 
CKD is associated with a high risk for Strokes, considering that several of the CKD-associated 
factors (Hypertension, Atherosclerosis, Anemia, Diabetes, Hypercholesterolemia, 
Hyperhomocystinemia, etc.) are risk factors for Strokes.
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There are generally three types of Strokes – (a) Ischemic Strokes, which are the commonest type, 
and which occur when a blood clot (thrombus or embolus) blocks an artery that supplies the 
brain (or a region of the brain), (b) Hemorrhagic Strokes, which occur when a blood vessel 
ruptures and bleeds into the brain, and (c) Transient Ischemic Attacks, which are brief 
interruptions of the blood flow to the brain (or a region of the brain) that do not cause lasting cell 
death or symptoms, but do indicate an impending major Stroke. The origins of up to 40% of 
ischemic Strokes are unknown.
24
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Strokes are usually caused by cardiac disorders and/or vascular disorders, and the common 
causes include – (a) Atherosclerosis in arteries, (b) Sickle-cell Anemia, (c) Arrhythmias, (d) 
Dysfunctions of Heart Valves, (e) Endocarditis, (f) Hypertension, and (g) Vascular 
Malformations within the brain.  
The signs and symptoms depend on which regions of the brain are specifically affected. The 
commonest symptoms of a Stroke are – (a) weakness and/or numbness on one side of the body, 
(b) confusion and lack of comprehension, (c) difficulty in speaking, (d) visual problems, (e) loss 
of balance and coordination, (f) dizziness, (g) loss of sensation on one side of the body, and (h) 
severe headaches. 
After immediate medical or surgical treatment to remove the thrombus/embolus (or to treat the 
cause of the bleed when a Hemorrhagic Stroke occurs), long-term management of Stroke patients 
involves Rehabilitation Therapy, which includes – (a) nursing care, even when at home, (b) 
physical therapy, (c) speech therapy, (d) occupational therapy, (e) use of artificial appliances (e.g. 
Wheelchairs), and (f) elimination or control of the risk factors for a subsequent Stroke (e.g. 
Diabetes, Hypertension, Heart Disease, Hypercholesterolemia, etc.). 
The prognosis for Stroke patients is generally not good. In about 75% of patients, Strokes cause 
disabilities that are sufficient to reduce employability.
25
 Apart from physical and mental 
problems, Strokes also lead to emotional problems, with 30 to 50% of Stroke survivors suffering 
from post-Stroke depression.
26
 Cognitive deficits and psychological problems (post-Stroke) are 
more likely in older patients, in patients with pre-Stroke brain pathology, and in patients with 
pre-Stroke psychiatric problems.
27
 Up to 10% of patients suffer seizures, post-Stroke, too.
28
 
Worldwide, Stroke is the second most frequent cause of death (after Heart Disease), and 
26 
accounted for about 11% of total deaths in 2008.
29
 In Canada, Stroke is the third leading cause of 
death (6% of all deaths), and approximately 14000 Canadians die from Strokes, each year. The 
risk of a Stroke increases with age, and men are more likely than women to suffer Strokes 
(although more women die from Strokes because they are usually older when afflicted).
30
  
Peripheral Vascular Disease 
Peripheral Vascular Disease (PVD) is a spectrum that refers to damage or blockage of blood 
vessels (arteries or veins) that are distant from the heart. 
The prevalence of PVD worldwide is 12 to 14%, with up to 20% of those over 70 years of age 
being affected; up to 80% of affected individuals are asymptomatic, though.
31
 
PVD can be arterial or venous.
32
 The commonest arterial diseases classified under PVD include – 
Arterial Blockages, and Aortic Aneurysms (i.e. bulges in the wall of the aorta, usually involving 
the abdominal portion of that large vessel). The commonest venous diseases classified under 
PVD involve blood clots in veins, with Deep Vein Thrombosis (i.e. clot formation in the deep 
veins of the leg) being the most serious condition out of those; Deep Vein Thrombosis affects 1 
in 1000 adults, per year.
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Peripheral Arterial Blockages (and the resulting ischemia) often begin in the legs and are usually 
caused by Atherosclerosis, which indicates that patients with CKD are at risk for PVD. Aortic 
Aneurysms can result from Atherosclerosis, high blood pressure, certain infections, and smoking; 
however, they can also be congenital in origin, or be precipitated by certain predisposing 
diseases (e.g. Marfan’s Syndrome). Venous clots are commonly caused by slow blood flow to the 
lower extremities, and the slow flow (in turn) could be caused by physical inactivity, smoking, 
high blood pressure, Diabetes, Heart Disease, pregnancy, tumors, or certain hormones. 
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Depending on where the block is, Peripheral Arterial Blockages can lead to pain that gets worse 
during exertion; this pain (the severity of which indicates the seriousness of the block) is called 
Intermittent Claudication, and disease progression can lead on to Cyanosis and Gangrene, with 
the latter necessitating an amputation. Other serious conditions that can be linked to blockages in 
peripheral arteries include – Strokes, Transient Ischemic Attacks, Kidney Disease, and Heart 
Disease. An Aortic Aneurysm can cause breathlessness, pain in the back, and referred pain to the 
shoulders; rupture of an Aortic Aneurysm is a life-threatening emergency due to the massive 
bleeding. Clots in the deep veins of the leg can cause pain, swelling, redness and warmth around 
the affected areas (usually – calves and ankles); these clots can break free, travel to the lungs, 
and cause death by impeding the blood flow to the lungs (i.e. Pulmonary Embolism). 
Peripheral Arterial Blockages that are not severe can be managed by controlling the risk factors 
(e.g. Diabetes, excess weight associated with Hypercholesterolemia, smoking, etc.); in more 
severe cases, Angioplasty/Stent Procedures or Bypass surgeries are performed. Surgery is 
required for Aortic Aneurysms that are close to the heart; for Aneurysms further away from the 
heart, the size determines whether surgery (to strengthen the weak arterial wall with a graft) or 
simple monitoring is the best option. Venous clots in the legs require anticoagulant therapy, as 
well as rest (lying down with raised legs during the periods of continuous rest is also helpful). 
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III. QUALITY OF LIFE WITHIN THE FIELD OF HEALTHCARE  
III.1 CONCEPTS 
In 1946, the constitution of the World Health Organization (WHO) defined health as “a state of 
complete physical, mental, and social well-being, and not merely the absence of disease or 
infirmity”. 
Quality of Life (QoL) generally refers to someone’s well-being as a whole, and it includes all 
aspects of that person’s life (i.e. the physical, mental, and social aspects, plus the correlates of 
those aspects – socioeconomic status, health risk factors, etc.). In the field of healthcare, QoL 
generally refers to how an individual’s well-being is affected by a specific medical condition.  
Unlike earlier when public health was evaluated using measures of mortality and morbidity, 
public health is now understood to comprise several dimensions. Therefore, as treatments to save 
lives improved over time, it was also deemed important to improve the QoL of those individuals 
under care – this way, both the years of survival and the QoL during those years would increase, 
together. And, measuring the QoL of such patients is a necessary first step. 
It is now accepted that the measurement of an individual’s QoL should be based on that 
individual’s own perceptions. This prevents the inconsistent subjectivity that is associated with 
any external rating (by a physician, for instance), and it also means that a subject can rate his/her 
situation based on his/her own expectations. So, QoL for practical purposes can be defined as – 
“a broad multi-dimensional concept that usually includes subjective evaluations of both positive 
and negative aspects of life”.34 The Centers for Disease Control and Prevention (CDC) in the 
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U.S. has defined Health-Related Quality of Life as – “an individual’s or group’s perceived 
physical and mental health over time.” 
It is often advantageous to measure the QoL of an individual at different points in time (while 
he/she is still affected by the same medical condition), in order to see if changes in lifestyle or 
treatment have a positive/negative effect on his/her QoL; for this reason, as well, self-rating is 
best because it maintains the consistency of the rater.  
 
III.2 QUESTIONNAIRES 
As a result of the benefits of self-rating, hundreds of patient-based questionnaires have been 
created to measure (health-related) QoL. These questionnaires are usually all-encompassing, 
covering the physical, emotional, social, and cognitive aspects of a patient’s life; in addition, 
specific questions (disorder-related, medication-related, profession-related, finance-related, etc.) 
are also included in some of these QoL questionnaires. 
Since subjective evaluations of several different dimensions (physical health, mental health, etc.) 
have to be part of any QoL measurement, techniques must be designed to define and measure 
these dimensions; the ways by which the respective dimensions relate to each other must be 
understood, too. In the field of healthcare, many QoL questionnaires have been developed, tested 
for validity/reliability, and then used as QoL-measuring instruments. These questionnaires 
generally fall into one of the following two categories – 
 Generic instruments that include general health-related questions - these are relevant to 
patients suffering from almost any medical condition (examples of these instruments are - 
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the Ferrans and Powers Quality of Life Index, the Sickness Impact Profile, the 
Nottingham Health Profile, the Health Utilities Index, and the various Medical Outcomes 
Study Short Form (SF) questionnaires). 
 Disorder-specific instruments - these include questions, which only pertain to one 
particular medical condition (examples of this are - the Migraine-Specific Quality of Life 
Questionnaire, the Adult Asthma Quality of Life Questionnaire, and the QLQ-LC13 
Module for patients with Lung Cancer). 
It may be noted that certain QoL instruments include both general health-related questions and 
disorder-specific questions in the same questionnaire (an example of this is the Kidney Disease 
Quality Of Life or KDQOL instrument). 
Some simple generic QoL questionnaires that are frequently used (due to their short length and 
the simplicity of their questions) are – (a) Healthy Day Measures (which is used by the CDC, and 
which has only four basic questions), (b) Manchester Short Assessment of Quality of Life (which 
has sixteen questions, and which is used among psychiatric patients), and (c) WHOQOL-BREF 
(which has been translated for use in several different countries/languages, and which contains 
twenty-six basic questions). 
 
III.3 BENEFITS 
Measuring QoL is useful for these reasons – (a) Measurement of QoL shows the levels of impact 
that various diseases/disabilities have on the population, (b) Treatment options for future patients 
can be better defined when treatment effects on the QoL of historical patients are understood, (c) 
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QoL data are important to obtain while conducting certain forms of research (e.g. during 
randomized controlled studies about community health services, and during clinical trials to test 
experimental therapies), (d) QoL data are necessary when comparing the effectiveness (including 
the cost-effectiveness) of various forms of therapy, (e) Tracking a community’s overall health 
over a period of time requires QoL data, in addition to the statistics of mortality and morbidity, 
(f) Identifying population sub-groups with poor perceived health requires an analysis of QoL 
data, (g) Health policy decisions (e.g. decisions pertaining to fund allocation when attempting to 
enhance the health of a particular population sub-group) require QoL data as a guide, (h) 
Analysis of QoL data provides useful insights about the relationship between QoL trends and the 
risk factors for certain diseases, and this, in turn, can lead to initiatives to combat those diseases, 
(i) QoL data can also relate self-reported chronic diseases (Diabetes, Hypertension, etc.) to 
respective risk factors (smoking, sedentary lifestyle, etc.) because personal habits are covered by 
several QoL-measuring instruments,
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 (j) Surveillance in a community to see if certain healthcare 
interventions are being successful also requires QoL data, (k) QoL measurements are particularly 
important in the elderly - as life expectancy increases, ways to make the increased living years 
more worthwhile are sought after, as well, (l) Health-related QoL information can help to co-
ordinate the different forms of medical services (psychiatric, physical, etc.), along with social 
services, (m) QoL information also helps those who are indirectly involved with healthcare (e.g. 
community planners, investors in pharmaceutical companies, charities, etc.) to contribute 
superior services and policy ideas,
36
 (n) Self-assessed health status has also been shown to be a 
more powerful predictor of mortality and morbidity than many objective measurements,
37
 and 
(o) In several jurisdictions, QoL improvement is now a central public health goal (in the U.S., 
this is evidenced by the government’s Healthy People 2020 publication). 
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III.4 DRAWBACKS 
As with any kind of measurement, there are obvious limitations, with regards to QoL measures, 
too, and these include – (a) Perceptions of life and health can vary widely among individuals 
with even the exact same disease/symptoms (especially when subjective self-ratings are 
concerned), thus potentially leading to “outliers” in datasets, (b) Allowance has to be made for 
the fact that even though different dimensions of health (physical, mental, social, etc.) may be 
measured separately, they all correlate with each other to varying extents, in every individual, (c) 
Since (health-related) QoL-measuring instruments almost exclusively comprise health-related 
questions, other factors (e.g. jobs, religious beliefs, family support, neighbourhoods, ethnicity-
based culture, etc.) that can also cause variations in an individual's QoL are often left 
unaccounted for, (d) It has been theorized that the “channel capacity” (i.e. the maximum amount 
of information that can be assimilated) of humans can impede the consistency of responses and 
skew the results, especially when long/complex questionnaires are used,
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 (e) In cross-sectional 
studies where answers to a QoL questionnaire are only utilized from one point in time, more 
allowances must be made for inconsistency of answers (as a discomfort may affect the individual 
at that particular moment, for example), (f) In longitudinal studies, there is always the possibility 
that an individual’s views/perceptions/expectations will change over the course of a Study (this is 
called “Response Shift Bias”),39 (g) In longitudinal studies that look at the effects of 
interventions, there are potential issues during statistical analysis, as a result of “ceiling” effects 
(i.e. patients who start with a higher QoL than the average patient do not have much room for 
post-intervention improvement, but have more chances of post-intervention worsening) and 
“floor” effects (i.e. patients who start with a lower QoL than the average patient have much more 
room for post-intervention improvement, but have less chances of post-intervention 
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worsening),
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 (h) The determination of which one of the many QoL questionnaires to administer 
to a particular sample population is rarely perfect because (especially in the elderly) two or more 
medical conditions can co-exist at the same time, thus necessitating questions that can somehow 
cover disparate symptoms, (i) Confounding variables (e.g. Age, Income, etc.) often need to be 
accounted for before the relationship between QoL and a medical condition is suggested, and (j) 
Summary scores are frequently calculated, in order obtain a single representative value for 
several QoL Domains (i.e. aspects) combined; however, these Summary scores must be 
calculated and interpreted with care because they can be influenced by Domains that they are not 
actually summarizing (Summary scores are also computed via comparisons with “norm” scores, 
but the “norm” scores are based on relatively small “non-diseased” population samples, which 
vary from country to country). 
 
III.5 ENHANCEMENTS 
To overcome the difficulties associated with QoL measurements, the following steps can be 
taken whenever possible – (a) Increase the sample size for the Study, so that any 
discrepancies/outliers do not exert undue influence on the overall results, (b) Adhere to strict pre-
defined inclusion/exclusion criteria, (c) In the case of longitudinal studies, try to ensure that the 
follow-up period and the number of times when the questionnaire is administered are exactly the 
same for everyone in the sample, (d) Analyse not just any Summary outcome variables (e.g. the 
Physical Component Summary and Mental Component Summary scores that arise from the SF-
36 instrument’s eight Domains), but also the constituent Domains (e.g. Pain, Vitality, etc.) of 
those Summary scores – that way, a broader picture of how a certain medical condition affects 
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each individual Domain can also be ascertained, (e) If applicable, use more than one method for 
statistical analysis to answer an identical question, just to reinforce/crosscheck the results of each 
method, (f) Compare and contrast the results of the QoL analysis with the results from other 
similar studies, so that the validity of the latest results can be demonstrated (the similarity of 
studies will be determined by – demographic factors, the medical condition being studied, the 
QoL questionnaire being used, the patient setting, etc.), (g) Whenever QoL Summary scores need 
to be calculated, it is best to compute them, based on “norm” values from the same country that 
the population being studied is in, and (h) Design a new QoL-measuring instrument and test it 
for reliability and validity, in case no satisfactory instrument currently exists for individuals with 
a particular medical condition of interest. 
 
III.6 PROGRESS 
There have been many advancements with the aim of improving QoL-measuring practices, and 
examples of these include – (a) Attempts to standardize QoL measures in certain jurisdictions 
(e.g. the Healthy Day Measures was developed and validated, thanks to a coordinated effort by 
five U.S. government bodies, in the 1990s
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), (b) More and more research is being done to study 
various QoL-measuring instruments, in order to check their respective benefits and drawbacks, 
(c) New techniques are being developed to better understand the various dimensions that 
constitute QoL, and to see how these dimensions relate to each other, and (d) The ethics 
governing studies that measure QoL have progressed over time, and some now argue that 
decisions on the continuation/termination of a life should be based on the QoL that the individual 
can potentially have, rather than on the “sanctity of life” concept.42 
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IV. INSTRUMENTS USED TO MEASURE HEALTH-RELATED QUALITY 
OF LIFE 
IV.1 CONCEPTS 
A questionnaire used in a clinical setting that elicits responses directly from the patient can be 
classified under the umbrella of – “Patient Reported Outcomes”. As such, it is designed to only 
obtain the views of the patient (about certain outcomes), and can be administered via an 
interview, in case the patient cannot fill out the answers to the survey on his/her own. 
A questionnaire can assess a single construct (or characteristic), or multiple constructs. If it 
measures a single construct, it is called uni-dimensional. However, in healthcare, the most 
frequently used QoL-measuring instruments are multi-dimensional questionnaires with several 
Domains (which are also known as – Scales or Subscales, depending on the literature); each 
Domain is scored and reported, differently. In some instances, one final “Summary” score can be 
derived from several individual Domain scores with the help of the procedure known as Factor 
Analysis.
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 Generic Health-Related Quality of Life questionnaires usually include Domains that 
cover – general health perceptions, physical/mental/social functioning, non-specific symptoms 
(e.g. Pain), and overall quality of life (based on - ability to perform day-to-day activities, 
emotional status, etc.). Disease-specific questionnaires, in addition to the afore-mentioned 
Domains, usually focus on – health status, specific symptoms of the disease, impairments 
associated with the disease, and perceptions of the care being provided. Attempts are being made 
to create shorter and easier-to-use questionnaires that can effectively and regularly monitor 
patients’ QoL.44 The objective of these attempts is to have a simple and easy way for patients to 
assess their own health status, all while the data is being aggregated and checked for sensitivity. 
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Of course, advances in psychometrics will also be necessary to ensure that the psychometric 
properties (reliability, internal consistency, validity, and responsiveness) of these newer 
questionnaires meet the appropriate standards. 
 
IV.2 REQUIREMENTS 
Before any QoL-measuring instrument (i.e. questionnaire) can be used in a population, it must 
meet certain standards, pertaining to its development, its psychometric properties, and its 
scaling/scoring methods. The requisites for a satisfactory QoL-measuring instrument include – 
(a) A sound theoretical basis; the definition of what QoL means to the instrument’s architects has 
to be shown to be reasonable, and the theory/model behind the instrument will be important 
when the instrument is subsequently checked for validity,
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(b) Relevant content/wording in the 
instrument; this ought to be based on interview responses from the target population,
46 
thus 
ensuring that specific concerns of the relevant population (in their own words) are included,
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while also ensuring that linguistic and cultural factors in the target population are taken into 
account, (c) Acceptability of the instrument to the target group(s); the response rate will be 
greater whenever a target population believes that the instrument is truly relevant to their 
particular health status (therefore, it is sometimes unwise to use a generic QoL-measuring 
instrument on a group of patients with one specific disease), (d) Equivalence of subsequent 
translations into other languages; a validated instrument can be translated into another language, 
as long as the psychometric properties do not change, and as long as the translation’s 
wording/format accommodates local linguistic idiosyncrasies and culture (therefore, technical 
word-for-word translations are often inappropriate), (e) Reliability; the results of the measuring 
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instrument must be reproducible (i.e. with negligible differences during random measurements 
on the same population) for it to correctly show changes in anyone’s QoL, and this means that 
scores ought to be consistent, after repeated use of the instrument on a target population, (f) 
Internal consistency, which can be evaluated by the Cronbach’s Alpha coefficient; it is important 
to ascertain how closely items (i.e. questions) that measure the same construct are related (an 
interrelationship between items is necessary, but a very strong relationship means that an item in 
the instrument is redundant
45
), (g) Uni-dimensionality, which should be assessed by Rasch 
analysis;
48
 every Domain in an instrument must cover only one construct because each Domain 
score should indicate valid changes in only one particular construct, (h) Face validity; members 
of the target populations should be interviewed to ensure that the instrument is understandable, 
suitable, comprehensive, and relevant (as per the perceptions of said target populations), (i) 
Construct validity, which means that the instrument measures the construct that is was designed 
to measure; this can be verified via comparison with other similar instruments (as long as the 
comparators are themselves valid and reliable), or via correlations with the status of patients who 
are at different stages of the disease in question, (j) Sensitivity; an instrument should be able to 
detect even small changes in any construct that it is designed to measure (therefore, it should be 
reliable, and also cover all aspects of the construct), and (k) Feasibility, which means that the 
instrument must be easy to administer, and also easy for the target individuals to answer; in order 
to minimize “missing” or inaccurate data points, the mode of administration ought to be simple 
(e.g. self-administration) and consistent, in all situations. 
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IV.3 THE MEDICAL OUTCOMES STUDY SHORT FORM 36 (SF-36) HEALTH 
SURVEY 
For this Study, the instrument of principal interest is the SF-36, which is a multi-purpose Health 
Survey that was developed as part of the Medical Outcomes Study – this was a two-year Study of 
patients with chronic conditions (Ware J.E. and Sherbourne C.D.; Health Institute, Boston; 
1992). Following the design of the SF-36, the RAND Corporation
49
 (a non-profit American 
research institution that was part of the original Study) put out a version of the original SF-36 
instrument called the RAND SF-36. This RAND SF-36 instrument contains the exact same 
questions as the original SF-36 instrument, although the scoring instructions recommended for 
the RAND SF-36 are slightly different. The original SF-36 instrument (and the proprietary 
software for scoring it) can only be obtained commercially by an individual/group with a pre-
approved license from the Medical Outcomes Trust, which comprises a group of researchers 
from the original Study; it may be noted that the Medical Outcomes Trust has subsequently 
merged their SF-36 licensing/registration programs with Qualitymetric Incorporated
50
 (who are 
now responsible for evaluating SF-36 license applications). On the other hand, the RAND SF-36 
questionnaire (and the scoring instructions for it) can be obtained for free by any interested 
individual/group. As a result of being freely available, the RAND SF-36 is now purported to be 
the most widely-used generic (health-related) QoL measure in the world.
51
 Earlier, in 2002, De 
Haan stated that the SF-36 (all versions) was the most commonly used generic instrument for 
measuring (health-related) QoL.
52
 The RAND SF-36 instrument has been translated into many 
languages, although not all translations have been deemed to be equivalent to the original; the 
most systematic efforts to produce equivalent, validated and culturally-cognizant translations 
were undertaken by the International Quality of Life Assessment (IQOLA) Project, which 
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enabled satisfactory translations to be used in more than fifty countries (including in other 
English-speaking countries).
53
 As compared to version 1 (which was released in standard form, 
in 1990)
54
, version 2 of the SF-36 (which was released in standard form, in 1996)
54
 is supposed 
to enable more precise scoring, while being easier to understand/answer;
55
 version 2 also has a 
better layout, improved wording, and more uniform response options
54
 (for example – the phrase 
“full of pep” was changed to “full of life” in the latter version, while sixteen items were made to 
be more consistent with other items in the instrument by having their 2-level and 6-level 
response options all changed to 5-level response options). The RAND SF-36 instrument takes 
about 7-10 minutes to self-administer, although it can also be administered via a computer, or by 
a trained interviewer (in person or via telephone).
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 All of the SF-36 questionnaires (including 
the RAND SF-36) have been designed with both 1-week recall and 4-week recall options for 
twenty of the thirty-six items (i.e, subjects have to answer those questions, based on their 
experiences during either the preceding week, or the preceding 4 weeks). In addition to being 
more commonly used and totally free to obtain, the RAND SF-36 also uses a simpler and more 
straightforward scoring algorithm that has been deemed to be superior to the original SF-36 
scoring algorithm
56
.  
This Study will be based on - (i) the RAND SF-36 4-week recall questionnaire (as dictated by 
the Study data), (ii) the format of version 1 of the SF-36 (as dictated by the Study data), and (iii) 
the RAND SF-36 scoring instructions (as dictated by the majority of the Study data, and also by 
the recommendations from the literature).    
The RAND SF-36 instrument is a 36-item generic measure of Health-related Quality of Life 
(QoL) that measures eight constructs via eight different Domains (or Scales), which are – 
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 Physical Functioning (PF): Calculated from the answers to questions 3 to 12. 
 Role limitations due to Physical Health (RP): Calculated from the answers to questions 
13 to 16. 
 Bodily Pain (BP): Calculated from the answers to questions 21 to 22. 
 General Health (GH): Calculated from the answers to questions 1, 33, 34, 35 and 36. 
 Vitality or Energy/Fatigue (VT): Calculated from the answers to questions 23, 27, 29 and 
31. 
 Social Functioning (SF): Calculated from the answers to questions 20 and 32. 
 Role limitations due to Emotional Health (RE): Calculated from the answers to questions 
17 to 19. 
 Mental Health or Emotional Well-being (MH): Calculated from the answers to questions 
24, 25, 26, 28 and 30. 
All thirty-six questions are scored on a scale from 0 to 100, although the pattern of scoring varies 
from question to question. The scores from a subject’s answers to the various questions under 
each particular Domain are averaged to create an aggregate score for each Domain (PF, RP, etc.); 
each of the eight Domains can have a minimum aggregate score of 0 and a maximum aggregate 
score of 100. The answers to thirty-five out of the thirty-six questions in the instrument are used 
to calculate the respective Domain scores via the specialized scoring algorithm; however 
Question # 2 is only aimed at finding out how the subject rates his/her current overall health 
status, in comparison to his/her overall health status at a year ago. For each question and also for 
each Domain, a score of 100 represents the highest possible level of functioning, and a score of 0 
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represents the lowest possible level of functioning; therefore, a score that is 100 or close to 100 
indicates a favourable perception by the subject of his/her status, regarding that particular 
question or Domain. In case a subject fails to answer all of the questions that come under a 
particular Domain, the aggregate score for that Domain can still be calculated, as long as a 
majority of questions that constitute that Domain have been answered (for example – if only two 
of the three questions under the Domain of RE have been answered, the aggregate score for RE 
can be computed by averaging the scores for the available two answers).
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The eight Domains listed above can be used to calculate two psychometrically-based “Summary” 
scores. These Summary scores were created, in order to simplify the statistical comparisons 
required during any analysis of SF-36 scores (i.e. instead of comparing all eight Domain scores 
between respective populations, just two Summary scores would suffice for the same purpose). 
These two Summary scores/measures are – 
 Physical Component Summary (PCS) score. 
 Mental Component Summary (MCS) score. 
The PCS and MCS scores for each subject are calculated, based on country-based “norms” 
where 50 (Standard Deviation = 10) is taken to be the mean of the “norm” (i.e. non-diseased) 
population. These PCS and MCS scores can be calculated via computerized Norm-Based Scoring 
(NBS) calculators, or manually. In any event, the calculation of the Summary scores for each 
subject involves this 3-step process
58
 – (i) Firstly, all eight Domain scores are standardized using 
a linear Z-score transformation (while calculating the Z-scores, only Domain means and standard 
deviations pertaining to the Study population’s own country should be used); (ii) Secondly, the 
Z-scores are multiplied by the Domain factor score coefficients for PCS and MCS (which are 
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available in Tables from J. E. Ware, et al.) and summed over all eight Domains, so that there is a 
PCS summed score and an MCS summed score; (iii) Thirdly, T-scores are calculated by 
multiplying the respective PCS and MCS sums (which were just obtained) by 10, before adding 
50 to the respective products (thereby ensuring a mean of 50 and a Standard Deviation of 10 for 
the “norm” population). 
The PCS score is primarily dependent on the Domains of PF, RP, and BP (as these Domains 
correlate most strongly with physical health), while the MCS score is primarily dependent on the 
Domains of MH, RE, and SF (as these Domains correlate most strongly with mental health). The 
GH and VT Domains correlate strongly with both physical and mental health. It should also be 
mentioned that the Domain of SF has a significant correlation with physical health, too. 
Some other noteworthy points about the SF-36 instrument are – 
 Even though the SF-36 instrument is a generic one, it has been used in both general and 
disease-specific populations to compare relative burdens of diseases, and also to compare 
the benefits of different forms of treatment in a population; the conditions most often 
studied with the help of the SF-36 instrument are chronic conditions (e.g. Cancer, 
Cardiovascular Disease, Chronic Kidney Disease, Diabetes, HIV/AIDS, Hypertension, 
Rheumatoid Arthritis, Stroke, etc.).
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 By 2003, the SF-36 had been mentioned in more than 4000 articles covering more than 
200 different conditions (with more than 500 articles in more than 20 countries 
mentioning a translated version of the SF-36 as a primary QoL-measuring instrument).
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 The SF-36 was designed to be a relatively short Health Survey, and was based on the 
149-item Functioning and Well-Being Profile (FWBP)
59
, which was itself based on 
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previously-constructed and widely-used instruments, such as the General Psychological 
Well-Being Inventory (GPWBI).
60
  
 Out of forty constructs measured in the Medical Outcomes Study, the final eight Domains 
chosen for the SF-36 were deemed to be the most commonly measured constructs in 
existing popular Health Surveys, and also the constructs that exhibited greatest changes 
due to disease and treatment; items representing various health indicators (e.g. behavioral 
changes, objective assessments, distress, etc.) were found to be important and included in 
the instrument, too.
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 Apart from the improvements that version 2 of the SF-36 is said to have (i.e. greater 
comparability with translations, better wording/layout, more consistent response options, 
smaller standard deviation, smaller “floor” and “ceiling” effects for the RP/RE Domains, 
etc.), other advances concerning the instrument included – (i) the introduction of Norm-
Based Scoring (NBS) algorithms for the eight Domains, which permitted NBS-based 
comparisons of the Domain scores and the Summary scores, and (ii) Re-estimation of 
“norms”, so that (via NBS algorithms) results from version 1 of the SF-36 could still be 
directly comparable with results from version 2. 
 To make the instrument more capable of detecting recent/acute changes in health status 
(as can occur during Asthma, for instance), the 1-week recall SF-36 instrument was 
created; in this adaptation, each of the Domains that have a recall period (i.e. RP, BP, VT, 
SF, RE, and MH) have a 1-week recall period, instead of a 4-week recall period. 
 Psychometric testing of the SF-36 instrument has been performed on several occasions 
(and in several different countries), and has led to the following findings – (i) 80-85% of 
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the reliable variance in the eight Domains is due to physical health and mental health 
factors, which were corroborated by Factor Analytical studies
54
 (this had been verified in 
more than ten countries, by 1998), (ii) Extensive testing of the scaling and scoring 
assumptions in the SF-36 was performed using guidelines from various American 
research bodies, and all items in the instrument have been shown to correlate strongly 
(correlation factor >0.4) with their respective Domains, on almost all occasions,
62
 (iii) 
Many studies have also confirmed that items can be aggregated without weighing the 
items, or standardizing the scores,
61
 (iv) Studies using Item Response Theory (IRT) have 
shown that improvements in the scaling/scoring of the PF Domain are possible, although 
these studies have also shown that the summated (Domain) scores have strong linear 
associations with scores from IRT models,
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 (v) Test-retest and internal consistency 
methods have shown that the reliability statistics for the eight Domains and two 
Summary measures are >0.8 in most publications (with the Summary measures actually 
having very high reliability statistics), and this is well above the minimum standard 
reliability statistic for instruments of this type (i.e. 0.7),
64
 (vi) 95% Confidence Intervals 
around individual scores were found to be much smaller for the Summary scores, as 
opposed to the Domain scores,
64
 (vii) The validity of the SF-36 has been proven in many 
studies that have compared it with other commonly-used generic (health-related) QoL-
measuring instruments - SF-36 Domains have been seen to achieve 80-90% of their 
empirical validity in studies that cover the criteria for physical health and mental health,
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(viii) The sensitivity and specificity of the SF-36 for certain conditions has been shown to 
be high, too (for example – the MCS measure had a specificity of 81% and a sensitivity 
of 74% in detecting patients with a diagnosis of depressive disorder),
64
 (ix) Cross-
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sectional and longitudinal studies have shown that there is no significant loss of 
information when only the Summary scores (rather than the Domain scores) are utilized 
for statistical comparisons between groups
64
 (although there remain advantages to 
analysing each Domain score, too), (x) Available information indicates high completion 
rates for the items in the SF-36, as well as adequate response consistency,
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 (xi) 
Interpretation of results is now easier, thanks to Norm-Based Scoring (as standardized 
mean scores and standard deviations help during the interpretation of differences across 
Domains, and also help when longitudinally studying a diseased population), and (xii) 
Subsequent advances have led to the creation of the SF-12 instrument (which is shorter, 
but still covers the same constructs that the SF-36 covers), to the creation of the SF-10 
instrument for children, and to the development of a preference-based Health Utility 
Index that can be used during economic evaluations. 
It should be mentioned that a common disorder-specific instrument that is used for measuring the 
QoL of patients with Kidney Disease is the Kidney Disease Quality of Life Short Form 
(KDQOL-SF) Health Survey; this instrument was originally developed for patients with Stage 5 
CKD, but can be used for other CKD patients, as well.
66
 The first part of this instrument is 
actually the SF-36 instrument (i.e. it contains the exact same thirty-six generic-based items that 
have been described, earlier), while the second part contains items that are specific to Kidney 
Disease. The second part comprises forty-three items that help constitute the following eleven 
Domains – (a) Symptoms, (b) Effects of Kidney Disease, (c) Burden of Kidney Disease, (d) 
Work Status, (e) Cognitive Function, (f) Quality of Social Interaction, (g) Sexual Function, (h) 
Sleep, (i) Social Support, (j) Dialysis Staff Encouragement, and (k) Patient Satisfaction. In a few 
instances, the first part of the KDQOL-SF (i.e. the generic part) is made to be the SF-12 
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questionnaire, instead of the SF-36 questionnaire; however, the Domains and Summary measures 
are the same for both the SF-36 and SF-12, even though the number of items is different. The 
KDQOL-SF instrument is also free to obtain from the RAND Corporation. However, as the 
disease-specific components of the KDQOL-SF are out of the realm of this Study, this instrument 
will not be discussed, further. 
 
IV.4 ARTICLES ABOUT THE SF-36 INSTRUMENT 
Publications that provided insights into the SF-36 QoL-measuring instrument would be useful, 
particularly in terms of – (a) understanding how results obtained through it can be interpreted, (b) 
confirming the validity of it, (c) understanding how the normative SF-36 data for Canada were 
obtained, and (d) understanding the usefulness of the Domain scores and Summary scores, 
respectively. 
The reasons for searching for such articles about the SF-36 are – 
 It is vital to (i) know how to interpret the Domains and Summary measures of the SF-36 
instrument, (ii) understand how to relate the SF-36 Domain and Summary scores to real 
life events, and (iii) know how to compare the SF-36 scores of a group or individual 
having a certain medical condition with the SF-36 scores of a general non-diseased 
population. 
 The SF-36 instrument must be proven to be an acceptable, widely-used, valid, and 
reliable QoL-measuring instrument before the results from this Study can be deemed to 
be useful. 
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 The methods by which the Canadian normative SF-36 data were compiled assume 
importance because the Norm Based Scoring method will be used to calculate the PCS 
and MCS scores during this Study, and it is worth knowing how these two Summary 
scores will actually be computed; it is also important to understand the theory behind the 
computations, and the strengths/weaknesses of the Study that was performed to compile 
the normative data for Canada. 
 It is important to know (i) how the SF-36 Domain scores and Summary scores relate to 
each other, (ii) what the Domain and Summary scores respectively signify, and (iii) where 
it is better to emphasize Domain scores instead of Summary scores (and vice versa). 
Interpretation of the SF-36 instrument: Using the search terms of “SF-36” and 
“Interpretation”, a search was performed in the PUBMED health database. Of the 280 
publications retrieved, only 1 publication was an article from Canada that described in detail how 
SF-36 results can be related to everyday life. As other health databases (i.e. EMBASE, 
COCHRANE LIBRARY, and UPTODATE) and general search engines did not provide any more 
informative publication that originated from Canada, the article found in the PUBMED database 
is summarized, as follows –  
TABLE IV.1: Interpreting the SF-36 Health Survey, 2002 (Canadian Association of 
Cardiac Rehabilitation)
A
 
Barbara Gandek 
Objective To help explain what the numbers associated with the SF-36 instrument actually mean. 
Interpretation 
Strategies 
Content-based interpretation. 
Construct-based interpretation. 
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Criterion-based interpretation. 
Content-based 
interpretation 
Meaning is assigned to scores, based on information about item content and patterns of response 
options. 
For example – an individual who is not limited in physical activities (e.g. bathing, dressing, etc.) 
due to his/her health will score highly on the PF Domain, while the reverse is true for someone 
who is limited in his/her physical activities, as a result of health issues. 
A research-based example using understandable figures is – 81% of people scoring less than 30 on 
the PCS measure had some limitation in walking a block, while only 0.6% of people scoring 60 or 
more on the PCS measure had such a limitation.  
Construct-
based 
interpretation 
This indicates how a Domain (i.e. a Scale) fits into the general health model. 
It has been shown that the PF, RP, and BP Domains have strong correlations with each other, while 
on the other hand, the SF, RE, and MH Domains have strong correlations with each other. 
Therefore, the first three are related to the construct of physical health, and the latter three are 
related to the construct of mental health. 
Research has also proved that the Domains that strongly measure physical health do well in 
detecting the impact of interventions that primarily affect physical health; the same applies to the 
Domains that strongly measure mental health. 
Criterion-
based 
interpretation 
This utilizes information about the relationship between scores and external variables (e.g. job 
loss, death, etc.) to determine the meaning of scores. 
For example - U.S. data showed that 48% of those who scored between 30 and 34 on the PCS 
measure visited a doctor during the past month, while only 26% of those who scored between 45 
and 49 on the PCS measure did so. 
Norm-Based Scoring helps to understand how all scores relate to scores of the general population. 
This helps to determine how different a Study population is from the general population. 
Normative values are usually listed separately for different Age Groups, and Genders. The main 
advantage of Norm-Based Scoring is - it makes it possible to infer that a score above 50 (for any 
Domain or Summary measure) is better than the average score of a general population, while a 
score below 50 is worse; this is so, even if the actual average Domain/Summary score of the 
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general population is any number between 0 and 100 (before conversion). Therefore, the way in 
which an individual’s score for (say) the PF Domain differs from 50 can also indicate the level of 
physical function that he/she is capable/incapable of. This advantage of Norm Based Scoring holds 
value while measuring the impacts of interventions, too. 
Conclusion Interpretation of results from specific studies can be done via the three techniques described, 
above. However, more evidence and details, regarding the interpretation of the SF-36 will be 
obtained over time. 
 
 This article adequately explains how to understand and interpret the various scores obtained 
via an SF-36 measurement (in terms of real life activities). 
Validity, reliability, and acceptability of the SF-36 instrument: Using the search terms of 
“SF-36”, “Validity”, “Reliability”, and “Acceptability”, a search was performed in the PUBMED 
health database. Of the 57 publications retrieved, only 1 publication described a Study where the 
primary objective was to test the validity of the SF-36 instrument in an English-speaking 
country. As other health databases (i.e. EMBASE, COCHRANE LIBRARY, and UPTODATE) 
and general search engines did not provide any other similar publication, the publication found in 
the PUBMED database is summarized, as follows – 
TABLE IV.2: Validating the SF-36 health survey questionnaire: new outcome measure for 
primary care, 1992 (British Medical Journal, 1992 July 18, 305 (6846): 160 – 164)B 
J. E. Brazier, R. Harper, N. M. Jones, A. O'Cathain, K. J. Thomas, T. Usherwood, and L. 
Westlake 
Objectives To test the acceptability, validity, and reliability of the SF-36 Health Survey, and compare it 
with another generic Health Survey being commonly used in Britain (i.e. the Nottingham 
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Health Profile). 
Country where the 
Study was based 
United Kingdom (city of Sheffield). 
Study design Cross-sectional Analysis. 
Number of 
subjects 
1980 patients of ages 16-74 randomly selected from lists of current patients at two general 
medical practices. 
Instrument(s) 
used 
Medical Outcomes Study SF-36 version 1 (note - the wordings of six questions in the original 
U.S. version were modified before the instrument was used on British patients). 
Nottingham Health Profile. 
Methods Both questionnaires were mailed out to the patients’ homes, along with questions about recent 
use of health services, and socio-demographic characteristics. 
The response rate, internal consistency, test-retest reliability, validity, and discriminatory power 
were subsequently checked for. 
Main statistical 
method(s) used 
Cronbach’s Alpha and two-way ANOVA for internal consistency. 
Bland-Altman technique
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for test-retest reliability. 
Kruskal-Wallis test and the Multitrait Multimethod Matrix
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 (which is specifically used to test 
convergent and discriminant validity) for construct validity. 
(To determine discriminant power, the frequency distributions of scores obtained by the 
respective measures were scrutinized, with less skewed distributions indicating greater 
discriminatory power). 
Results The overall response rate was 83%, and the rate of completion for each SF-36 Domain was 
>95%; the proportion of missing data for the SF-36 was only 0.5-4% (as opposed to 4-7% for 
the Nottingham Health Profile).  
Internal consistency of the SF-36 was acceptable (item to own Domain correlations were >0.5 
for 33 of the 36 items). Cronbach’s Alpha was >0.85 (as required), and reliability coefficients 
were >0.75 for all Domains, except SF. 
Test-retest scores were highly correlated with those from the main survey. For all Domains, 91-
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98% of cases fell within the 95% Confidence Interval constructed for a normal distribution. 
Validity was satisfied. The distribution of scores was as expected. Men perceived their health to 
be slightly better than women (p < 0.001) on all Domains, except GH. Significant age gradients 
were found for the Domains of PF and BP (p < 0.001), but there was no gradient for MH (p = 
0.585). Health perceptions decreased as socio-economic class decreased (p < 0.05) across all 
Domains, except GH. For 77 patients who had been diagnosed with, at least, one chronic 
physical condition, health was perceived to be worse (p < 0.001) across all Domains, except 
MH (i.e. when they were compared to a chronic disease-free patient sample that was matched 
for Age, Sex, and Medical Centre). Discriminant validity was also satisfied with Correlation 
Coefficients for four comparable Domains on the SF-36 and Nottingham Health Profile being 
higher than the Correlation Coefficients for non-comparable Domains. 
Discriminatory Power of the SF-36 was also good because the frequency distributions of SF-36 
scores were less skewed than the frequency distributions of comparable scores from the 
Nottingham Health Profile. 
(Patients were grouped into two groups, based on their health perceptions – the group 
consisting of patients with poorer health perceptions had a higher proportion of women, an 
older mean age, a lower proportion of full-time employed people, and a greater number of 
medical consultations; however, between the two groups, the only significantly different 
Domain scores were those for PF, BP, and SF (p < 0.05). 
Conclusions The SF-36 is a suitable instrument for measuring (health-related) QoL in a general population 
because it is easy to use, acceptable to patients, and fulfils strict criteria for reliability and 
validity. It was also superior to the Nottingham Health Profile, overall. 
Recommendations Further studies are required to demonstrate that the SF-36 can be used to study patient groups 
with specific diseases. 
The higher level of missing data in the 65-74 Age Group may mean that caution should be 
applied when using the SF-36 on elderly patients. 
It would be advisable to design one valid health-related QoL score, which can replace the two 
Summary scores.   
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 This Study adequately proves that the SF-36 is a valid, reliable, and acceptable QoL-
measuring instrument; it is also worth noting that the usefulness and strengths of the SF-
36 instrument were proven, reasonably early after its creation (and when version 1 of the 
SF-36 was the only available version). 
 Even though the Study took place in the United Kingdom, the analysis has an important 
bearing on the utilization of the SF-36 in Canada, too because it has been shown that SF-
36 normative data are similar for both Canadian and British general populations.
69
 
 The large sample size and the wide-ranging analyses used indicate that the Study was 
robust. 
 The favourable comparison of the SF-36 with the Nottingham Health Profile further 
strengthened the relevance of the Study’s results because the latter instrument had been 
widely and commonly used in Britain, prior to the creation of the SF-36 (as noted by the 
authors). 
Preparation of Canadian normative data for the SF-36: Using the search terms of “SF-36”, 
“Normative”, and “Canada”, a search was performed in the PUBMED health database. Of the 39 
publications retrieved, only 1 publication described the Study through which the first (and, so far, 
only) normative Canadian data for the SF-36 were prepared and published. As other health 
databases (i.e. EMBASE, COCHRANE LIBRARY, and UPTODATE) and general search 
engines did not provide any other publication about the compilation of Canadian SF-36 
normative data, the publication found in the PUBMED database is summarized, as follows – 
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TABLE IV.3: Canadian normative data for the SF-36 health survey, 2000 (Canadian 
Medical Association Journal, 2000 August 8, 163 (3): 265 – 271)C 
Wilma M. Hopman, Tanveer Towheed, Tassos Anastassiades, Alan Tenenhouse, Suzette Poliquin, 
Claudie Berger, Lawrence Joseph, Jacques P. Brown, Timothy M. Murray, Jonathan D. Adachi, 
David A. Hanley, Emmanuel Papadimitropoulos, and the Canadian Multicentre Osteoporosis 
Study Research Group 
Objective To publish the first normative Canadian data for the SF-36 because only normative data can show 
whether an individual/group is scoring above or below an average SF-36 score for their country 
(and, for their Age and Gender). 
Country where 
the Study was 
based 
Canada (multiple cities). 
Study design Cross-sectional Analysis. 
Number of 
subjects 
9423 subjects (aged 25 years, or more) that formed the prospective cohort for the Canadian Multi-
centre Osteoporosis Study; the sample (men = 30.6 %; women = 69.4 %; mean age = 62.1 years 
with a Standard Deviation of 13.4) was drawn from residents within a 50 kilometre radius of the 
following nine Canadian cities – St. John’s, Halifax, Quebec City, Kingston, Toronto, Hamilton, 
Saskatoon, Calgary, and Vancouver.    
Instrument(s) 
used 
Medical Outcomes Study SF-36 (the U.S. English version was used for English-speaking 
subjects, as only “mile” had to be changed to “kilometre” for Canadians, while the Canadian 
French-language version from the IQOLA Project Group was used for French speakers). 
Methods The main Study was aimed at estimating the incidence and prevalence of Osteoporosis and 
osteoporotic fractures in the Canadian population, and to check for any regional variation, 
regarding the rates for those conditions. During the collection of baseline data for the main Study, 
the SF-36 instrument was administered at the end of that interview (this therefore presented a 
unique opportunity to develop normative SF-36 data). 
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To develop normative data for the general Canadian population that was adjusted for Age and 
Gender, only data from those who fully participated in the main Study were analysed. However, 
to estimate any selection bias, Regression models were used to predict whether results would 
have been any different, if the data points of those who did not fully participate were also 
included (there was subsequently shown to be no difference). 
Results  The normative scores for all eight Domains and two Summary measures were obtained.  
Just as in the U.S., men scored higher than women in Canada on all eight Domains and on both 
Summary measures (with the difference being most pronounced on the RP, VT, and RE 
Domains). 
The physical health-related Domains and the PCS score decreased with increasing Age, while 
there was no definitive age-related pattern for the mental health-related Domains and the MCS 
score. 
Several Domains (especially the RE Domain) exhibited a “ceiling” effect, but there was no strong 
“floor” effect for any Domain. 
(Incidentally, Canadians scored higher than Americans on all eight Domains and on both 
Summary measures, although the differences were small). 
Inferences The differences in SF-36 scores across Ages, Genders, and Nations prove that Canadian SF-36 
norms are very important to have whenever the SF-36 is used to compare (health-related) QoL 
among Canadian populations. 
These norms will be useful (in Canada) when looking into the health status of the general 
population and specific patient populations, and also while monitoring the effects of interventions 
in a population. 
 
 The sample is large and includes people from the various regions of Canada (individuals 
from anywhere within a 50-kilometre radius of the cities were selected, so that there 
would be a balance between rural and urban residents). 
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 A complex sampling framework was also employed to ensure that the sample was truly 
representative. 
 The authors state that multiple imputation methods proved that selection bias could not 
have substantially changed the mean values, even though participation in the Study was 
voluntary (it is worth mentioning that normative SF-36 data for the U.S. and the U.K. 
were also derived via voluntary participants). 
 Prior to conversion into a “norm” mean score (i.e. 50) for the purposes of Norm Based 
Scoring, each Domain has a mean score of between 0 and 100 for the Canadian general 
population, and as per this Study, those values are – (a) PF: 85.8, (b) RP: 82.1, (c) BP: 
75.6, (d) GH: 77, (e) VT: 65.8, (f) SF: 86.2, (g) RE: 84, and (h) MH: 77.5. 
Domain (or Subscale) and Summary scores of the SF-36: Using the search terms of “SF-36”, 
“Subscale”, “Summary”, and “Scores”, a search was performed in the PUBMED health database. 
Of the 96 publications retrieved, only 1 publication described a Study that primarily looked into 
the relationship between the SF-36 Domain scores and Summary scores (all within a normative 
sample population, so that the effects of any medical condition did not come into play). 
Substituting the keyword “Domain” for “Subscale” and performing the same search in the 
PUBMED health database did not lead to any more relevant publication being found. As other 
health databases (i.e. EMBASE, COCHRANE LIBRARY, and UPTODATE) and general search 
engines did not provide any other publication that looked into the relationship between the SF-36 
Domain and Summary scores (without considering any disease-specific variables), the 
publication found in the PUBMED database is summarized, as follows – 
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TABLE IV.4: Do SF-36 summary component scores accurately summarize subscale scores?, 
2001 (Quality of Life Research, 2001, 10: 395 – 404)D 
Charles Taft, Jan Karlsson & Marianne Sullivan 
Objectives To analyse and understand - (i) the relationships between the eight Domain scores and the two 
Summary scores, (ii) the relationships between the two Summary scores, and (iii) the 
implications of the two Summary scores (and their respective relationships) during the 
interpretation of research results.  
Country where the 
Study was based 
Sweden. 
Study design Cross-sectional Analysis 
Number of 
subjects 
8930 subjects who constitute the Swedish SF-36 normative sample (however, as not all of 
these subjects had been scored on each of the eight Domains, only the 8004 subjects with 
computable PCS/MCS scores were ultimately utilized for this Study). 
Methods Firstly, theoretical analyses to describe how the SF-36 scoring algorithm influences the 
relationships between Domain and Summary scores were completed. 
Secondly, correlations between the two Summary scores were calculated, at different intervals 
of the scoring range. 
Thirdly, step-wise Regression analysis was performed to find out the proportion of the 
variance in PCS and MCS scores that is explained by each Domain, at different scoring levels. 
Results All eight Domain scores are required for the computation of the PCS and MCS scores; the 
greater the deviation of an individual’s Domain score from the general population’s mean 
Domain score and the smaller the variance for that particular Domain, the greater will be the 
impact of scoring coefficients on the Summary scores.  
Significant correlations were found between PCS and MCS scores, at their respective upper 
scoring intervals (therefore, they are not totally independent of each other). Regression 
analyses showed that, in these upper ranges, PCS primarily measures aspects of mental health, 
while MCS primarily measures aspects of physical health. The implications of those analyses 
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are - the computation procedure for the PCS and MCS scores can sometimes inaccurately 
summarize the Domain scores. 
Recommendations Until further revisions are made to the computation procedure for the SF-36 Summary scores, 
PCS and MCS scores must be interpreted with caution, and also be always interpreted in 
combination with the respective Domain scores. 
 
 The Study is relevant and instructional, as it was based on a large number of people who 
were already part of a national SF-36 normative sample. 
 The recommendation to never discard the Domain scores in favour of the Summary 
scores, alone is worth following, as far as possible. 
 
Footnote to Chapter IV:  
 Appendix I – RAND SF-36 Questionnaire. 
 Appendix II – Scoring Instructions for the RAND SF-36 Instrument. 
 Appendix III – Reliability, Central Tendency, and Variability of the RAND SF-36 
Domains. 
 Appendix IV – Summary of Information about the SF-36 Domains and the SF-36 
Summary measures. 
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V. CHRONIC KIDNEY DISEASE AND ITS POTENTIAL IMPACTS ON 
QUALITY OF LIFE 
V.1 OVERVIEW 
Health is now said to be more than just a means to a longer life, and its objective is also to make 
life more satisfying and meaningful while improving the Quality of Life (QoL).  
Improved healthcare has led to longer lifespans, which have led to greater susceptibilities to 
chronic diseases, which have led to relatively lower QoL levels in the elderly of today. Increasing 
age in tandem with the progression of various chronic diseases provides many challenges to QoL 
because each factor is capable of reducing QoL levels, on its own. A survey of “healthy days” by 
the Centers for Disease Control and Prevention (CDC) in the U.S. has indicated that self-rated 
“healthy” days decrease, as age increases (particularly after 65 years).70 And, Canadian statistics 
indicate that the number of patients with Stage 5 Chronic Kidney Disease (CKD) who require 
Renal Replacement Therapy is increasing by approximately 10%, each year.
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 It should be noted 
that every chronic disease can impact a patient’s QoL in a different way, and as the 
manifestations of the same disease can also vary among individuals, QoL can even diverge 
among those with an identical condition.  
However, based on knowledge of the symptomatology (but prior to any in-depth perusal of the 
literature concerning the relationships between CKD and QoL), it would be prudent to state some 
expectations/hypotheses, with regards to how QoL may be affected by CKD. 
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V.2 CHRONIC KIDNEY DISEASE 
Based on just knowledge of the symptomatology, the respective stages of CKD would be 
expected to lead to the following general impacts on QoL - 
 Stages 1 and 2 of CKD should have no significant impacts on any of the physical health-
related Domains of an individual’s QoL due to the paucity of symptoms during the early 
stages of the disease; while Social Functioning ought not to be affected, there could be a 
short-term negative impact on emotional health due to the stress of a serious new 
diagnosis. 
 Stage 3 CKD patients should start to perceive physical limitations due to the associated 
lethargy and poor appetite while their work/employment may also be adversely affected, 
but certain physical health-related Domains (e.g. Pain) should not be impacted; the onset 
of physical limitations, the worry about the disease’s progression, and the inherent 
lifestyle changes could all negatively affect certain mental health-related Domains (e.g. 
Vitality), although Social Functioning ought not to be affected, as yet. 
 Stage 4 CKD patients should perceive even greater negative impacts on the same physical 
health-related Domains that are affected by Stage 3 CKD (e.g. everyday Physical 
Functioning and General Health) because the symptoms of Stage 3 and Stage 4 of CKD 
are quite similar, but more pronounced in the latter; patients whose mental health-related 
Domains were negatively impacted by Stage 3 CKD ought to perceive further negative 
impacts on those same Domains (especially - Vitality) when they have Stage 4 of the 
disease, and Social Functioning should be negatively impacted in these patients during 
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Stage 4 CKD, too (note - plans to treat the impending Stage 5 CKD with Renal 
Replacement Therapy are usually made when patients have Stage 4 of the disease). 
 In comparison with the other stages of CKD, Stage 5 CKD (i.e. “end-stage” kidney 
disease) should lead to the greatest negative impacts on all physical health-related 
Domains (with the possible exception of Pain), as this is the stage when most patients are 
on a form of Dialysis therapy; while Vitality ought to be more severely impacted, other 
mental health-related Domains including Social Functioning should be impacted to a 
relatively lesser degree by Stage 5 of the disease, and mental health-related QoL scores in 
general would be expected to stabilize and even improve, as patients adjust to living 
long-term with Stage 5 CKD. 
Notes: The following noteworthy points should also be mentioned - 
 Patients with CKD should exhibit lower QoL scores across all Domains when compared 
with the general population (note - the most significant differences should be observed 
under the physical health-related Domains, with the possible exception of Pain). 
 Patients with CKD should exhibit sequentially lower physical health-related QoL scores, 
as their disease progresses from Stage 1 to Stage 5, while mental-health related QoL 
scores, though negatively impacted in general, are unlikely to follow such a clear-cut 
pattern (for instance – getting used to a life on Dialysis or getting used to a donor kidney 
could lead to better perceptions of mental health by Stage 5 CKD patients, as compared 
to patients with the preceding stages of the disease, but on the other hand, the actual 
initiation of Dialysis therapy could lead to depressive symptoms,
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 and lower mental-
health related QoL scores at that time). 
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V.3 CHRONIC KIDNEY DISEASE ASSOCIATED WITH DIABETES 
Based on just knowledge of the symptomatology, a combination of CKD and Diabetes would be 
expected to lead to the following general impacts on QoL - 
 Patients with CKD and uncomplicated Diabetes should generally not have significantly 
different QoL scores, as compared to patients with only CKD (because Diabetes per se is 
usually both non-debilitating, and controllable); however, the stress of being diagnosed 
with two serious coexisting diseases could lower the mental health-related QoL scores of 
these patients, in the short-term. 
 Patients with CKD and the complications of Diabetes (e.g. ulcers, dysfunctional nerves, 
visual disturbances, etc.) should have lower QoL scores across all Domains, as compared 
to patients with only CKD (and, due to the added external aggravation that Dialysis 
entails, this negative impact would be accentuated in those patients who are on Dialysis 
while suffering from diabetic complications); the complications of Diabetes should cause 
the greatest impacts on the physical health-related Domains, rather than on the mental 
health-related Domains. 
 
V.4 CHRONIC KIDNEY DISEASE ASSOCIATED WITH HEART DISEASE 
Based on just knowledge of the symptomatology, a combination of CKD and Heart Disease 
would be expected to lead to the following general impacts on QoL - 
 Patients with CKD and non-acute IHD (without Heart Failure) should generally not have 
significantly different QoL scores, as compared to patients with only CKD (because 
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stable Angina is usually both non-debilitating, and controllable); however, the stress of 
being diagnosed with two serious coexisting diseases should lower the mental health-
related QoL scores of these patients, in the short-term. 
 Patients with CKD plus acute manifestations of IHD and/or recent Myocardial Infarction 
(without Heart Failure) should have lower QoL scores across all Domains, as compared 
to patients with only CKD; relatively greater impacts on the physical health-related 
Domains would be expected in this case, too. 
 Patients with CKD and Heart Failure (without IHD) should have lower QoL scores, as 
compared to patients with only CKD, and this ought to be equally true across all 
Domains, with the exception of Pain; overall, physical health-related QoL should be 
impacted to a greater degree, as compared to mental health-related QoL. 
Notes: The following noteworthy points should also be mentioned - 
 In patients who already have CKD, conditions such as Stroke and Peripheral Vascular 
Disease (PVD) would likely lead to further decreases in QoL scores, across all Domains; 
in general, Stroke should impact each Domain more severely than PVD due to the greater 
degree of debilitation that is usually caused by the former condition. 
 Due to the combined debilitation, patients with CKD plus both IHD and Heart Failure 
should have physical health-related QoL scores that are among the lowest within any 
cohort of CKD patients; however, mental health-related QoL scores would not follow a 
definitive pattern due to differing individual traits. 
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 The general QoL in patients with CKD plus both Diabetes and Heart Disease cannot be 
adequately compared to the QoL in other groups because the symptoms among patients 
with all three diseases (CKD, Diabetes, and Heart Disease) would be widely disparate. 
 
V.5 CHRONIC KIDNEY DISEASE AND DEMOGRAPHIC FACTORS 
The demographic factors of Age and Gender would also significantly contribute to differences in 
QoL, among patients with the conditions discussed in the preceding paragraphs. Based on 
clinical experience, the potential impacts of these two demographic factors may be summarized, 
as follows – 
 The perceptions of QoL in patients with chronic diseases should be worse in younger Age 
Groups (where general expectations include having full-time occupations and active 
family lives), as compared to older age groups (where responsibilities are fewer, 
expectations are more modest, and medications for other concurrent age-related 
conditions may provide additional palliation). 
 Women (especially working women who have to invest time toward family affairs, too) 
generally have more responsibilities than men, and since women also generally live 
longer (therefore being susceptible to more age-related disabilities), women with chronic 
diseases may perceive their QoL to be worse than that of comparable men; however, a 
significant difference in QoL between men and women with an identical disease may be 
unlikely without other coexisting factors playing a part, too.  
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VI. LITERATURE REVIEW 
VI.1 OVERVIEW 
The search for past publications was performed, in order to find articles on studies/research that 
looked at –  
 QoL among (preferably) North American adult patients afflicted with different stages of 
CKD (note - the presence and evaluation of associated co-morbidities would be 
advantageous but not mandatory). 
 QoL among (preferably) North American adult patients with CKD or (if necessary) even 
other chronic conditions, along with particular evaluation of the effects of Age and 
Gender on QoL (note - the presence and evaluation of associated co-morbidities would be 
advantageous but not mandatory). 
.  
VI.2 STUDIES THAT COMPARED QUALITY OF LIFE ACROSS ADULT 
PATIENTS SUFFERING FROM DIFFERENT STAGES OF CHRONIC KIDNEY 
DISEASE 
Utilizing both healthcare-related web-sites and general search engines, online searches were 
conducted, in order to find - Studies in English that compared QoL across adult patient groups in 
North America where each group had a different stage of CKD (with or without co-morbidities), 
and where a version of the SF-36 was one of the instruments (or the only instrument) used for the 
measurement of QoL. If a Study primarily looked into the effects of Diabetes and/or Heart 
Disease on the QoL of CKD patients, that Study would be worth perusing, too. 
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The reasons for the rationale stated above are – 
 This Study is not trying to compare the QoL of a group of CKD patients with the QoL of 
a non-CKD sample; therefore, studies that have done so (e.g. compared the QoL of a 
specific ethnic group with CKD to the QoL of the general population, or compared the 
QoL of Hemodialysis patients to the QoL of the general population, and so on) would not 
provide many useful insights. 
 Unless a complete English translation is available, publications in other languages would 
be undecipherable. 
 Analyses of QoL in countries outside of North America would likely be based upon SF-
36 normative scores that are significantly different from Canadian norms (while QoL data 
from outside of North America might also reflect medical care, which is not comparable 
with the care that is generally provided to CKD patients in Canada); therefore, such 
studies will not be extensively dissected, although their salient features could be 
instructive, and will be summarized. 
 If a Study used a QoL-measuring instrument other than the SF-36, the interpretation and 
comparison of results from that Study would require an in-depth understanding of the 
other instrument (in terms of – scales, computations, validity, reliability, etc.), and that is 
outside the scope of this particular Study; however, the salient features of instructive 
studies that evaluated QoL without using the SF-36 would still be summarized. 
 Those studies that only looked into QoL differences within a particular stage of CKD 
(e.g. only across patients on different forms of Dialysis) would not be very relevant to 
this particular Study. 
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 Those studies that tried to ascertain whether QoL among CKD patients was affected by 
the use/non-use of a certain intervention would not be very relevant to this particular 
Study. 
 Publications about how a particular co-morbidity (other than Diabetes, or Heart Disease) 
impacts the QoL of CKD patients would also provide few valuable insights, regarding the 
current analyses. 
 Studies that attempted to connect QoL information from CKD patients with other 
outcomes (e.g. utility, daily activities, disease coping methods, etc.) would not be of 
much relevance to the current analyses, unless QoL across the stages of CKD was also 
incidentally evaluated. 
 Studies that compared only one dimension of health (i.e. only Pain, only Sleep, etc.) 
across groups of CKD patients would provide few relevant insights; however, such 
studies may be used as references during the interpretations of results from the current 
analyses. 
 Studies that looked into QoL differences among CKD patients as a non-primary outcome 
(e.g. during validation studies on the SF-36 instrument) would also not be of much 
assistance, unless the relevant analyses were explained in detail; however, those studies 
could be used as references during the interpretations of results from the current analyses. 
The search for relevant publications was conducted, as follows –  
 Using the search terms of “Chronic”, “Kidney Disease”, and “SF-36”, a search was 
performed in the PUBMED health database. 
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 Of the 298 publications that were retrieved in the PUBMED health database, only 3 
publications were about studies that used a version of the SF-36 to measure QoL across 
North American patients with two or more stages of CKD.  
 Using the same search terms (“Chronic”, “Kidney Disease”, and “SF-36”), searches were 
also performed in the EMBASE, COCHRANE LIBRARY, and UPTODATE health 
databases; however, no additional studies of relevance were discovered. 
 A general Google search found no further studies of relevance, either. 
 
The 3 publications that were found to be the most relevant to this particular Study are 
summarized, as follows – 
 
 
TABLE VI.1: Quality of life in Chronic Kidney Disease (CKD): A cross-sectional analysis in 
the Renal Research Institute-CKD study, April 2005 (American Journal of Kidney Diseases 45 
(4): 658 – 666)E 
(Rachel L. Perlman, Fredric O. Finkelstein, Lei Liu, Erik Roys, Margaret Kiser, George Eisele, 
Sally Burrows-Hudson, Joseph M. Messana, Nathan Levin, Sanjay Rajagopalan, Friedrich K. 
Port, Robert A. Wolfe, Rajiv Saran) 
Objective To compare the QoL of non-Dialysis CKD patients with the QoL of both (a) CKD patients on 
Hemodialysis and (b) Healthy controls. 
Country where the 
Study was based 
U.S.A. (state of Michigan). 
Study design Cross-sectional Observational Study. 
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Number of 
subjects 
634 subjects with CKD, of whom only 505 completed the SF-36 questionnaire in full - 2 had 
Stage 2, 151 had Stage 3, 360 had Stage 4, 118 had Stage 5 but were not on Dialysis, and 3 
had an unknown stage (the main inclusion criterion was – a GFR of 50 mL/min/1.73m2, or 
less). 
Instrument(s) used Medical Outcomes Study 4-week recall SF-36. 
Methods The QoL of patients enrolled in a multi-center prospective observational study about CKD 
was compared with (i) the QoL of a prevalent cohort of Hemodialysis patients (from U.S. 
historical data) and (ii) the QoL of healthy controls (from U.S. historical data). 
Correlations of QoL with Age, Sex, Race, Marital Status, Education, GFR levels, Diabetes, 
Heart Disease, Hypertension, Body Mass Index, Hemoglobin levels, and Albumin levels were 
checked for within the CKD cohort, as well. 
P values <0.05 were indicative of statistical significance. 
Main Statistical 
Analytical 
Method(s) 
Fisher’s Exact tests and Student’s T tests to compare the respective demographic factors, 
biochemical markers, and co-morbidities for all of the patients who were surveyed (i.e. all of 
those in the CKD cohort). 
Student’s T tests to compare the mean QoL scores of CKD patients with the mean QoL scores 
of each of the other 2 groups (i.e. the Hemodialysis group, and the healthy controls group), in 
turn. 
Multiple Linear Regression to study how the ten scales (i.e. the Domain and Summary 
measures) of the SF-36 were related to biochemical parameters, while controlling for 
demographic factors, and co-morbidities. 
Results Non-Dialysis CKD patients had significantly higher QoL scores on all eight Domains and on 
both Summary scales, when compared with patients on Hemodialysis (p < 0.0001), but they 
had significantly lower QoL scores on seven Domains (all except MH) and on one Summary 
scale (PCS), when compared with the healthy controls (p < 0.0001).  
The only other significant finding was that higher Hemoglobin levels (which are directly 
related to Erythropoietin levels) were associated with higher scores, across both Summary 
scales and across all Domains, except Pain (p < 0.05). 
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Within the CKD cohort, patients with Stage 4 CKD actually had lower scores on most 
Domains and across both Summary scales, as compared to patients with Stage 5 CKD; 
however, none of these differences were statistically significant. Even when GFR was used as 
a continuous variable (instead of “Stage of CKD”), there was no linear or quadratic 
relationship between that and QoL (probably because Kidney Disease is usually “silent” until 
the latter stages). 
Effects of demographic factors and co-morbidities on Domain and Summary scores were also 
checked for; there were no significant correlations, although patients with Heart Failure were 
seen to have lower scores on several Domains and on the MCS measure, as compared to 
patients without Heart Failure. 
Conclusions SF-36 scores for the CKD cohort were higher than those for Hemodialysis patients. 
SF-36 scores for the CKD cohort were lower than those for the healthy controls, especially 
with regards to the measures of physical health.  
Hemoglobin level significantly predicted Domains related to both mental health and physical 
health (with the exception of Pain). 
Recommendations Longitudinal studies are required to better define changes in QoL during the course of CKD, 
and also to explore interventions to improve the QoL of these patients. 
 
Critical appraisal of this Study identified the following noteworthy points – 
 The Study primarily compared the QoL of CKD patients on Hemodialysis with the QoL 
of CKD patients who were not on Hemodialysis, but comparisons of QoL across the 
various stages of CKD were not actually performed (except for the incidental comparison 
between Stage 4 CKD and Stage 5 CKD patients). 
 The sample size was relatively small, in comparison with other such studies, with only 
80% (505) of the original 634 subjects actually completing the survey and being part of 
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the final analyses; in addition, only 222 out of those 505 subjects had absolutely no 
“missing” data. 
 The Study considered co-morbidities, such as Diabetes and Heart Disease; however, by 
the authors’ own admissions, Diabetics were under-represented in the sample that 
completed the SF-36 (just 35%). 
 The lack of centralized laboratory testing was cited by the authors as another weakness, 
along with the number of subjects who had “missing” data points. 
 It would have been preferable to obtain the data for the Hemodialysis group from a 
prospective cohort, rather than from a historical dataset (note - in terms of QoL, a group 
of Stage 5 CKD patients on Hemodialysis could be very distinct from a group of Stage 5 
CKD patients not on Hemodialysis because the latter group would likely consist of less 
symptomatic patients). 
 
TABLE VI.2: Health-related quality of life and estimates of utility in chronic kidney disease, 
2005 (Kidney International 68: 2801–2808)F 
(Irina Gorodetskaya, Stefanos Zenios, Charles E. McCulloch, Alan Bostrom, Chi-Yuan Hsu, 
Andrew B. Bindman, Alan S. Go, and Glenn M. Chertow) 
Objective To determine the relations among kidney function, health-related QoL, and estimates of 
utility. 
Country where the 
Study was based 
U.S.A. (state of California). 
Study design Cross-sectional Observational Study (for all CKD patients), and Longitudinal Analysis (with 
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readings 2-8 times over the following two years) for only those patients with CKD stages 4 
and 5 (i.e. those patients with GFR <30 mL/min/1.73m
2
). 
Number of subjects 205 patients with CKD (GFR <70 mL/min/1.73m
2
), 38 of whom were on Hemodialysis. 
Instrument(s) used KDQOL-SF (with the generic part being the 1-week recall RAND SF-12 questionnaire). 
Health Utilities Index (HUI-3). 
Time Trade Off (TTO) Questionnaire. 
Methods Cross-sectional analysis was performed using the whole sample (which was pooled from two 
prospective cohorts that were both under one research team), in order to see if differences in 
the stage of CKD had a significant impact on QoL and Utility; measurements using each of 
the three instruments were performed.  
Longitudinal analyses were performed to evaluate self-reported outcomes among those with 
GFR <30 mL/min/1.73m
2
, with administration of all three questionnaires attempted at 3-
month intervals, even after any patient initiated Dialysis. 115 patients in total were 
longitudinally evaluated (with, at least, two measurements over two years). 
All analyses were adjusted for - Age, Sex, Race/Ethnicity, and Diabetes. 
P values <0.01 were considered to be statistically significant. 
(Covariates included – Age, Sex, Race/Ethnicity, Socio-economic Status, select Medications, 
and some Laboratory Values, as well as multiple co-morbidities that were all summarized into 
the Charlson Co-morbidity Index
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). 
Main Statistical 
Analytical 
Method(s) 
ANOVA tests (normal distributions) and Kruskal-Wallis test (non-normal distributions) for 
comparisons of the means/medians between groups. 
Spearman Rank Correlation Coefficient to analyse trends between categories (adjustments 
were made for Age, Sex, Race/Ethnicity, and Diabetes). 
Mixed Effect Regression models to analyse the change in QoL and utility over time 
(longitudinal analysis), with GFR being a time-varying covariate. 
Results Cross-sectional analyses showed that the lower levels of kidney function (based on GFR 
values, rather than the “Stage of CKD” variable) were associated with significantly lower PCS 
scores (p = 0.002), as well as significantly lower Burden of Kidney Disease and Effects of 
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Kidney Disease Domain scores (both of the latter two Domains with p < 0.0001, and both of 
those Domains being from the KDQOL-SF Questionnaire). In addition - hospitalization was 
associated with further declines in the PCS score, while Emergency Department visits were 
associated with declines in the MCS score; the initiation of Dialysis for some of those who 
were being longitudinally studied did not significantly impact either Summary score. 
The other noteworthy findings (with an emphasis on QoL) were – (a) Longitudinal decline in 
GFR significantly impacted the Burden of Kidney Disease Domain in a negative way, (b) 
Mean scores across all three instruments suggested considerable loss of function and well-
being in CKD patients, as compared to general population norms, (c) No significant changes 
in the PCS and MCS scores were observed during longitudinal analyses, and (d) Results from 
both the cross-sectional and longitudinal analyses were not affected significantly by Age, Sex, 
Race/Ethnicity, or Diabetes.  
Conclusions Health-related QoL and estimates of utility are extremely low in CKD patients (with the PCS 
score being <43, which indicates a perception that physical health problems are definitely 
impeding normal life functioning
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). 
Recommendations Health policy decisions affecting CKD patients should take self-reported outcomes into 
consideration. 
 
Critical appraisal of this Study identified the following noteworthy points – 
 The total sample size was very small; however, the study population was still reasonably 
diverse, and it was possible to obtain multiple measurements of QoL and Utility for the 
purpose of analysis. 
 The sample size of the group that was longitudinally followed was even smaller than the 
initial sample, although several analyses were still performed using the available data, 
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and the face validity of scores in response to major life events (e.g. initiation of Dialysis) 
was evaluated, too. 
 One of the limitations was that all of the subjects were from an ambulatory nephrology 
clinic in a single institution, thereby restricting generalizability. 
 The sample was slightly skewed towards younger Age Groups (while non-responders 
were older), and this could have led to more favourable perceptions of health among the 
sample. 
 There was a relatively high proportion of patients of Asian descent (25%) in the sample. 
 The authors state that there might have been misclassification of some subjects within the 
“GFR category” variable due to imprecision in determining the change in kidney 
function, based on the change in GFR; this may have reduced the power of the 
longitudinal analysis. 
 A relatively large faction of the sample (25%) was lost to follow-up, which may have 
biased the longitudinal analyses, too. 
 While the SF-12 (which was used for this Study) is comparable to the SF-36, using the 
SF-36 is still preferable because the greater number of items in it lead to slightly more 
representative Domain and Summary scores. 
 The administration of three questionnaires at the same time to each patient could have 
created response inconsistencies due to “channel capacity” issues. 
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 The results were primarily reported in terms of the continuous variable of “GFR value”, 
rather than the ordinal variable of “Stage of CKD”; using the latter would have provided 
clearer delineations, with regards to QoL trends. 
 
TABLE VI.3: Symptom Burden, Depression, and Quality of Life in Chronic and End-Stage 
Kidney Disease, 2009 (Clinical Journal of the American Society of Nephrology, June 2009, 4 
(6): 1057 – 1064)G 
Khaled Abdel-Kader, Mark L. Unruh, Steven D. Weisbord 
Objective To compare (i) symptom burden, (ii) levels of depression, and (iii) QoL between those with 
advanced CKD (i.e. CKD just prior to Stage 5) and those with Stage 5 CKD (i.e. End-Stage 
Kidney Disease). 
Country where the 
Study was based 
U.S.A. (state of Pennsylvania). 
Study design Cross-sectional Prospective Observational Study.  
Number of subjects 177 patients - 90 with Stage 5 CKD (70 were on Hemodialysis, and 20 were on Peritoneal 
Dialysis), and 87 with either Stage 4 CKD or severe Stage 3 CKD (note - patients’ GFR levels 
and patients’ functional status were estimated, prior to inclusion).  
(4 patients from the Stage 5 CKD group and 7 patients from the Stage 3-4 CKD group did not 
complete the SF-36, and were subsequently excluded from final QoL analysis; patients who 
had severe co-morbidities, patients who were not 18-90 years of age, and patients who were 
not residing at home were all excluded from the start of the Study). 
Instrument(s) used Dialysis Symptom Index (DSI). 
Patient Health Questionnaire–9 (PHQ-9). 
Medical Outcomes Study 4-week recall SF-36. 
Methods Cross-sectional analysis was performed to compare differences between the two groups (i.e. 
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the Stage 5 CKD group and the Stage 3-4 CKD group), with regards to - demographic 
characteristics, clinical variables, individual symptoms, overall symptom burden, overall 
symptom severity, depression, and QoL.  
Impacts of demographic and clinical variables on group differences (pertaining to - 
symptoms, depression, and QoL) were also studied.  
Correlations in each group among overall symptom burden, overall symptom severity, 
depression, and QoL were studied, as well. 
Except when analysing the differences in prevalence/severity of individual symptoms on the 
DSI instrument (for which a p value <0.002 was indicative of statistical significance), a p 
value of <0.05 indicated significance during all of the other analyses.   
(It should be noted that, with regards to QoL, all eight Domains and two Summary scores of 
the SF-36 were compared between the two groups; however, during correlation analysis, only 
the PCS and MCS scores of the SF-36 were relevant).  
Main Statistical 
Analytical 
Method(s) 
Student’s T tests or Mann-Whitney U tests for the comparison of means (continuous 
variables) between the two groups; Fisher’s Exact test or Chi-Square Statistic for the 
comparison of means (categorical variables) between the two groups.  
Multiple Linear Regression, Logistic Regression, or the Wilcoxon-Mann-Whitney Rank Sum 
test for analysing the impacts of demographic and clinical variables on group differences, 
regarding – (i) symptoms, (ii) depression, and (iii) QoL (which was indicated by the 
respective PCS and MCS scores).  
Spearman’s Correlation Coefficient for assessing the correlations within each group among (i) 
overall symptom burden, (ii) overall symptom severity, (iii) depression, (iv) PCS, and (v) 
MCS. 
(Also – Cronbach’s Alpha for assessing the internal consistency of the DSI instrument, and 
Bonferroni Correction for analysing the differences in individual symptoms on the DSI 
instrument).  
Results QoL-related scores (as well as symptom-related and depression-related scores) were similar, 
across both groups (Stage 5 CKD patients had lower scores than Stage 3-4 CKD patients on 
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the PF Domain of the SF-36, but this did not translate into a significant difference in the PCS 
score). 
Adjustment for demographic and clinical variables did not unmask differences in overall 
symptom burden/severity, depression, or QoL, and did not attenuate the mild difference in the 
PF Domain of the SF-36. 
Overall symptom burden and overall symptom severity were correlated with (i) depression in 
both patient groups, (ii) PCS scores in patients with Stage 5 CKD, and (iii) MCS scores in 
patients with Stage 3-4 CKD.  
Depression was strongly correlated with MCS scores in both groups. 
Conclusions A comparable low QoL is seen in the following groups - (i) patients with Kidney Failure and 
(ii) patients with advanced stages of CKD who do not yet have Kidney Failure. 
(The burden of symptoms and the prevalence of depression are similar across both of these 
groups, too). 
Recommendations Significant attention should be paid to health-related Domains in the growing number of 
patients who suffer from advanced CKD, even before their kidneys go into failure mode. 
 
Critical appraisal of this Study identified the following noteworthy points – 
 The sample size was relatively small, which may hinder the generalizability of the 
results. 
 The CKD cohort included a disproportionate number of men (66%), while the Dialysis 
cohort included a relatively high proportion of African-American patients (41%). 
 The exclusion of patients with severe co-morbidities may have led to the Dialysis (i.e. 
Kidney Failure) cohort that was selected being healthier than Dialysis patients in general. 
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 The cross-sectional nature of the Study did not permit any evaluation of the evolution of 
QoL (as well as – symptoms and depression) over a period of time, and across potential 
future adverse events. 
 The questionnaires were all administered in the selected patients’ homes, which could 
have led to those patients having more favourable perceptions of their health status, as 
compared to CKD/Dialysis patients in general.  
 The administration of three questionnaires at the same time might have hampered the 
consistency of responses due to “channel capacity” issues. 
 
In addition to the studies that have already been summarized, the following 4 studies from 
outside of North America (which also compared QoL in adult patients across the stages of CKD, 
while using the SF-36) will be briefly summarized, too – 
Health-related quality of life in different stages of chronic kidney disease and at initiation of 
dialysis treatment, 2012 (Health and Quality of Life Outcomes, June 18 2012, 10: 71)
H 
Pagels A.A., Söderkvist B.K., Medin C., Hylander B., Heiwe S. 
 This cross-sectional Study in Sweden utilized the SF-36 to compare (health-related) QoL 
among 535 CKD patients with stages 2-5 of the disease (inclusive of some patients who 
were at the start of Dialysis therapy), while also exploring possible correlating and 
influencing factors; 55 healthy controls were part of the Study, too. 
 All Domain and Summary scores significantly deteriorated, as the stage of CKD 
worsened, with greatest impacts on physical health perceptions (i.e. the PF, RP, and GH 
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Domains, plus the PCS score), and the smallest impacts on the Domains of MH and BP. 
Even patients with stages 2-3 of CKD had much lower scores than healthy controls, with 
regards to the GH Domain and the PCS score. Stage 4 CKD patients had much lower PF, 
GH, and PCS scores, as compared to those with stages 2-3 of CKD. Stage 5 CKD 
patients even had lower RE and MCS scores than Stage 4 CKD patients. QoL 
deteriorated further, as Dialysis was initiated. GFR values of around 45 mL/min/1.73m
2
 
seemed to be a demarcating line for a fall in QoL (particularly with regards to the PCS 
score). All of the considered co-existing conditions were significant predictors of 
impaired QoL (note - Cardiovascular Disease and Inflammation were slightly stronger 
predictors than Diabetes). 
Critical appraisal of this Study identified the following noteworthy points – 
 The sample size was relatively small, which may hinder the generalizability and accuracy 
of the results. 
 The subjects (both patients and healthy controls) were not randomly selected, and this 
fact would have increased the risk of biases. 
 The group sizes (with regards to the different stages of CKD) were disproportionate, with 
most patients having had Stage 5 CKD and with no patients having had a GFR of 
between 31 and 50  mL/min/1.73m²; however, the authors state that Regression analyses 
were performed with more proportionate group sizes. 
 There was a majority of males in the Study, although the percentages of each Gender 
were similar to the general male-female distribution of CKD patients. 
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 The usual limitations of any cross-sectional QoL analysis (“ceiling and floor” effects, 
“response shift” phenomenon, effects of a known diagnosis on the health perceptions of 
asymptomatic patients, etc.) were present, as well.  
 
Quality of life in patients with chronic kidney disease, 2011 (Clinics–Sao Paolo, 2011, 66 (6): 
991-995)
I 
Cruz M.C., Andrade C., Urrutia M., Draibe S., Nogueira-Martins L.A., Sesso R de C. 
 This cross-sectional Study of 155 patients in Brazil utilized the SF-36 to compare the 
dimensions of (health-related) QoL in patients with the respective stages (1-5) of CKD, 
while also evaluating the influences of socio-demographic, clinical, and laboratory data 
on QoL; in addition, the Karnofsky Performance Scale was used to measure functional 
status. 
 QoL in this cohort of CKD patients was lower than the QoL of the general population. 
The PF, RP, and PCS scores were seen to progressively decrease, as the stage of CKD 
worsened, but these decreases were not statistically significant. Older patients performed 
worse on the PCS measure, but better on the MCS measure. Higher Hemoglobin levels 
were associated with better PCS scores. Males had significantly higher MCS scores than 
females. Regarding co-morbidities - only patients with three or more associated co-
morbidities showed significant decreases in their PF, RP, and PCS scores, as compared to 
those without co-morbidities. Professionally active individuals with higher education 
levels displayed higher PCS scores, while individuals with higher incomes had higher 
MCS scores. 
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Critical appraisal of this Study identified the following noteworthy points – 
 The sample size was relatively small, which may hinder the generalizability and accuracy 
of the results. 
 The lack of a significant difference in any Domain score between the “Stage of CKD” 
groups could be due to the small sample size. 
 The authors admit that it was extremely difficult to recruit subjects with the early stages 
of CKD. 
 The cross-sectional study design prevented any causal relationships being determined. 
 
Quality of life in chronic kidney disease, 2011 (Nefrologia, 2011, 31 (1): 91-96)
J 
Fructuoso M., Castro R., Oliveira L., Prata C., Morgado T. 
 This cross-sectional Study of 111 patients in Brazil utilized the KDQOL-SF to compare 
(health-related) QoL between four groups – (i) patients with stages 1-4 of CKD, (ii) 
patients who had undergone Kidney Transplants, (iii) patients who were on 
Hemodialysis, and (iv) patients who were on Peritoneal Dialysis. 
 There were no significant differences in Domain scores between the four groups, but the 
scores for the SF Domain were highest, in each of the four groups, while the scores for 
the GH Domain were lowest, in each of the four groups. Peritoneal Dialysis patients 
scored significantly higher on the PCS measure (as well as on the PF and BP Domains) 
when compared to the other three groups, but even these differences disappeared when 
adjustments were made for confounding factors. Age, Gender, and Hemoglobin levels 
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were significant predictors of the PF, BP, and PCS scores. Only Peritoneal Dialysis 
patients indicated a significant improvement in their health, relative to a year ago. In 
terms of KDQOL-SF Domains that were not part of the SF-36 – Peritoneal Dialysis 
patients had significantly better scores when compared to Hemodialysis patients, on the 
Domains of “Effects of Kidney Disease”, “Burden of Kidney Disease”, and “Patient 
Satisfaction”. 
Critical appraisal of this Study identified the following noteworthy points – 
 The sample size was extremely small, which may hinder the generalizability and 
accuracy of the results. 
 There was no actual comparison of QoL across the respective stages of CKD, which 
makes any inference (even if there had been a significant difference in an SF-36 Domain 
score between any of the analysed groups) not very constructive. 
 The small sample size (due to the low power) probably also contributed to the lack of a 
significant difference in an SF-36 Domain score between any of the analysed groups. 
Moderately decreased renal function negatively affects the health-related quality of life among 
the elderly Korean population: a population-based study, 2008 (Nephrology, Dialysis, 
Transplantation – official publication of the European Dialysis and Transplant Association, 
September 2008, 23 (9): 2810-2817)
K 
Chin H.J., Song Y.R., Lee J.J., Lee S.B., Kim K.W., Na K.Y., Kim S., Chae D.W. 
 This cross-sectional Study (which was part of a larger longitudinal Study) of 944 CKD 
patients in a South Korean city  looked at the impact of kidney function on (health-
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related) QoL, and the risk factors for poor QoL in an elderly population (all patients in 
the Study were >65 years of age). 
 Five groups were defined, based on GFR levels - those with a GFR of 90 mL/min/1.73m2 
or more made up the first group, while those with a GFR <45 mL/min/1.73m
2
 made up 
the last group. All of the SF-36 Domain and Summary scores (except for the GH and MH 
scores) were significantly reduced in the last group, as compared to the other four groups; 
even after adjusting for confounders, the PCS score was still much lower in the last 
group, as compared to the other four groups. Across the sample, physical health-related 
QoL scores were lower than mental health-related QoL scores with the VT and BP scores 
being similar for the last group, only. A GFR value of <45 mL/min/1.73m
2
 was an 
independent predictor of poor physical health-related QoL. Apart from GFR levels, the 
other significant predictors of the PCS and/or MCS score were – Age, Gender, Duration 
of Education, Living Spouse, Income Status, Regular Exercise Habits, Depression, 
History of Stroke, Serum Albumin levels, Serum Hemoglobin levels, and Serum 
Cholesterol levels (in general, lower scores on one or both of the Summary measures 
were associated with older Age Groups, females, lower levels of education/income, less 
settled home life, less exercise, associated physical/mental debilitation, and worse 
laboratory-based parameters). 
Critical appraisal of this Study identified the following noteworthy points – 
 The sample was not totally representative of all age groups, as all of the subjects were 
>65 years of age. 
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 Of the 1000 subjects initially selected for the Study, the 56 who did not complete the SF-
36 questionnaire and had to be excluded were all relatively older, less educated, poorer, 
and more anemic than those who actually completed the questionnaire; this fact may have 
skewed some of the results. 
 The groups were created, based on GFR values that do not actually correlate with the 
GFR values used to determine the five stages of CKD; therefore, direct comparisons with 
existing CKD stage-related QoL data would not be appropriate. 
 Due to high degrees of imprecision associated with estimating GFR levels >60, there 
would have been greater chances of patient misclassification occurring among the GFR-
based groups.  
 The Study was planned to be a prospective one, but the analyses were only carried out 
using data from the first year of the Study. 
 The authors state that the sample was too small to be demarcated into a greater number of 
groups (which had been the original intention). 
 The sample was not very representative of Stage 4 and Stage 5 of CKD (note - all of the 
subjects with a GFR <45 mL/min/1.73m
2 
were combined into a single group). 
 
In addition to the studies that have already been summarized, the following 2 studies from North 
America that compared QoL in adult patients across the stages of CKD with the help of 
instruments other than the SF-36 will be briefly summarized, too – 
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Cross-sectional study of quality of life and symptoms in chronic renal disease patients: the 
Modification of Diet in Renal Disease Study, 1997 (American Journal of Kidney Diseases, 
June 1997, 29 (6): 888-896)
L
 
Rocco M.V., Gassman J.J., Wang S.R., Kaplan R.M. 
 The aim of this cross-sectional study in the U.S. was to measure (health-related) QoL in 
the 1284 CKD patients who were enrolled during the baseline period of the Modification 
of Diet in Renal Disease Clinical Trial. Each of the patients had to have completed a 
measurement of QoL/symptoms using one of the following questionnaires – (a) Quality 
of Well-Being (QWB) scale, (b) Symptom Checklist-90R (SCL-90R), and (c) Patient 
Symptom Form (PSF). 
 This Study did not categorize patients by the stage of CKD. However, multivariate 
analyses indicated that QoL  (measured either by the QWB, or the SCL-90R) worsened as 
GFR decreased. QoL was also generally worse in older Age Groups, female patients, 
those with lower levels of education, those with lower incomes, and those with lower 
serum Albumin levels. The commonest symptoms reported in this cohort were – 
difficulty sleeping, fatigue, and abdominal bloating. The overall conclusion was that 
those with moderate-to-severe renal insufficiency had a reduced QoL, as well as more 
frequent (and severe) symptoms and psychological distress; the magnitude of these 
effects was negatively correlated with GFR. 
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Critical appraisal of this Study identified the following noteworthy points – 
 Despite the satisfactory sample size, there was no demarcation of patients by stage of 
CKD (to be fair, the staging approach towards CKD was not routine at the time of this 
particular Study). 
 Some patients (though a minority, overall) had completed just one out of the three 
measuring instruments, which meant that it was not possible to correlate QoL and 
symptomatology for every subject in the Study. 
 
Quality of life and psychosocial relationships in patients with chronic renal insufficiency, 1998 
(American Journal of Kidney Diseases, October 1998, 32 (4): 557-566)
M
 
Shidler, N.R., Peterson R.A., Kimmel P.L. 
 The aim of this cross-sectional study involving 50 outpatients with CKD (prior to Stage 
5) in the U.S. was to assess the psychological functioning level, and the relationship 
between - (a) psychosocial variables,  (b) psychological functioning, and (c) social 
support buffering effects. The measuring instruments used were - (a) Beck Depression 
Inventory, (b) Illness Effects Questionnaire, (c) Multidimensional Scale of Social 
Support, and (d) Satisfaction With Life Scale (in addition to the Karnofsky scale rating 
that a nephrologist provided for the assessment of physical functioning). This cohort was 
compared with – (a) a previously reported  sample of non-Dialysis Stage 5 CKD patients, 
and (b) a previously reported sample of patients who had just been started on 
Hemodialysis therapy. 
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 Satisfaction with life and cognitive depression scores were similar across all of the 
groups (i.e. the CKD prior to Stage 5 group, the non-Dialysis Stage 5 CKD group, and 
the Dialysis Stage 5 CKD group). Even in the first group, there was minimal depression, 
as well as significant inter-correlations between – (a) perception of illness, (b) depression, 
and (c) QoL. The mean level of perceived social support was highest in the Dialysis 
group, though. In conclusion, higher negative perception of illness is associated with 
higher depression scores and lower QoL (even in early-stage CKD patients); however, 
social support may play an important role in the perceptions of those beginning to 
experience kidney impairment.  
Critical appraisal of this Study identified the following noteworthy points – 
 The sample size of the main cohort was very small, which may hinder the generalizability 
and accuracy of the results. 
 Only aspects of mental-health related QoL were analysed; however, the inference that 
these aspects do not vary to a great degree across patients with different degrees of 
kidney impairment is noteworthy. 
 The comparisons between groups were not straightforward, as each of the three groups 
had been measured at different times, and each of the sample sizes was different, too. 
 The respective stages of CKD were not mentioned in this publication, and it should be 
noted that two of the three groups both contained Stage 5 CKD patients, while the other 
group was defined as the CRI (Chronic Renal Insufficiency) group. 
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 Several instruments were used during the same Study, which might have led to ``channel 
capacity`` issues. 
 
VI.3 STUDIES THAT COMPARED THE QUALITY OF LIFE OF ADULT 
PATIENTS HAVING CHRONIC KIDNEY DISEASE (OR EVEN OTHER 
CHRONIC CONDITIONS) WITH THE QUALITY OF LIFE OF A GENERAL 
POPULATION, ALONG WITH EVALUATION OF THE EFFECTS OF AGE, 
GENDER AND CO-MORBIDITIES 
Utilizing both healthcare-related web-sites and general search engines, online searches were 
conducted, in order to find - Studies in English that compared the QoL of North American adult 
patients afflicted with CKD (or even other chronic conditions) with the QoL of a “norm” (i.e. 
disease-free) population, while using a version of the SF-36 QoL-measuring instrument, and 
while also evaluating the effects of the variables of Age, Gender, and Co-morbidities on QoL. 
Specific efforts were also made to find a Study that was conducted in Canada during the past five 
years.  
The reasons for the rationale stated above are – 
 Before the results of this particular Study are interpreted, it would be helpful to 
understand how CKD (or even chronic conditions, in general) can affect (health-related) 
QoL, particularly in relation to the general Canadian population. 
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 Before the results of this particular Study are interpreted, it would be helpful to know 
how Age, Gender, and Co-morbidities can affect the QoL of Canadians with CKD (or 
even chronic conditions, in general). 
 Understanding some of the methods that were used (e.g. to categorize the variable of Age 
into groups, to build the predictor models, etc.) would be very helpful before the current 
analyses are carried out.  
 Studies that used the SF-36 QoL-measuring instrument and Canadian SF-36 normative 
data would be primarily sought for, so that comparisons with this particular Study could 
be straightforward. 
 Studies from the recent past would be much preferred because only recent studies could 
reflect how present-day trends in healthcare and disease progression (with regards to – 
CKD in Canada) might be impacting patients’ QoL. 
The search for relevant publications was conducted, as follows –  
 Using the search terms of “Quality of Life”, “SF-36”, “Chronic”, “Kidney Disease”, 
“Age”, and “Gender”, a search was performed in the PUBMED health database. 
 Of the 57 publications that were retrieved in the PUBMED health database, only 1 
publication was about a Study that utilized the SF-36 to compare the QoL of Canadian 
patients having one or more chronic conditions (CKD being one such condition) with the 
Canadian normative SF-36 data, while also evaluating the effects of co-morbidities on 
QoL; none of the other retrieved studies were performed on Canadian patients. 
 Using the same search terms (“Quality of Life”, “SF-36”, “Chronic”, “Kidney Disease”, 
“Age”, and “Gender”), searches were also performed in the EMBASE, COCHRANE 
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LIBRARY, and UPTODATE health databases; however, no additional studies of 
relevance were discovered. 
 A general Google search found no further studies of relevance, either. 
 
The single publication that has been found to have the most relevance to this Study is 
summarized, as follows - 
 
TABLE VI.4: Associations between chronic disease, age and physical and mental health 
status, 2009 (Chronic Diseases in Canada 29 (3): 108-116)
N
 
W. M. Hopman; M. B. Harrison; H. Coo; E. Friedberg; M. Buchanan; E. G. Van Den Kerkhof 
Objective To examine the associations between chronic disease, Age, and QoL (both physical health-
related and mental health-related). 
Country where the 
Study was based 
Canada (province of Ontario). 
Study design Cross-sectional Analysis 
Number of 
subjects 
2418 patients aged 25 years, or more (129 had Kidney Failure, 366 had Osteoarthritis, 487 had 
Heart Failure, 1160 had chronic Leg Ulcer, and 276 had Multiple Sclerosis). 
Instrument(s) used Medical Outcomes Study 4-week recall SF-36 (or SF-12, in some cases). 
Methods Age was categorized in 10-year increments (just as the Canadian normative data is categorized 
for the variable of Age). 
Five condition-specific databases were created, and the mean PCS and MCS scores (graphed 
by Age Group and Condition) were compared with the Canadian normative data that were 
adjusted for Age and Gender. 
Multiple Linear Regression models were created to predict PCS and MCS scores, while 
controlling for – Condition, Age Group, Gender, Living Circumstances, Cardiovascular 
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Disease, Diabetes, and any other Co-morbidities (note - Diabetes and Cardiovascular Disease 
were the predominant co-morbidities in these patients). 
Two-way interactions were also assessed. 
(During comparison with the normative data, the reference Age Group was set as 25-34 years, 
while Heart Failure was set as the reference Condition because it had the highest mean Age, 
out of all five chronic conditions). 
Main Statistical 
Analytical 
Method(s) 
Multiple Linear Regression. 
Results The respective mean PCS scores for those with the chronic diseases were much lower than the 
mean PCS score from the Canadian normative data; the respective mean MCS scores for those 
with the chronic diseases were only slightly lower than the mean MCS score from the 
Canadian normative data (note - the mean MCS score for CKD patients was actually near 
identical to the mean MCS score from the Canadian normative data). 
Further decreases in both the PCS and MCS scores were observed in female patients. 
Further decreases in both the PCS and MCS scores (with greater decreases on the PCS 
measure) were observed in patients with co-morbid conditions. 
Increased Age was significantly associated with decreased PCS scores (even after controlling 
for - Condition, Gender, and Co-morbidities); on the other hand, increased Age was 
significantly associated with increased MCS scores. 
(There was no significant difference in PCS or MCS scores between the condition-based sub-
groups; however, on the PCS measure, it is worth mentioning that Osteoarthritis patients 
scored lowest, while Leg Ulcer patients scored highest, with CKD and Heart Failure patients 
scoring similarly - in between Leg Ulcer and Osteoarthritis patients). 
Conclusions Chronic diseases caused great impairments in physical health, but only mild impairments in 
mental health (as per patients’ perceptions). 
Female patients with chronic conditions perceived their health (physical and mental) to be 
worse than that of their male counterparts, which is consistent with other studies (note - QoL 
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in acute conditions does not appear to involve any Gender-based difference
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). 
Co-morbidities (Diabetes and Cardiovascular Diseases, in particular) led to further decreases 
in both physical and mental health perceptions, which is also consistent with the results from 
most other studies on this topic. 
Increasing Age by itself leads to more physical hardships, even in disease-free individuals, 
which may explain why older persons with chronic diseases have worse PCS scores than 
younger individuals; mental health stabilizes over time, as individuals learn to cope with their 
ailments and therapies, and this may help to explain the increases in the MCS scores of older 
patients. 
Recommendations Additional research on patients with other chronic conditions, as well as longitudinal studies 
would be useful in better defining the complex relationship between chronic disease, physical 
health, mental health, and advancing age. 
A validated co-morbidity index would be advantageous, too. 
 
Critical appraisal of this Study suggested the following noteworthy points – 
 Since the Study data had to be extracted from ten databases, only six variables that were 
common to each database could be used (with no obtainable information about socio-
economic status and illness severity, for example). 
 A large proportion of the total sample (48%) had Leg Ulcer as their chronic condition, 
thus limiting the generalizability of the results, even though the sample size was large. 
 The number of co-morbidities entered in each of the ten “source” databases was different; 
in addition, the severity of the co-morbid conditions in each patient (though important) 
could not be defined before analysis. 
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 The authors state that there were too few young patients with Osteoarthritis and Heart 
Failure, and too few older patients with Multiple Sclerosis. 
 The cross-sectional nature of the Study meant that Age had to be stratified, but this is 
inferior to following the same cohort, longitudinally, and looking at how QoL changes 
along with ageing. 
 
VI.4 SUMMARY OF THE NOTEWORTHY POINTS FROM THE LITERATURE 
REVIEW 
Based on the literature that has been reviewed, the following impressions should be briefly stated 
- 
 Physical health-related QoL appears to significantly and progressively worsen, as CKD 
advances from the early stages to Stage 5; this appears to particularly be true, with 
regards to the SF-36 Domains of PF, RP, and GH. 
 Mental health-related QoL appears to be impacted to a mild degree (if at all) by CKD 
with no definitive pattern of QoL change being obvious, as CKD advances from the early 
stages to Stage 5; this appears to be the case, especially with regards to the SF-36 
Domains of MH, RE, and SF.  
Additional notes: The following observations should also be mentioned -  
 Ageing appears to generally worsen physical-health related QoL in CKD patients, 
although the perception of pain does not appear to be significantly affected by ageing; on 
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the other hand, mental health-related QoL generally appears to improve, as CKD patients 
become older. 
 Across the board, male CKD patients appear to perceive their QoL as being better (when 
compared to corresponding female patients). 
 In general, associated co-morbidities appear to lead to further decreases in the QoL of 
CKD patients, with greater impacts on physical health-related QoL; however, it has not 
been possible to clearly ascertain how each respective co-morbidity impacts the QoL of 
CKD patients.  
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VII. DATA AND DESIGN 
VII.1 DATA 
The data used for this Study were amalgamated from three existing datasets that were each part 
of a Medical Research Study, in the past. These three datasets will now be described, along with 
the pertinent points, regarding each of the three studies. 
Dataset from the Patient's Perception of life on Hemodialysis Scale (PPHS) Study 
This dataset was obtained from my supervisor (Dr. Brendan Barrett) who was one of the Primary 
Investigators on this project (note - Dr. Patrick Parfrey who is another member of my 
Supervisory Committee was also a Primary Investigator on this project). The complete dataset 
was obtained in April, 2012, at the Patient Research Centre, Faculty of Medicine, Memorial 
University of Newfoundland, St. John’s, Newfoundland and Labrador. Clarifications (regarding - 
the compilation of the dataset, the structure of the dataset, and the definitions of the various 
variables in the dataset) were subsequently obtained over the next few weeks via Dr. Barrett, as 
well. 
The important features of this particular dataset were, as follows - 
 The dataset was in SPSS format, and it contained a total of 236 subjects with no personal 
identifiers. 
 All of the subjects in this dataset had been on Hemodialysis therapy, at the time of data 
collection. 
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 The subjects in this dataset had been enrolled from five Hemodialysis centres (located in 
Newfoundland & Labrador, Quebec, and Ontario, respectively), and the time that patients 
had been on Hemodialysis therapy ranged from 3 months to 276 months. 
 The entry dates of subjects (into this dataset) ranged from July, 1998 to February, 2000. 
 All of the subjects in this dataset had been interviewed in their respective centres (to 
ascertain their perceptions of their own QoL); 120 of these subjects had answered to the 
RAND SF-36 instrument, while 71 had answered to the Ferrans and Powers Quality of 
Life Index instrument, and 45 had answered to both of those instruments. 
 For every subject who had answered to the SF-36 instrument - the “raw” scores, the 
recoded “raw” scores (as per RAND SF-36 scoring instructions), and the eight SF-36 
Domain scores were available. 
 There were two “missing” data points for each of the two demographic variables of 
interest (i.e. Age and Gender), but no further “missing” data points were present. 
The relevant aspects of the Study from which this dataset was derived could be summarized, as 
follows – 
TABLE VII.1: Psychometric Properties of the Patient’s Perception of life on Hemodialysis 
Scale, 2012 (Thesis - Extract)
O
 
(J. Creina Twomey, Brendan J. Barrett, Christine Y. Way, Tom A. Hutchinson, David N. 
Churchill, and Patrick S. Parfrey) 
Objectives To assess the reliability and validity of the revised Patient's Perception of life on Hemodialysis 
Scale (PPHS) instrument.  
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Country where 
the Study was 
based 
Canada. 
Study design Cross-sectional Observational Study. 
Number of 
subjects 
236 patients on Hemodialysis (in five respective centres) – all of the patients contributed 
towards the testing of the psychometric properties of the revised PPHS instrument, while data 
from just 30 of them were used to examine the stability of said instrument. 
Instruments used PPHS (revised version). 
RAND SF-36. 
Ferrans and Powers Quality of Life Index. 
 
Note: It should be mentioned that along with the Study that has just been described, a subset of 
85 patients from the original sample was also assessed, longitudinally (with two measurements 
taken, six months apart), in order to (i) evaluate the changes in physical health, psycho-social 
health, and quality of supports among these Hemodialysis patients, at the two different time 
periods, (ii) evaluate the inter-relationship among patients’ experiences, demographics, illness 
characteristics, and biochemical indicators, and (iii) determine the sensitivity of the PPHS 
instrument, while evaluating its ability to measure changes. However, these 85 patients included 
the 71 patients whose QoL was solely measured by the Ferrans and Powers Quality of Life 
Index; therefore, the data from most of these patients was unusable during the current Study.  
Inclusion Criteria: The data collection for the PPHS Study was conducted in five Hemodialysis 
centres (three in Newfoundland & Labrador, one in Quebec, and one in Ontario), and data was 
only collected from patients who met the following criteria – 
 Were on in-centre Hemodialysis therapy for, at least, 12 weeks. 
97 
 Were mentally competent. 
 Were not experiencing any episode of acute illness.  
 Were over the age of 19. 
 Were able to understand and speak English. 
The variables of interest in this dataset were only those entered at Time 1 (i.e. the initial time 
when patients' QoL was measured), and they were the following –  
 “Age”: Defined as - “Age in years, at Time 1”. 
 “Sex”: Defined as - “Gender of subject”. 
 “CHF1”: Defined as – “Presence of Congestive Heart Failure on exertion, at Time 1”. 
 “CHF2”: Defined as – “Presence of Congestive Heart Failure during rest, at Time 1”. 
 “Unstable”: Defined as – “Attack of Angina and/or Myocardial Infarction event within 
the 6 months prior to Time 1”. 
 “IHD”: Defined as - “Attack of Angina and/or Myocardial Infarction event in the past 
history, but with no such episode occurring within the 6 months prior to Time 1”. 
 “Diabetes”: Defined as – “Presence of diabetic symptoms and/or reliance on anti-diabetic 
medication(s), at Time 1”. 
 “PVD”: Defined as – “Presence of symptoms of Peripheral Vascular Disease, at Time 1”. 
 “Stroke”: Defined as – “Occurrence of a thrombotic Stroke event within the 6 months 
prior to Time 1”. 
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 “Sf361”, “Sf362”, etc.: Defined as – “The ‘raw’ scores for each respective answer to the 
SF-36 questionnaire, at Time 1”. 
 “ReSf1”, “ReSf2”, etc.: Defined as – “The recoded ‘raw’ scores for each respective 
answer to the SF-36 questionnaire, at Time 1”. 
 “Tpf”, “Trp”, “Tbp”, “Tgh”, “Tvt”, “Tsf”, “Tre”, and “Tmh”: Defined as – “The 
respective SF-36 Domain scores, as derived from the subjects’ original answers to the SF-
36 questionnaire, at Time 1”. 
(It should be noted that, due to being irrelevant to the question being posed and/or 
incompatibility with the other “source” datasets, there was no further use of the variables in the 
PPHS dataset that concerned the following – (a) time on Dialysis, (b) native language, (c) 
province of residence, (d) living arrangements, (e) cause of the Kidney Failure, (f) laboratory-
based parameters, (g) Cancer, and (h) Lung Disease).    
Dataset from the CANPREVENT Study 
This dataset was obtained from my supervisor (Dr. Brendan Barrett) who was one of the Primary 
Investigators on this project (note - Dr. Patrick Parfrey who is another member of my 
Supervisory Committee was also a Primary Investigator on this project). The complete dataset 
was obtained in February, 2012, at the Patient Research Centre, Faculty of Medicine, Memorial 
University of Newfoundland, St. John’s, Newfoundland and Labrador. Clarifications (regarding - 
the compilation of the dataset, the structure of the dataset, and the definitions of the various 
variables in the dataset) were subsequently obtained over the next few weeks via Dr. Barrett, as 
well. 
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The important features of this particular dataset were, as follows – 
 The dataset was in SPSS format, and it contained a total of 474 subjects with no personal 
identifiers. 
 All of the subjects in this dataset had had Stage 2, Stage 3, or Stage 4 of CKD when they 
were surveyed. 
 The subjects in this dataset were selected from five urban centres in Canada. 
 The entry dates of subjects (into this dataset) ranged from May, 2005 to June, 2008, and 
the subjects had also had their QoL measured, longitudinally (four measurements were 
taken, with an interval of four months between each measurement). 
 Co-morbidity information for each subject in this dataset was based on that patient’s 
medical history, alone; a perusal of the dataset showed that the dates of diagnosis (for 
respective co-morbidities) ranged from 1 year prior to a subject’s first measurement of 
QoL to 25 years prior to said measurement.  
 Each subject in this dataset had been required to answer to three respective QoL-
measuring instruments, which were – (a) KDQOL-SF, (b) WHOQOL-BREF, and (c) HUI 
Mark 3. 
 While none of the subjects had absolutely no “raw” SF-36 scores entered, at Time 1 (i.e. 
at the first time when their QoL was measured), some “raw” SF-36 scores had not been 
entered for a few subjects, at Time 1.  
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 55 subjects did not have the stage of their CKD entered and/or could not have their SF-36 
Summary scores calculated, as a result of insufficient “raw” scores under a particular SF-
36 Domain, at Time 1 (this was particularly the case when just one of the two questions 
under the BP Domain or the SF Domain had been answered). 
 For every subject who had provided sufficient “raw” SF-36 scores for the calculation of 
the SF-36 Domain scores - the recoded “raw” scores (as per RAND SF-36 scoring 
instructions) and the eight SF-36 Domain scores were also available. 
 8 subjects did not have any information entered, with regards to the status of their hearts. 
The Study from which this dataset was derived led to the following publication (and the 
relevant aspects of that Study are subsequently summarized, too) – 
TABLE VII.2: A Nurse-coordinated Model of Care versus Usual Care for Stage 3/4 Chronic 
Kidney Disease in the Community: A Randomized Controlled Trial, February 2011 (Clinical 
Journal of the American Society of Nephrology 6: 1241-1247)
P
 
(Brendan J. Barrett, Amit X. Garg, Ron Goeree, Adeera Levin, Anita Molzahn, Claudio 
Rigatto, Joel Singer, George Soltys, Steven Soroka, Dieter Ayers, and Patrick S. Parfrey) 
Objectives To compare a new coordinated model of care for CKD patients with the usual care that CKD 
patients receive. 
Country where the 
Study was based 
Canada. 
Study design Randomized Unblinded Controlled Trial. 
Number of subjects 474 patients with median estimated GFR of 42 mL/min/1.73m
2
 (as identified by laboratory 
criteria) – of these patients, 32% had Diabetes and 60% had Cardiovascular Disease. 
101 
Instruments used KDQOL-SF (including the RAND SF-36). 
WHOQOL-BREF. 
HUI Mark 3. 
 
Inclusion Criteria: The data collection for the CANPREVENT Study was conducted in five 
urban Canadian centres, and data was only collected from patients who met the following criteria 
– 
 Were between 40 and 75 years of age. 
 Had documented CKD with a GFR of between 25 and 60 mL/min/1.73m2. 
Exclusion Criteria: Patients who met the following criteria were excluded from the Study - 
 Were expected to die within 6 months. 
 Had either advanced Cardiovascular Disease, or had recent unstable Cardiovascular 
Disease. 
 Were being treated for malignancy. 
 Were receiving immunotherapy for Kidney Disease. 
 Were either on Dialysis, or had received an organ transplant (already, or even with 
transplant surgery being planned within the next 6 months). 
 Were already enrolled in a Kidney/Cardiovascular Disease management program (or in 
another interventional clinical trial). 
 Were residing in a location that was too distant for them to attend Study visits. 
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The variables of interest in this dataset were only those entered at Time 1 (i.e. the initial time 
when their QoL was measured), and they were the following –  
 “Age”: Defined as - “Age in years, at Time 1”. 
 “Gender”: Defined as - “Gender of subject”. 
 “Angina”: Defined as – “Diagnosis of Angina Pectoris in subject's history”. 
 “HeartAttack”: Defined as – “Diagnosis of a Myocardial Infarction in subject’s history”. 
 “HeartFailure”: Defined as – “Diagnosis of Congestive Heart Failure in subject's 
history”. 
 “Diabetes”: Defined as – “Diagnosis of Diabetes Mellitus in subject's history”. 
 “Stroke”: Defined as – “Diagnosis of a thrombotic Stroke in subject’s history”. 
 “AORAN”: Defined as – “Diagnosis of an Aortic Aneurysm in subject's history”. 
 “INTCL”: Defined as – “Diagnosis of Intermittent Claudication in subject's history”. 
 “GANG”: Defined as - “Diagnosis of Gangrene in subject's history”. 
 “DVT”: Defined as – “Diagnosis of Deep Vein Thrombosis in subject's history”. 
 “MDRD0_stage”: Defined as – “Stage of CKD, at Time 1”. 
 “a_KDQOLQ1”, “a_KDQOLQ2”, etc.: Defined as – “The ‘raw’ scores for each 
respective answer to the SF-36 portion of the KDQOL-SF questionnaire, at Time 1”. 
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 “a_KDQOLQ1_rec”, “a_KDQOLQ2_rec”, etc.: Defined as – “The recoded ‘raw’ scores 
for each respective answer to the SF-36 portion of the KDQOL-SF questionnaire, at Time 
1”. 
 “a_SF36PFscale”, “a_SF36RPscale”, “a_SF36Painscale”, “a_SF36GHscale”, 
“a_SF36EnergyFatiguescale”, “a_SF36SFscale”, “a_SF36REscale”, and 
“a_SF36Emotionalscale”: Defined as - “The respective SF-36 Domain scores, as derived 
from the subjects’ original answers to the SF-36 portion of the KDQOL-SF questionnaire, 
at Time 1”. 
(It should be noted that, due to being irrelevant to the question being posed and/or 
incompatibility with the other “source” datasets, there was no further use of the variables in the 
CANPREVENT dataset that concerned the following – (a) randomization methods, (b) 
race/ethnicity, (c) education, (d) employment/occupation, (e) living arrangements, (f) marital 
status, (g) answers to questions in the KDQOL-SF questionnaire that were not part of the SF-36 
instrument, (h) history of medical conditions that were not related to either Diabetes, or Heart 
Disease (e.g. Asthma, Tuberculosis, etc.), (i) history of heart-related conditions/procedures that 
did not clearly indicate symptomatic Heart Disease (e.g. Congenital Heart Disease, Heart Valve 
Replacement, etc.), and (j) laboratory-based parameters). 
Dataset from the EPO-INTERNATIONAL Study 
This dataset was obtained from Dr. Patrick Parfrey (a member of my Supervisory Committee 
who was also a Primary Investigator on this project) with the permission of Janssen Ortho (the 
company that both owns and is responsible for this dataset). The complete dataset was obtained 
in April, 2012, at the Patient Research Centre, Faculty of Medicine, Memorial University of 
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Newfoundland, St. John’s, Newfoundland and Labrador. While a “dictionary of variables” for 
this dataset was indeed accessible, further clarifications about this particular dataset were 
unobtainable due to the set-out regulations of Janssen Ortho.  
The important features of this particular dataset were, as follows – 
 The dataset was in Statistical Analysis System (SAS) format, and it contained a total of 
596 subjects with no personal identifiers. 
 All of the subjects in this dataset had been on Hemodialysis therapy, at the time of data 
collection. 
 The subjects in this dataset were from the following countries - Canada, Austria, 
Germany, United Kingdom, Belgium, Poland, Hungary, Spain, France, and Greece. 
 The entry dates of subjects into this dataset ranged from February, 2000 to February, 
2003, and most of the subjects had had their QoL measured, longitudinally (eight separate 
measurements were attempted - at the time of entry into the Study, and subsequently at 
24, 36, 48, 60, 72, 84, and 96 weeks). 
 For the purpose of ascertaining their QoL, all of the subjects in this Study had answered 
to the KDQOL-SF instrument. 
 Heart Disease (not including Arrhythmias) was part of the exclusion criteria for this 
Study; while there was no specific labelling of patients with Diabetes in this dataset, 
those subjects whose CKD had been caused by Diabetic Nephropathy could be identified 
as Diabetics because the “Primary Cause of Kidney Disease” was actually a variable in 
this dataset. 
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 Only the Domain scores for each subject were available in this dataset, with no “raw” 
scores or recoded “raw” scores being available for any subject; upon detailed perusal, it 
was confirmed that the SF-36 Domain scores for every subject had been obtained via the 
original (i.e. MOS) SF-36 scoring algorithm. 
 In this dataset, there were absolutely no SF-36 scores for 45 subjects, while SF-36 scores 
from the first time of entry into the Study were not included for another 58 subjects 
(however, SF-36 scores from, at least, one subsequent visit were entered for those 58 
subjects). 
The Study from which this dataset was derived led to the following publication (and the relevant 
aspects of that Study are subsequently summarized, too) – 
TABLE VII.3: Erythropoietin therapy, hemoglobin targets, and quality of life in healthy 
hemodialysis patients: a randomized trial, April 2009 (Clinical Journal of the American 
Society of Nephrology 4 (4): 726-733)
Q
 
(Robert N. Foley, Bryan M. Curtis, Patrick S. Parfrey) 
Objectives To analyse the effects of different Hemoglobin targets (when using Erythropoiesis-stimulating 
agents) on QoL because predictors of change in QoL during end-stage Kidney Disease have 
not been well characterized, thus far.  
Countries where 
the Study was 
based 
Canada, Austria, Germany, United Kingdom, Belgium, Poland, Hungary, Spain, France, and 
Greece. 
 
Study design Randomized Double-Blind Controlled Trial. 
Number of 
subjects 
596 patients on Hemodialysis, in the respective countries that are mentioned, above. 
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Instrument used KDQOL-SF (including the Medical Outcomes Study SF-36). 
 
Inclusion Criteria: The data collection for the EPO-INTERNATIONAL Study was conducted in 
the ten respective countries, and data was only collected from patients who met the following 
criteria – 
 Were 18 years of age, or older. 
 Had been started on Maintenance Hemodialysis Therapy, 3 to 18 months before the first 
measurement of their QoL. 
 Had a pre-dialysis Hemoglobin reading of between 8 and 12 g/dl. 
 Had a Left Ventricular Volume Index <100 ml/m2. 
 Had a pre-dialysis Diastolic Blood Pressure reading <100 mmHg. 
Exclusion Criteria: Patients who met the following criteria were excluded from the Study - 
 Clinical evidence or history of symptomatic Cardiac Failure or Ischemic Heart Disease. 
 Daily Prednisone dose that was 10 mg, or more. 
 Medical conditions likely to reduce Erythropoietin responsiveness (including uncorrected 
Iron Deficiency). 
 Concurrent malignancy. 
 Blood transfusion in the preceding month. 
 Therapy with cytotoxic agents. 
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 Seizure in the preceding year. 
 Hypersensitivity to intravenous Iron. 
 Current pregnancy or breastfeeding. 
The variables of interest in this dataset were only those entered at Time 1 (i.e. the initial time of 
entry into the Study), and they were the following –  
 “AGE”: Defined as - “Age in years, at Time 1”. 
 “SEX”: Defined as - “Gender of subject”. 
 “PRIM”: Defined as – “Primary cause of the Chronic Kidney Disease” (note – this 
variable was only beneficial, in terms of identifying the subjects who definitely had 
Diabetes, at Time 1). 
 “PHYFUN10”, “ROLEP4”, “PAIN2”, “GENH5”, “ENFAT4”, “SOCFUN2”, “ROLEE3”, 
and “EMOT5”: Defined as - “The respective SF-36 Domain scores, as derived from the 
subjects’ original answers to the SF-36 portion of the KDQOL-SF questionnaire, at Time 
1”. 
(It should be noted that, due to being irrelevant to the question being posed and/or 
incompatibility with the other “source” datasets, there was no further use of the variables in the 
EPO-INTERNATIONAL dataset that concerned the following – (a) randomization methods, (b) 
time on Dialysis, (c) country of residence, (d) race/ethnicity, (e) answers to questions in the 
KDQOL-SF questionnaire that were not part of the SF-36 instrument, and (f) laboratory-based 
parameters).    
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The combination of variables from the three datasets into the final dataset: The variables of 
interest were pooled and combined from the three described datasets, based on the following 
guidelines –  
 The demographic variables (“AGE” and “GENDER”) were combined into the final 
dataset in a straightforward manner, as they were each defined in the exact same way 
across each of the three “source” datasets; it was only necessary to ensure that the 
abbreviations (i.e. codes) for each of these demographic variables were exactly the same 
in the “source” datasets, prior to the combination. 
 The relevant variables concerning the SF-36 scores (i.e. the Domain scores, and where 
available, the “raw” scores) were combined into the final dataset in a straightforward 
manner, as they were each defined in the exact same way across each of the three 
“source” datasets; it was only necessary to ensure that the abbreviations (i.e. codes) for 
these QoL variables were exactly the same in the “source” datasets, prior to the 
combination. 
 The variable of “STAGE OF CKD” was created in the final dataset in the following 
manner – (i) all subjects from the PPHS and EPO-INTERNATIONAL datasets were 
labelled as having Stage 5 CKD, and (ii) each subject from the CANPREVENT dataset 
was labelled as having the stage of the disease that matched the entry for him/her under 
the “MDRD0_stage” variable in the CANPREVENT dataset. 
 The variable of “DIABETES” was created in the final dataset in the following manner – 
it was constituted from (i) the Presence/Absence variable of “Diabetes” in the PPHS 
dataset, (ii) the Presence/Absence variable of “Diabetes” in the CANPREVENT dataset, 
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and (iii) the variable of “PRIM” in the EPO-INTERNATIONAL dataset, from which only 
those subjects who had had Diabetic Nephropathy were extracted  (note – only the 
CANPREVENT dataset contained a variable that described the specific type of Diabetes 
present). 
 The variable of (symptomatic) “HEARTDISEASE” was created in the final dataset in the 
following manner – it was constituted from (i) the Presence/Absence variables of 
“CHF1”, “CHF2”, “Unstable”, and “IHD” in the PPHS dataset, and (ii) the 
Presence/Absence variables of “Angina”, “HeartAttack”, and “HeartFailure” in the 
CANPREVENT dataset (note – these constituent variables were used due to being 
available, and also because patients with IHD and/or Heart Failure were specifically 
excluded from the EPO-INTERNATIONAL Study). 
 The variable of “HEARTFAILURE” was created in the final dataset in the following 
manner – it was constituted from (i) the Presence/Absence variables of “CHF1”, and 
“CHF2” in the PPHS dataset, and (ii) the Presence/Absence variable of “HeartFailure” in 
the CANPREVENT dataset. 
 The variable of “ANGINA” was created in the final dataset in the following manner – it 
was constituted from (i) the Presence/Absence variable of “Unstable” in the PPHS 
dataset, and (ii) the Presence/Absence variable of “Angina” in the CANPREVENT 
dataset (note – the “IHD” variable in the PPHS dataset was neglected because that 
variable encompassed subjects who had experienced symptoms of IHD >6 months prior 
to their baseline QoL measurement, and it was also unclear whether these subjects who 
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were labelled as having IHD had experienced Angina, or a Myocardial Infarction, or 
both). 
 The variable of symptomatic “PVD” was created in the final dataset in the following 
manner – it was constituted from (i) the Presence/Absence variable of “PVD” in the 
PPHS dataset, and (ii) the Presence/Absence variables of “AORAN”, “INTCL”, 
“GANG”, and “DVT” in the CANPREVENT dataset. 
 The variable of (thrombotic) “STROKE” was created in the final dataset in a 
straightforward manner, as it was a ‘Presence/Absence” variable in the two datasets that 
included patients with thrombotic Strokes. 
 
VII.2 DESIGN 
The Study Design being employed for this particular analysis is a – Retrolective Cross-sectional 
Observational Study (note – it is “retrolective” because, while this Study is utilizing data from 
historical studies, each of those already-completed studies was actually a Prospective Study, at 
the time). 
Cross-sectional study 
A cross-sectional study is basically a “snapshot” at a specific point in time of an outcome and the 
factors that are associated with that particular outcome
76
. A cross-sectional study is descriptive in 
nature, and survey-based data is commonly the focus of cross-sectional studies. Cross-sectional 
studies are usually conducted when a given population needs to be described in terms of an 
outcome and a set of risk factors for that outcome, but they can also be used when the prevalence 
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of a particular outcome of interest (within a given population) needs to be determined
76
. Cross-
sectional studies are rarely used to prove/disprove hypotheses, as they cannot conclusively prove 
causality. Cross-sectional studies also cannot describe associations between an outcome and risk 
factors over a long period of time; however, repeated cross-sectional studies with the same 
variables (e.g. looking into the annual prevalence of CKD in Canada by analysing a different 
randomly-selected sample, every year) could still provide valuable information for the longer 
term. 
In the field of medicine, cross-sectional studies are primarily used for the generation of 
hypotheses and/or the development of public health policy (regarding certain medical 
conditions). 
Ideally, for it to be truly representative, a cross-sectional study should be based on a large sample 
that has been selected at random
77
. In addition, whenever cross-sectional analyses are being 
performed using responders to a survey, the response rate to the survey must not be connected in 
any way to something that may skew the results
77
 (e.g. a survey should not be exclusively 
completed at a clinic because a disproportionate majority of the responders would then be 
ambulatory patients, rather than bed-ridden patients who would be relatively more debilitated). 
Therefore, survey-based cross-sectional studies should involve multiple methods of survey-
taking, in order to ensure both a high response rate, and a non-biased sample of responders. 
The main advantages of a cross-sectional study design are – (a) it is relatively inexpensive, (b) it 
is less time-consuming than most other study designs, and (c) loss to follow-up does not occur, 
thus allowing many variables to be part of the study (as opposed to a longitudinal study where it 
makes more sense to have a small number of both independent and dependent variables).  
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The main disadvantages of a cross-sectional study design are – (a) two cross-sectional studies on 
the same population (with identical variables) that are conducted at different times may each 
produce significantly different results, (b) results of a single “snapshot” are insufficient to 
concretely prove any etiology, and (c) particularly when chronic diseases are being studied, any 
risk factor that may cause death will not be well-represented among those afflicted with the 
disease. 
Reasons for the cross-sectional study design in this case (taking the available datasets into 
account): The utilization of a cross-sectional design for this particular Study was appropriate due 
to the following main reasons – 
 Despite only historical data being available, the fact that data from Time 1 (in each 
“source” Study) could be satisfactorily extracted made a cross-sectional approach 
possible. 
 Each of the three historical studies were disparate, in terms of times and locations; this 
fact means that any present/future follow-up of the included subjects would be 
unfeasible. 
 The dataset from the PPHS Study did not permit any longitudinal evaluation for 151 out 
of the 165 patients who had answered to the SF-36 instrument (note - the majority of 
those who had been followed, longitudinally had only been measured by the Ferrans and 
Powers Quality of Life Index instrument). 
 The available historical data made using a cross-sectional design to compare QoL across 
the stages of CKD more logical because, for one thing, subjects from the PPHS and EPO-
INTERNATIONAL datasets had Stage 5 CKD (and were on Dialysis) throughout the 
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period of their QoL measurements, whereas many subjects from the CANPREVENT 
dataset did not have the exact same CKD stage throughout the period when their QoL 
was measured, longitudinally. 
 Each of the three studies had followed different criteria for the follow-up of patients 
during longitudinal assessments (for example – the time intervals between consecutive 
surveys and the durations of follow-up were different, in each of the three studies). 
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VIII. METHODS 
VIII.1 STEPS 
The analysis associated with this Study was conducted while following these steps (in sequential 
order) - 
 Although a cross-sectional study cannot prove/disprove any hypothesis, the basic 
objectives of the Study (which had to be borne in mind) were to find out whether the 
following statements may be true, or not - (i) The QoL of patients with Stage 3 CKD is 
the same as the QoL of patients with Stage 4 CKD, and is also the same as the QoL of 
patients with Stage 5 CKD, (ii) the QoL of patients who have both CKD and Diabetes is 
the same as the QoL of patients who have CKD but not Diabetes, and (iii) the QoL of 
patients who have both CKD and symptomatic Heart Disease is the same as the QoL of 
patients who have CKD but not symptomatic Heart Disease. 
 Ethics approval for this project was obtained from the Health Research Ethics Authority 
(HREA), in St. John's, Newfoundland and Labrador.  
 The three (PPHS, CANPREVENT, and EPO-INTERNATIONAL) datasets were 
collected, following which it was determined that, with regards to QoL info, only the SF-
36 Domain scores were common to each of those datasets (note - the “raw” SF-36 scores 
and the recoded “raw” SF-36 scores were only available for subjects in the PPHS and 
CANPREVENT datasets). 
 As the dataset from the EPO-INTERNATIONAL Study was originally in SAS format, it 
was converted into SPSS format (using an option available within the SPSS program), so 
that it could be compatible with the other two “source” datasets. 
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 All QoL-related data points in the three datasets that were obtained via instruments other 
than the SF-36 were deleted because those data points would not be compatible with the 
information obtained via the SF-36 questionnaire (note - different questionnaires 
comprise different questions, dimensions, scoring patterns, etc.). It should be mentioned 
that this requisite led to the removal of (i) 71 out of 236 subjects in the PPHS dataset who 
had had their QoL measured solely by the Ferrans and Powers Quality of Life Index, and 
(ii) all QoL-related scores in the CANPREVENT and EPO-INTERNATIONAL datasets 
that were obtained via questions 12–24 of the KDQOL-SF Instrument (i.e. the questions 
in that instrument that are distinct from the SF-36 questions). 
 With regards to the data points that were only based on the SF-36 instrument, several 
errors of entry and/or calculation were corrected, following a perusal of each subject’s (i) 
“raw” scores, (ii) re-coded “raw” scores, and (iii) Domain scores. This was done, 
specifically with regards to – (i) several random wrongly-calculated GH Domain scores 
in the PPHS dataset, and (ii) the recoded scores for Answer # 3 to SF-36 Questions # 34 
and # 36 in the CANPREVENT dataset (note - this particular answer had been 
consistently recoded as “30”, instead of the correct “50”). 
 Variables from each of the three “source” datasets that would have no bearing on the 
particular research question behind this Study were deleted, except for a few variables 
(e.g. the “raw” SF-36 scores from the PPHS and CANPREVENT datasets), which could 
be used for cross-check purposes, later. 
 Any information (for each subject across all three datasets) that was not collected at 
baseline (i.e. not collected at first “visit”) was deleted; however, for a few subjects in the 
EPO-INTERNATIONAL dataset whose baseline SF-36 Domain scores were unavailable, 
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it was decided to include the SF-36 Domain scores from the subjects' earliest subsequent 
visit when those scores were actually obtained/entered (this was possible and done for 58 
subjects). It was necessary to delete non-baseline information because (i) only baseline 
information was available for most of the subjects in the PPHS dataset who had answered 
to the SF-36 instrument, thereby preventing any worthwhile longitudinal analysis, and (ii) 
in such a cross-sectional evaluation, applying uniform criteria (such as – only including 
QoL info from the time of first “visit”) is more logical, and also more beneficial during 
the interpretation of results. 
 A small number of cases for whom the stage of CKD was not entered at baseline were 
deleted (this was only true for a few cases in the CANPREVENT dataset); it may be 
noted that two subjects in the PPHS dataset had not had their Age and Gender entered, 
but it was decided to include these two cases in the final dataset because they would still 
be useful data points when QoL across the stages of CKD (and across each co-morbidity) 
was compared. 
 The eight variables comprising baseline data that were common to and comparable across 
all three “source” datasets (i.e. Age, Gender, PF Domain score, RP Domain score, VT 
Domain score, SF Domain score, RE Domain score, and MH Domain score) were 
combined in the merged dataset, such that each of these variables would singly 
encompass all of the relevant cases from the “source” datasets. 
 The three variables comprising baseline data that were common to and comparable across 
only the PPHS and CANPREVENT datasets (i.e. BP Domain score, GH Domain score, 
and Recoded SF-2 Question score) were also combined in the merged dataset, such that 
each of these variables would singly encompass all of the relevant cases from the two 
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“source” datasets; it may be noted that while BP and GH Domain scores were also 
present in the EPO-INTERNATIONAL dataset, they were calculated there via the MOS 
SF-36 scoring algorithm (rather than via the RAND SF-36 scoring algorithm, which was 
the method used in the other two datasets), and this fact plus the lack of “raw”/recoded 
“raw” SF-36 scores in the EPO-INTERNATIONAL dataset precluded the use/comparison 
of the differently-calculated Domain scores from the EPO-INTERNATIONAL dataset. 
 Stage of CKD was created as a variable in the merged dataset by (i) labelling all of the 
subjects from the PPHS and EPO-INTERNATIONAL datasets as having Stage 5, and (ii) 
labelling each subject from the CANPREVENT dataset as having the stage of the disease 
that he/she had at the time of his/her first QoL measurement. 
 Diabetes was constituted as a Yes/No variable in the merged dataset after combining (i) 
the subjects from the PPHS and CANPREVENT datasets who were labelled as having 
Diabetes at baseline, and (ii) the subjects in the EPO-INTERNATIONAL dataset for 
whom Diabetic Nephropathy was entered as the cause of their CKD (note - the specific 
type of Diabetes was a variable in only the CANPREVENT dataset, which meant that 
that piece of information was unusable in a merged dataset). 
 Heart Disease was constituted as a new Yes/No variable in the merged dataset, after 
combining the constituents of Heart Disease in the PPHS and CANPREVENT datasets 
that were (i) present as individual variables, (ii) suggestive of symptomatic Heart Disease 
at baseline, and (iii) definitely part of the exclusion criteria during the EPO-
INTERNATIONAL Study (notes – (a) in the merged dataset, all of the EPO-
INTERNATIONAL subjects were labelled as being free of Heart Disease due to the 
exclusion criteria of that particular Study, and (b) Arrhythmia was a variable in both the 
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PPHS and CANPREVENT datasets, but it was decided to completely exclude this 
constituent of Heart Disease from the merged dataset because, unlike all of the other 
Heart-related disorders, Arrhythmia was not part of the exclusion criteria during the EPO-
INTERNATIONAL Study). 
 Four Cardiovascular Disease-related variables comprising baseline data that were 
common to and comparable across the PPHS and CANPREVENT datasets (i.e. Heart 
Failure, Angina, Peripheral Vascular Disease, and Stroke) were also constituted as Yes/No 
variables in the merged dataset, such that each variable would singly encompass all of the 
relevant cases from the two “source” datasets. It should be mentioned that, in the 
CANPREVENT dataset, the variable of Peripheral Vascular Disease had to be constituted 
from these separate variables – (a) Aortic Aneurysm, (b) Gangrene, (c) Intermittent 
Claudication, and (d) Deep Vein Thrombosis (note - while the last mentioned condition is 
the only venous disorder out of the four, it has been recently classified as a Peripheral 
Vascular Disease
32
). 
 The PCS score and the MCS score were individually calculated (using the Norm Based 
Scoring (NBS) calculator) for each subject who had been in the PPHS and 
CANPREVENT datasets. It was not possible to calculate Summary scores for the EPO-
INTERNATIONAL subjects because of (i) the incompatible BP Domain scores and GH 
Domain scores in the EPO-INTERNATIONAL dataset, and (ii) the non-availability of 
“raw”/recoded “raw” SF-36 scores in the EPO-INTERNATIONAL dataset. It may be 
noted that the NBS calculator is freely available online at www.SF-36.org, which is a 
web-site that is run by Qualitymetric Incorporated (i.e. the company that took over all of 
the SF-36 processes from the Medical Outcomes Trust); this calculator can compare the 
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entered Domain scores with Canadian “norm” Domain scores, and then extrapolate that 
information into the two respective Summary scores. The NBS calculator was used to 
calculate the Summary scores because (i) the purchasable proprietary scoring software 
from Qualitymetric Incorporated does not work with RAND SF-36 scoring instructions, 
does not work with SF-36 version 1 answers, and also does not work with Canadian 
“norm” scores (unlike the NBS calculator, which does), (ii) it is important to obtain 
Summary scores, but as this Study is only comparing QoL scores between diseased 
groups, it is not really important to understand how patients’ Domain scores differ from 
“norm” Domain scores, and (iii) the Summary scores for every patient are computed 
identically by the NBS calculator, after first comparing the entered Domain scores with 
the “norm” Domain scores for Canada (this ensures that all calculations are consistent 
with each other, as long as all entered Domain values come via one particular scoring 
algorithm). 
 A variable that indicated the specific cause of CKD could not be included in the merged 
dataset due to it being absent in the CANPREVENT dataset, while a variable that 
indicated a past history of Heart Disease could not be included in the merged dataset due 
to it being absent in the PPHS dataset. 
 A new variable was created in the merged dataset, in order to indicate which original 
Study each individual subject had been extracted from. 
 After being created, the merged dataset was cross-checked for errors, while the codes 
(and answers) for all of the variables were verified to make sure that they were consistent 
with the entries in the respective “source” datasets. For a few variables that were coded 
differently in their respective original datasets, a new coding system was created to 
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encompass all of the subjects in the merged dataset (for example – for medical condition-
related variables in the PPHS dataset, “1” indicated “presence of disease”, while “0” 
indicated “absence of disease”, but the opposite was true in the CANPREVENT dataset; 
in the merged dataset, it was decided to follow the coding system used in the PPHS 
dataset because “0” seemed to be more appropriate for an absence). 
 All of the respective Domain scores (in addition to the two Summary scores, and the 
Recoded SF-2 Question score) would be utilized as Outcome variables because (i) no 
general trend can be expected in advance across the Study sample, with regards to either 
physical health, or mental health, and (ii) nothing concerning this particular Study 
necessitates a restriction of the number of Outcome variables. 
 To permit bivariate comparison of “outcome by age”, the continuous variable of Age was 
broken down into the ordinal variable of Age Category (with six respective categories). 
 Statistical significance was inferred if the p value was <0.05. 
 Descriptive Statistics (overall numbers, means, medians, standard deviations, variances, 
as well as informative bar charts and histograms) were obtained for all of the relevant 
Grouping variables (i.e. Age Category, Gender, Stage of CKD, Diabetes, and Heart 
Disease). 
 Descriptive Statistics (overall numbers, means, medians, standard deviations, variances, 
as well as informative bar charts and histograms) were obtained for all of the relevant 
Outcome variables (i.e. PF Domain score, RP Domain score, VT Domain score, SF 
Domain score, RE Domain score, MH Domain score, BP Domain score, GH Domain 
score, Recoded SF-2 Question score, PCS score, and MCS score). It may be noted that 
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the latter five of these variables were not applicable to subjects from the EPO-
INTERNATIONAL dataset due to reasons that have already been explained. 
 Means were obtained (without any statistical tests) for all of the Outcome variables, 
across each of the Grouping variables, just to get a general sense of the data patterns; 
means were similarly obtained for all of the Outcome variables with the Grouping 
variable being – the Original Study. 
 For the purpose of providing a diagrammatic overview - bar charts were plotted, in order 
to indicate what the means of each of the relevant Outcome variables were for (i) CKD 
patients with no co-morbidities, (ii) CKD patients with Diabetes, but not Heart Disease, 
(iii) CKD patients with Heart Disease, but not Diabetes, and (iv) CKD patients with both 
Diabetes and Heart Disease. 
 Tests of Normality were performed (each Outcome variable versus each Grouping 
variable), in order to determine whether the means/medians were best compared by 
parametric or non-parametric methods. 
 As non-parametric comparisons of medians/ranks were indicated by the Tests of 
Normality, the Kruskal-Wallis Test (for Grouping variables – Age Category and Stage of 
CKD) and the Mann-Whitney U Test (for Grouping variables – Gender, Diabetes, Heart 
Disease, Heart Failure, Angina, Peripheral Vascular Disease, and Stroke) were performed, 
in order to find out which differences in mean ranks were actually significant. It may be 
noted that (i) the Levene’s Non-parametric Test was performed for each comparison, in 
order to test the assumption of “homogeneity of variance”, and (ii) medians for each 
Outcome variable (across each Grouping variable) were also subsequently obtained, in 
order to bolster the results of the non-parametric comparisons of mean ranks. 
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 Multiple Linear Regression models were built for each one of the eleven Outcome 
variables (i.e. PF Domain score, RP Domain score, VT Domain score, SF Domain score, 
RE Domain score, MH Domain score, BP Domain score, GH Domain score, Recoded 
SF-2 Question score, PCS score, and MCS score), in order to see which of the five 
Grouping variables (i.e. Age, Gender, Stage of CKD, Diabetes, and Heart Disease), if 
any, were significant predictors of each of the outcomes. Any non-significant predictors 
of each outcome were eliminated, step-by-step until only the significant predictor(s) 
remained in the final model (for each of the eleven Outcome variables); these final 
models were each subsequently evaluated for validity and “fit”. 
 Results primarily from (i) the Kruskal-Wallis/Mann-Whitney U Tests, and (ii) the 
Multiple Linear Regression models were analysed and interpreted. 
Notes: Other points that are related to the described steps (and worth mentioning) are, as follows 
- 
 The variables of “Heart Failure”, “Angina”, and “PVD” were each defined in the merged 
dataset as – “presence or history of (the respective condition)”; the variable of “Stroke” 
was defined in the merged dataset as - “history of (the condition)”. 
 The only variable in any of the “source” datasets that definitely indicated a Myocardial 
Infarction (in the patient’s history) was the variable called “HeartAttack” in the 
CANPREVENT dataset; therefore, a single variable in the merged dataset to indicate a 
prior Myocardial Infarction was unfeasible, although the “HeartAttack” variable in the 
CANPREVENT dataset did help to constitute the variable of Heart Disease, in the 
merged dataset. 
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 For the purpose of getting a general impression, the mean Age was obtained for each of 
the following – (i) the respective genders, (ii) the respective stages of CKD, (iii) CKD 
patients with and without Diabetes, and (iv) CKD patients with and without Heart 
Disease. 
 For the purpose of getting a general impression, the gender distribution was obtained 
across each of the following – (i) the respective stages of CKD, (ii) CKD patients with 
and without Diabetes, and (iii) CKD patients with and without Heart Disease. 
 For all of the “Yes/No” variables: 0 = No (or Absent) while 1 = Yes (or Present); 
similarly, with regards to Gender: 0 = Female, while 1 = Male. 
 As per the requisites of the respective statistical tests - Age (continuous variable) was 
used as a Predictor variable during the Multiple Linear Regression analyses, while Age 
Category (ordinal variable) was used as a Grouping variable during the Kruskal-Wallis 
Test. 
 Prior to the Multiple Linear Regression analyses, the Stage of CKD variable was re-
coded, as follows: Stage 2/3/4 = 0, and Stage 5 = 1; this was done due to the relatively 
small number of patients with Stage 2 and Stage 4 CKD (i.e. a total of 19 out of the 1135 
patients in the whole sample), and also because it will be of greater interest in clinical 
settings to know if QoL significantly differs between CKD patients on Dialysis and CKD 
patients not on Dialysis. 
 Prior to the Kruskal-Wallis/Mann-Whitney U Tests, the Stage of CKD variable was re-
coded for the single case with Stage 2 CKD, as follows: 2 = 3; this was done because 
there was just one case in the final dataset with Stage 2 CKD, and this was proving 
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difficult to handle, statistically (e.g. during the Levene’s Non-Parametric Test, following 
the comparison of medians/ranks). 
 
VIII.2 SUMMARY OF RELEVANT VARIABLES IN THE FINAL (MERGED) DATASET 
Codes and explanations for the Grouping variables: The respective Grouping variables would 
be, as follows - 
 AGE (continuous variable) = Age in years, at Time 1 (i.e. at baseline). 
 AGEGROUPS (ordinal variable) = Age Category, at Time 1 (i.e. at baseline): 30 years 
and under (coded as “1”), 31 to 40 years (coded as “2”), 41 to 50 years (coded as “3”), 51 
to 60 years (coded as “4”), 61 to 70 years (coded as “5”), and 71 years and over (coded as 
“6”). 
 SEX (binary variable) = Gender: Female (coded as “0”), or Male (coded as “1”). 
 STAGECKD (ordinal variable) = Stage of Chronic Kidney Disease, at Time 1 (i.e. at 
baseline): Stage 2 or mild decrease in kidney function (coded as “2”), Stage 3 or 
moderate decrease in kidney function (coded as “3”), Stage 4 or severe decrease in 
kidney function (coded as “4”), and Stage 5 or Kidney Failure (coded as “5”). 
 DIABETES (binary variable) = Presence/absence of any type of Diabetes, at Time 1 (i.e. 
at baseline): No (coded as “0”), or Yes (coded as “1”). 
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 HEARTDISEASE (binary variable) = Presence/absence of (symptomatic) Heart Disease 
or history of (symptomatic) Heart Disease, at Time 1 (i.e. at baseline): No (coded as “0”), 
or Yes (coded as “1”). 
 HEARTFAILURE (binary variable) = Presence/absence of Congestive Heart Failure or 
history of Congestive Heart Failure, at Time 1 (i.e. at baseline): No (coded as “0”), or Yes 
(coded as “1”). 
 ANGINA (binary variable) = Presence/absence of Angina or history of Angina, at Time 1 
(i.e. at baseline): No (coded as “0”), or Yes (coded as “1”). 
 PVD (binary variable) = Presence/absence of Peripheral Vascular Disease or history of 
Peripheral Vascular Disease, at Time 1 (i.e. at baseline): No (coded as “0”), or Yes (coded 
as “1”). 
 STROKE (binary variable) = Presence/absence of history of Stroke, at Time 1 (i.e. at 
baseline): No (coded as “0”), or Yes (coded as “1”). 
Codes and explanations for the Outcome variables: The respective Outcome variables would 
be, as follows - 
 PHYFUNC (continuous variable, but with mild ordinal characteristics) = Transformed 
Physical Functioning Domain score. 
 ROLEPHY (continuous variable, but with mild ordinal characteristics) = Transformed 
Role-Physical Domain score. 
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 ENERFAT (continuous variable, but with mild ordinal characteristics) = Transformed 
Vitality Domain score. 
 SOCIALFUNC (continuous variable, but with mild ordinal characteristics) = 
Transformed Social Functioning Domain score. 
 ROLEEMOTION (continuous variable, but with moderate ordinal characteristics) = 
Transformed Role-Emotional Domain score. 
 EMOTION (continuous variable, but with mild ordinal characteristics) = Transformed 
Mental Health Domain score. 
 PAIN (continuous variable, but with mild ordinal characteristics) = Transformed Bodily 
Pain Domain score. 
 GENHEALTH (continuous variable, but with mild ordinal characteristics) = Transformed 
General Health Domain score. 
 SF2_RECODED (continuous variable, but with pronounced ordinal characteristics) = 
Transformed score that pertains to the perception of current health, as compared to health 
at a year ago. 
 PCS (continuous variable) = Physical Component Summary score. 
 MCS (continuous variable) = Mental Component Summary score. 
Other variables: The other variables that require a mention would be, as follows - 
 PATIENTID = Patient Identification Number (note – as it was luckily appropriate, the 
respective number for each subject in the merged dataset was exactly the same number 
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that he/she had been designated with in his/her “source” dataset; no number identified 
more than a single patient in the merged dataset). 
 ORIGIN = Original dataset from which the case was obtained: PPHS (coded as “1”), 
EPO-INTERNATIONAL (coded as “2”), and CANPREVENT (coded as “3”). 
 SF1, SF2, SF3, and so on… up to SF36 = The “raw” SF-36 scores (i.e. the answers at 
baseline to each of the thirty-six questions in the SF-36 instrument); it may be noted that 
the questions in the SF-36 instrument are actually numbered, as follows – 1, 2, 3a, 3b, 3c, 
3d, 3e, 3f, 3g, 3h, 3i, 3j, 4a, 4b, 4c, 4d, 5a, 5b, 5c, 6, 7, 8, 9a, 9b, 9c, 9d, 9e, 9f, 9g, 9h, 9i, 
10, 11a, 11b, 11c, and 11d. 
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IX. RESULTS 
IX.1 DESCRIPTIVE STATISTICS 
General numbers for all of the relevant variables 
The numbers of subjects within each of the relevant variables of interest are detailed in the 
following tables - 
TABLE IX.1: Main Grouping variables (at baseline)               
 Age in Years Gender Stage of Chronic Kidney Disease Diabetes Heart Disease               
N 
Valid 1133 1133 1135 1135 1127               
Missing 2 2 0 0 8               
Range 73 N/A 3 N/A N/A               
Minimum 18 N/A 2 N/A N/A               
Maximum 91 N/A 5 N/A N/A               
 
TABLE IX.2: Outcome variables (at baseline) 
             
 PF 
Domain 
score 
RP 
Domain 
score 
VT 
Domain 
score 
SF 
Domain 
score 
RE 
Domain 
score 
MH 
Domain 
score 
BP 
Domain 
score 
GH 
Domain 
score 
Recoded SF-2 
Question score 
PCS 
score 
MCS 
score 
N 
Valid 1135 1135 1135 1135 1135 1135 584 584 584 584 584 
Missing 0 0 0 0 0 0 551 551 551 551 551 
             
Range 100.00 100.00 100.00 100.00 100.00 96.00 100.00 100.00 100.00 61.0 65.7 
            
Percentile - 25 45.00 0.00 40.00 62.50 66.67 64.00 45.00 40.00 50.00 28.73 45.83 
            
Percentile - 50 70.00 50.00 55.00 75.00 100.00 76.00 68.75 55.00 50.00 39.15 53.90 
Percentile - 75 85.00 100.00 73.33 100.00 100.00 88.00 90.00 70.00 75.00 48.53 58.90 
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TABLE IX.3: Other Grouping variables (sub-categories of Cardiovascular Disease, 
at baseline) 
             
 Heart Failure Angina Peripheral Vascular Disease Stroke 
N 
Valid 1127 1127 582 576 
Missing 8 8 553 559 
 
Notes: (1) 2 subjects in the PPHS dataset did not have any information about their ages, or their 
genders entered into said dataset; (2) 8 subjects in the CANPREVENT dataset did not have any 
information about the status of their hearts entered into said dataset (also in said dataset - a 
further 2 subjects had no information entered about the presence/absence of PVD, while a 
further 8 subjects had no information entered about the presence/absence of a history of Stroke); 
(3) The 551 subjects from the EPO-INTERNATIONAL dataset had to constitute “missing” data 
points under the variables of Peripheral Vascular Disease and Stroke because, while these two 
conditions were not part of the exclusion criteria during that particular Study, no information 
about the respective conditions was entered into said dataset, either; (4) The 551 subjects from 
the EPO-INTERNATIONAL dataset had to remain without entries for two Domain scores (BP 
and GH), the Recoded SF-2 Question score, and the two Summary scores because of the different 
scoring algorithm used during the compilation of said dataset, and also because of the total lack 
of “raw” scores in said dataset. 
 
 
General numbers for each Grouping variable (including subdivisions) of interest 
The numbers of subjects within the subdivisions of each relevant Grouping (i.e. Independent) 
variable are detailed in the following table - 
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TABLE IX.4: Sub-classification of each Grouping variable (at baseline) 
 
 
Age Category 
(N = 1133) 
30 and under 70 
31-40 108 
41-50 148 
51-60 238 
61-70 342 
71 and over 227 
Gender 
(N = 1133) 
Male 609 
Female 524 
 
Stage of Chronic Kidney Disease 
(N = 1135) 
Stage 2 1 
Stage 3 400 
Stage 4 18 
Stage 5 716 
Presence of Diabetes 
(N = 1135) 
Yes 281 
No 854 
Presence of Heart Disease 
(N = 1127) 
Yes 164 
No 963 
Presence of Heart Failure 
(N = 1127) 
Yes 67 
No 1060 
Presence of Angina (no Myocardial Infarction) 
(N = 1127) 
Yes 51 
No 1076 
Presence of PVD 
(N = 582) 
Yes 84 
No 498 
History of Stroke 
(N = 576) 
Yes 28 
No 548 
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General view of the mean SF-36 scores across the respective datasets 
The mean SF-36 scores, as per each of the three “source” datasets (individually) are detailed in 
the following tables - 
TABLE IX.5: Means for the scores that are common to all three datasets              
Original Study/Dataset PF RP VT SF RE MH 
PPHS 
Mean 52.09 44.70 47.46 70.15 76.36 74.35 
Std. Deviation 29.31 41.12 24.43 28.68 38.44 20.05 
EPO-INTERNATIONAL 
Mean 65.90 49.62 56.43 72.44 68.30 70.33 
Std. Deviation 24.81 42.05 22.37 24.77 41.09 20.79 
CANPREVENT 
Mean 65.22 64.26 57.29 83.23 82.70 77.93 
Std. Deviation 26.66 40.01 20.58 21.44 32.01 15.87 
Total 
Mean 63.64 54.31 55.44 76.09 74.79 73.72 
Std. Deviation 26.60 41.87 22.28 24.83 38.13 19.31 
 
TABLE IX.6: Means for the scores that are common to only two datasets 
              
Original Study/Dataset BP GH Recoded SF-2 
Question 
PCS MCS 
PPHS 
Mean 68.67 45.58 65.00 34.20 49.22 
Std. Deviation 28.68 22.36 32.53 11.82 12.78 
CANPREVENT 
Mean 66.49 58.08 53.52 39.71 52.03 
Std. Deviation 25.60 20.52 21.69 12.27 10.44 
Total 
Mean 67.11 54.55 56.76 38.15 51.23 
Std. Deviation 26.50 21.78 25.72 12.39 11.21 
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Notes: (1) Subjects from the PPHS dataset had Stage 5 CKD at baseline, having been on 
Hemodialysis therapy for anywhere between 3 and 276 months; (2) Subjects from the EPO-
INTERNATIONAL dataset had Stage 5 CKD at baseline, having been on Hemodialysis therapy 
for 3-18 months; (3) Subjects from the CANPREVENT dataset had CKD Stage 2/3/4 at baseline, 
and were not on any form of Dialysis therapy.  
Observations (with regards to general relationships between each dataset and the SF-36 
scores): Patients on Hemodialysis therapy appear to be clearly scoring lower (compared to non-
Dialysis patients) on the Domains of Role-Physical, Social Functioning, Role-Emotional, and 
General Health, as well as on the Physical Component Summary measure; these patients on 
Hemodialysis therapy also appear to be scoring marginally lower on the Domains of Vitality and 
Mental Health, as well as on the Mental Component Summary measure. There appears to be no 
distinct difference between Dialysis and non-Dialysis patients, with regards to the Domains of 
Physical Functioning and Bodily Pain. There is a suggestion that patients on Hemodialysis 
therapy perceived a greater improvement (in QoL) than those not on Dialysis when current 
health status was compared to health status at one year ago (however, the answer to this question 
was only available from 23% of the total number of patients who had been on Hemodialysis 
therapy). 
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General relationships between mean SF-36 scores and each relevant Grouping variable 
Prior to in-depth statistical analyses, a general idea of how each relevant Grouping variable (i.e. 
Stage of CKD, Age Category, Gender, Diabetes, and Heart Disease) impacts each SF-36 score 
was obtained via the following observations -   
 
TABLE IX.7: Means (across each stage of Chronic Kidney Disease) for the scores that 
are common to all three datasets 
             
STAGE OF CHRONIC KIDNEY 
DISEASE 
PF RP VT SF RE MH 
CKD - STAGE 2 
Mean 50.00 100.00 50.00 100.00 100.00 76.00 
Std. Deviation - - - - - - 
CKD – STAGE 3 
Mean 65.56 64.13 57.35 83.31 82.46 77.72 
Std. Deviation 26.68 40.21 20.82 21.47 32.21 15.97 
CKD – STAGE 4 
Mean 58.49 65.28 56.39 80.56 87.04 82.89 
Std. Deviation 26.66 36.52 15.42 21.53 28.33 13.50 
CKD – STAGE 5 
Mean 62.72 48.49 54.36 71.91 70.16 71.25 
Std. Deviation 26.54 41.86 23.16 25.72 40.61 20.68 
TOTAL 
Mean 63.64 54.31 55.44 76.09 74.79 73.72 
Std. Deviation 26.60 41.87 22.28 24.83 38.13 19.31 
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TABLE IX.8: Means (across each stage of Chronic Kidney Disease) for the 
scores that are common to only two datasets 
             
STAGE OF CHRONIC KIDNEY DISEASE BP GH Recoded SF-2 
Question 
PCS MCS 
CKD – STAGE 2 
Mean 70.00 65.00 50.00 40.80 55.30 
Std. Deviation . . . . . 
CKD – STAGE 3 
Mean 66.88 58.30 53.56 39.90 51.89 
Std. Deviation 25.44 20.52 21.57 12.31 10.52 
CKD – STAGE 4 
Mean 57.78 52.78 52.78 35.46 54.86 
Std. Deviation 29.00 21.09 25.57 11.35 8.62 
CKD – STAGE 5 
Mean 68.67 45.58 65.00 34.20 49.22 
Std. Deviation 28.68 22.36 32.53 11.82 12.78 
TOTAL 
Mean 67.11 54.55 56.76 38.15 51.23 
Std. Deviation 26.50 21.78 25.72 12.39 11.21 
              
Observations (with regards to general relationships between the Stage of CKD and the SF-
36 scores): Neglecting the single patient with Stage 2 CKD, patients with Stage 5 CKD appear to 
be scoring markedly lower on five of the Domains (Role-Physical, Social Functioning, Role–
Emotional, Mental Health, and General Health) when compared to patients with Stage 3 CKD 
and Stage 4 CKD. There is no clear trend across the three stages, with regards to the other three 
Domains (Physical Functioning, Vitality, and Bodily Pain).  Stage 5 CKD patients appear to be 
scoring marginally lower on each of the two Summary measures when compared to patients with 
the preceding two stages of the disease, but on the other hand, Stage 5 CKD patients exhibit 
relatively higher scores when rating their current health (compared to their health at one year 
ago). 
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Stage 4 CKD patients appear to be clearly scoring lower than Stage 3 CKD patients on the 
Domains of Physical Functioning, Bodily Pain, and General Health (but also lower than Stage 5 
CKD patients on the former two Domains, strangely). It should, however, be remembered that (i) 
the latter two Domain scores were measured across a smaller sample, and (ii) the total number of 
Stage 4 CKD patients in the sample was small (N = 18). 
Observations (with regards to general relationships between the Age Category of CKD 
patients and the SF-36 scores): There is no clear trend for any of the 
Domain/Summary/Recoded SF-2 Question scores, across the six Age Categories, except that (i) 
CKD patients >50 years of age appear to have lower Physical Functioning Domain scores when 
compared to CKD patients who are 50 years of age and under, and (ii) CKD patients >50 years 
of age appear to have higher General Health Domain scores, compared to those who are 50 years 
of age and under (however, General Health Domain scores were only obtainable from a smaller 
overall sample, of course). 
[See Appendix VII.1 & VII.2 for Tables] 
Observations (with regards to general relationships between the Gender of CKD patients 
and the SF-36 scores): Male CKD patients appear to have a marginally better QoL on each of 
the Summary measures when compared to female CKD patients. Across the Domain scores (and 
the Recoded SF-2 Question score), there appears to be little difference between male CKD 
patients and female CKD patients, except for the Domains of Physical Functioning, Vitality and 
Bodily Pain where male patients appear to be clearly scoring higher (however, it should be 
emphasized, again that Bodily Pain Domain scores were only obtainable from a smaller overall 
sample). 
[See Appendix VII.3 & VII.4 for Tables] 
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Observations (with regards to general relationships between Diabetes in CKD patients and 
the SF-36 scores): CKD patients with Diabetes appear to score lower than CKD patients without 
Diabetes on the Domains of Physical Functioning, Role–Physical, and General Health, as well as 
on the Physical Component Summary measure; mental health-related QoL in general appears to 
not be clearly impacted by the presence/absence of Diabetes (in CKD patients), though. 
[See Appendix VII.5 & VII.6 for Tables] 
Observations (with regards to general relationships between Heart Disease in CKD patients 
and SF-36 scores): As compared to CKD patients without Heart Disease, CKD patients with 
Heart Disease appear to clearly score lower on all of the primary physical health-related 
Domains (Physical Functioning, Role–Physical, and Bodily Pain), as well as on the General 
Health Domain and the Physical Component Summary measure. However, there is no obvious 
difference between the two groups, regarding the Domain scores that primarily relate to mental 
health, to the Mental Component Summary score, or to the Recoded SF-2 Question score. 
[See Appendix VII.7 & VII.8 for Tables] 
 
IX.2 ILLUSTRATIONS OF THE GENERAL RELATIONSHIPS BETWEEN SF-36 
SCORES AND CHRONIC KIDNEY DISEASE (WITH AND WITHOUT CO-
MORBIDITIES) 
Mean SF-36 scores (for each Domain, each Summary measure, and the Recoded SF-2 Question) 
were compared across the sample, with respect to (i) patients with CKD and no co-morbidities, 
(ii) patients with CKD and Diabetes, (iii) patients with CKD and Heart Disease, and (iv) patients 
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with CKD and both Diabetes and Heart Disease; these are the diagrammatic representations of 
the general relationships - 
 
 
(a) PHYSICAL FUNCTIONING Domain Score [N = 411 (CKD Stages 2-4); N = 716 (CKD 
Stage 5)] 
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(b) ROLE-PHYSICAL Domain Score [N = 411 (CKD Stages 2-4); N = 716 (CKD Stage 5)] 
 
 
 
(c) VITALITY Domain Score [N = 411 (CKD Stages 2-4); N = 716 (CKD Stage 5)] 
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(d) SOCIAL FUNCTIONING Domain Score [N = 411 (CKD Stages 2-4); N = 716 (CKD 
Stage 5)] 
 
 
(e) ROLE-EMOTIONAL Domain Score [N = 411 (CKD Stages 2-4); N = 716 (CKD 
Stage 5)] 
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(f) MENTAL HEALTH Domain Score [N = 411 (CKD Stages 2-4); N = 716 (CKD Stage 5)] 
 
 
(g) BODILY PAIN Domain Score [N = 411 (CKD Stages 2-4); N = 165 (CKD Stage 5)] 
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(h) GENERAL HEALTH Domain Score [N = 411 (CKD Stages 2-4); N = 165 (CKD 
Stage 5)] 
 
(i) PHYSICAL COMPONENT SUMMARY Score [N = 411 (CKD Stages 2-4); N = 165 
(CKD Stage 5)] 
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(j) MENTAL COMPONENT SUMMARY Score [N = 411 (CKD Stages 2-4); N = 165 (CKD 
Stage 5)] 
 
(k) RECODED SF-2 QUESTION Score [N = 411 (CKD Stages 2-4); N = 165 (CKD Stage 5)] 
 
 
143 
IX.3 COMPARISONS OF SF-36 SCORES ACROSS THE GROUPING VARIABLES 
 
As none of the respective distributions were normal, non-parametric comparisons of median SF-
36 scores (along with mean ranks of those scores) were performed across the primary Grouping 
variables of (i) Stage of Chronic Kidney Disease, (ii) Age Category, (iii) Gender, (iv) Diabetes, 
and (v) Heart Disease; the observations are, as follows – 
Kruskal-Wallis Test (Grouping Variable – Stage Of Chronic Kidney Disease) 
 
TABLE IX.9: Significance of each Outcome variable (i.e. each SF-36 score) 
             
 PF RP VT SF RE MH BP GH Recoded SF-2 
Question 
PCS MCS 
Chi-Square 4.362 37.416 5.248 58.772 25.690 26.888 3.480 41.102 22.479 27.295 5.456 
Df 2 2 2 2 2 2 2 2 2 2 2 
Asymp. Sig. .113 .000 .073 .000 .000 .000 .176 .000 .000 .000 .065 
 
TABLE IX.10: Significantly different Mean Ranks and Medians (N = 1135) 
 
             
 Stage of Chronic Kidney Disease N Mean Rank Median 
   
ROLE-PHYSICAL 
CKD STAGES 2-3 401 642.66 75 
   
CKD STAGE 4 18 644.64 75 
   
CKD STAGE 5 716 524.26 50 
   
SOCIAL FUNCTIONING 
CKD STAGES 2-3 401 664.39 100 
   
CKD STAGE 4 18 612.39 87.5 
   
CKD STAGE 5 716 512.90 75 
   
ROLE-EMOTIONAL 
CKD STAGES 2-3 401 621.20 100 
   
CKD STAGE 4 18 652.92 100 
   
CKD STAGE 5 716 536.07 100 
   
 CKD STAGES 2-3 401 
 
627.62 
 
80 
   
MENTAL HEALTH CKD STAGE 4 18 
 
725.92 
 
84 
   
 CKD STAGE 5 716 
 
530.64 
 
76 
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TABLE IX.11: Significantly different Mean Ranks and Medians (N = 584) 
 
 
             
 Stage of Chronic Kidney Disease N Mean Rank Median 
GENERAL HEALTH 
CKD STAGES 2-3 401 322.04 60 
CKD STAGE 4 18 276.81 50 
CKD STAGE 5 165 222.41 40 
RECODED SF-2 QUESTION 
CKD STAGES 2-3 401 273.05 50 
CKD STAGE 4 18 271.72 50 
CKD STAGE 5 165 342.03 75 
PHYSICAL COMPONENT SUMMARY 
CKD STAGES 2-3 401 317.08 41.9 
CKD STAGE 4 18 252.53 35.15 
CKD STAGE 5 165 237.12 34.1 
Notes: (1) The Levene’s Non-parametric Test results proved the Homogeneity of Variance, with 
regards to this analysis; (2) For reasons already discussed, the comparisons of the GH Domain 
Score, the Recoded SF-2 Question score, and the PCS score during this analysis could only be 
performed across a smaller sample (utilizing only 23% of the total number of Hemodialysis 
patients from the whole dataset). 
Observations: The significantly different SF-36 scores are those that pertain to - (1) ROLE-
PHYSICAL (RP): As compared to patients with the preceding stages of CKD, Stage 5 CKD 
patients appear to perceive greater limitations in their life roles (due to their poor physical 
health); (2) SOCIAL FUNCTIONING (SF): In a systematic manner – the worse the stage of the 
disease (CKD), the worse the social functioning abilities appear to be; (3) ROLE-EMOTIONAL 
(RE): Stage 5 CKD patients appear to perceive comparatively greater limitations in their life 
roles (due to their poor emotional health), although the degree of difference across the stages is 
mild; (4) MENTAL HEALTH (MH): Patients with Stage 5 CKD appear to perceive their 
mental/emotional health as being worse, in relation to CKD patients with the preceding stages of 
CKD; (5) GENERAL HEALTH (GH): In a systematic manner – the worse the stage of the 
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disease (CKD), the worse the perceptions of overall health appear to be; (6) RECODED SF-2 
QUESTION: Unlike patients with the preceding stages of CKD, patients with Stage 5 CKD 
appear to perceive their current health status as being better than their health status at one year 
ago (this could be due to Stage 5 CKD patients’ lesser worries of disease progression and/or 
greater satisfaction with their Hemodialysis therapy); (7) PHYSICAL COMPONENT 
SUMMARY (PCS): Patients with Stage 3 CKD appear to perceive their overall physical health 
as being better than that of patients with the subsequent stages of the disease (note – the PCS 
scores for Stage 4 CKD patients and Stage 5 CKD patients in this analysis are similar). 
Kruskal-Wallis Test (Grouping Variable – Age Category) 
 
TABLE IX.12: Significance of each Outcome variable (i.e. each SF-36 score) 
             
 PF RP VT SF RE MH BP GH Recoded SF-2 
Question 
PCS MCS 
Chi-Square 64.624 3.548 6.653 20.058 8.908 32.264 2.170 28.503 11.154 6.543 26.301 
Df 5 5 5 5 5 5 5 5 5 5 5 
Asymp. 
Sig. 
.000 .616 .248 .001 .113 .000 .825 .000 .048 .257 .000 
 
             
Notes: (1) The Levene’s Non-parametric Test results proved the Homogeneity of Variance, with 
regards to this analysis; (2) For reasons already discussed, the comparisons of the GH Domain 
score, the Recoded SF-2 Question score, and the MCS score during this analysis could only be 
performed across a smaller sample (utilizing only 23% of the total number of Hemodialysis 
patients from the whole dataset). 
Observations: The significantly different SF-36 scores are those that pertain to - (1) PHYSICAL 
FUNCTIONING (PF): CKD patients’ physical functioning capacities appear to have a uniformly 
inverse relationship with age (note - almost every older Age Category comprises a worse median 
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PF score than the preceding younger Age Category); (2) SOCIAL FUNCTIONING (SF): Up to 
50 years of age, CKD patients’ social functioning abilities appear to remain stable and similar 
across the various Age Categories, but >50 years of age, these abilities seem to improve with age 
(note - >50 years of age, each older Age Category appears to comprise a better SF score than the 
preceding younger Age Category); (3) MENTAL HEALTH (MH): Mental/emotional health 
appears to have an inverse relationship with age among CKD patients of 50 years of age and 
younger, but the reverse appears to be true among CKD patients who are >50 years of age (note 
– up to 50 years of age, median MH scores appear to get gradually worse when going from one 
Age Category to the next oldest Age Category, but >50 years of age, median MH scores appear 
to get gradually better when going from one Age Category to the next oldest Age Category); (4) 
GENERAL HEALTH (GH): CKD patients who are >60 years of age appear to perceive their 
overall health as being better, in relation to CKD patients who are <60 years of age; (5) 
RECODED SF-2 QUESTION: CKD patients across all of the stated Age Categories seem to rate 
their baseline health status as being similar to their health status at one year ago, with the 
exception of those who were 31-40 years of age who rated their current health status as being 
better (however, the significance level of this SF-2 Question-based variable in the above analysis 
is borderline); (6) MENTAL COMPONENT SUMMARY (MCS): Similar to the afore-mentioned 
observation pertaining to the more specific (and less comprehensive) Mental Health Domain, 
overall mental/emotional health appears to have an inverse relationship with age among CKD 
patients of 50 years of age and younger, but the reverse appears to be true among CKD patients 
who are >50 years of age (note – up to 50 years of age, median MCS scores appear to get 
gradually worse when going from one Age Category to the next oldest Age Category, but >50 
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years of age, median MCS scores appear to get gradually better when going from one Age 
Category to the next oldest Age Category). 
[See Appendix IX.1 for Table] 
Mann-Whitney U Test (Grouping Variable – Gender) 
 
 
TABLE IX.13: Significance of each Outcome variable (i.e. each SF-36 score)              
 PF RP VT SF RE MH BP GH Recoded 
SF-2 
Question 
PCS MCS 
Mann-
Whitney 
U 
132991.5 154404.5 141858.5 153511.0 157714.0 147092.0 34949.5 41250.5 40999.0 38409.5 39211.0 
Wilcoxon 
W 
270541.5 340149.5 279408.5 291061.0 295264.0 284642.0 81920.5 88221.5 79225.0 85380.5 86182.0 
Z -4.846 -.977 -3.230 -1.136 -.395 -2.276 -3.617 -.484 -.646 -1.885 -1.489 
Asymp. 
Sig. (2-
tailed) 
.000 .329 .001 .256 .693 .023 .000 .629 .518 .059 .136 
 
 
             
Notes: (1) The Levene’s Non-parametric Test results proved the Homogeneity of Variance, with 
regards to this analysis; (2) For reasons already discussed, comparisons of the BP Domain score 
and the PCS score during this analysis could only be performed across a smaller sample 
(utilizing only 23% of the total number of Hemodialysis patients from the whole dataset). 
Observations: The significantly different SF-36 scores are those that pertain to - (1) PHYSICAL 
FUNCTIONING (PF): Male CKD patients appear to have greater physical functioning capacities 
when compared to female CKD patients; (2) VITALITY (VT): Male CKD patients appear to 
have more energy (and less fatigue) when compared to female CKD patients; (3) MENTAL 
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HEALTH (MH): Male CKD patients appear to perceive their mental/emotional health as being 
better when compared to female CKD patients; (4) BODILY PAIN (BP): Male CKD patients 
appear to experience less pain when compared to female CKD patients; (5) PHYSICAL 
COMPONENT SUMMARY (PCS): Male CKD patients appear to have better physical health, 
overall when compared to female CKD patients (however, the significance level of the PCS 
variable in the above analysis is borderline). 
[See Appendix IX.2 for Table] 
Mann-Whitney U Test (Grouping Variable – Diabetes) 
 
 
TABLE IX.14: Significance of each Outcome variable (i.e. each SF-36 score)     
 
PF RP VT SF RE MH BP GH Recoded 
SF-2 
Question 
PCS MCS 
   
Mann-
Whitney 
U 
95373.0 112265.5 105778.5 116915.5 119135.5 113896.0 35443.5 29408.0 36517.0 28754.5 34149.5 
   
Wilcoxon 
W 
134994.0 151886.5 145399.5 156536.5 158756.5 478981.0 53209.5 47174.0 115123.0 46520.5 112755.5 
   
Z -5.173 -1.686 -2.988 -.665 -.210 -1.281 -.941 -4.112 -.395 -4.446 -1.614 
   
Asymp. 
Sig. (2-
tailed) 
.000 .092 .003 .506 .834 .200 .347 .000 .693 .000 .107 
   
     
Notes: (1) The Levene’s Non-parametric Test results proved the Homogeneity of Variance, with 
regards to this analysis; (2) For reasons already discussed, comparisons of the GH Domain 
score and the PCS score during this analysis could only be performed across a smaller sample 
(utilizing only 23% of the total number of Hemodialysis patients from the whole dataset). 
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Observations: The significantly different SF-36 scores are those that pertain to - (1) PHYSICAL 
FUNCTIONING (PF): CKD patients with Diabetes appear to have lesser physical functioning 
capacities when compared to CKD patients without Diabetes; (2) VITALITY (VT): CKD 
patients with Diabetes appear to have less energy (and more fatigue) when compared to CKD 
patients without Diabetes; (3) GENERAL HEALTH (GH): CKD patients with Diabetes appear to 
perceive their overall health as being worse, in relation to CKD patients without Diabetes; (4) 
PHYSICAL COMPONENT SUMMARY (PCS): CKD patients with Diabetes appear to have 
worse physical health, overall when compared to CKD patients without Diabetes. 
[See Appendix IX.3 for Table] 
Mann-Whitney U Test (Grouping Variable – Heart Disease) 
TABLE IX.15: Significance of each Outcome variable (i.e. each SF-36 score)              
 PF RP VT SF RE MH BP GH Recoded 
SF-2 
Question 
PCS MCS 
Mann-
Whitney 
U 
55465.5 71402.0 61955.0 74038.0 77123.0 73462.0 29283.0 24380.5 33483.5 23332.5 32104.5 
Wilcoxon 
W 
68995.5 84932.0 75485.0 87568.0 541289.0 537628.0 42813.0 37910.5 118561.5 36862.5 45634.5 
Z -6.110 -2.043 -4.425 -1.319 -.562 -1.432 -2.514 -5.228 -.178 -5.798 -.932 
Asymp. 
Sig. (2-
tailed) 
.000 .041 .000 .187 .574 .152 .012 .000 .859 .000 .351 
              
Notes: (1) The Levene’s Non-parametric Test results proved the Homogeneity of Variance, with 
regards to this analysis; (2) For reasons already discussed, comparisons of the BP Domain 
score, the GH Domain score, and the PCS score during this analysis could only be performed 
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across a smaller sample (utilizing only 23% of the total number of Hemodialysis patients from 
the whole dataset). 
Observations: The significantly different SF-36 scores are those that pertain to - (1) PHYSICAL 
FUNCTIONING (PF): CKD patients with Heart Disease appear to have lesser physical 
functioning capacities when compared to CKD patients without Heart Disease; (2) ROLE-
PHYSICAL (RP): CKD patients with Heart Disease appear to perceive marginally more 
limitations in their life roles (due to their poor physical health), as compared to CKD patients 
without Heart Disease; (3) VITALITY (VT): CKD patients with Heart Disease appear to have 
less energy (and more fatigue) when compared to CKD patients without Heart Disease; (4) 
BODILY PAIN (BP): CKD patients with Heart Disease appear to experience more pain when 
compared to CKD patients without Heart Disease; (5) GENERAL HEALTH (GH): CKD patients 
with Heart Disease appear to perceive their overall health as being worse, in relation to CKD 
patients without Heart Disease; (6) PHYSICAL COMPONENT SUMMARY (PCS): CKD 
patients with Heart Disease appear to have worse physical health, overall when compared to 
CKD patients without Heart Disease. 
[See Appendix IX.4 for Table] 
As the available data permitted comparisons of median/mean rank SF-36 scores across certain 
Grouping variables that were each a subdivision of Cardiovascular Disease, these 
supplementary comparisons were performed, as well; the respective Grouping variables were 
(i) Heart Failure, (ii) Angina, (iii) Peripheral Vascular Disease, and (iv) Stroke, and all 
comparisons were performed while using non-parametric tests due to the respective 
distributions not being normal. 
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Mann-Whitney U Test (Grouping Variable – Heart Failure) 
 
TABLE IX.16: Significance of each Outcome variable (i.e. each SF-36 score)   
 PF RP VT SF RE MH BP GH Recoded 
SF-2 
Question 
PCS MCS 
Mann-
Whitney 
U 
19069.5 27031.0 23737.0 28170.0 34281.0 34083.0 15401.0 10692.5 16421.5 9755.5 15963.5 
Wilcoxon 
W 
21347.5 29309.0 26015.0 30448.0 36559.0 596413.0 17679.0 12970.5 146216.5 12033.5 18241.5 
Z -6.374 -3.415 -4.566 -2.930 -.559 -.554 -1.298 -4.977 -.524 -5.698 -.850 
Asymp. 
Sig. (2-
tailed) 
.000 .001 .000 .003 .576 .580 .194 .000 .600 .000 .396 
 
Notes: (1) The Levene’s Non-parametric Test results proved the Homogeneity of Variance, with 
regards to this analysis; (2) For reasons already discussed, comparisons of the GH Domain 
score and the PCS score during this analysis could only be performed across a smaller sample 
(utilizing only 23% of the total number of Hemodialysis patients from the whole dataset). 
Observations: The significantly different SF-36 scores are those that pertain to - (1) PHYSICAL 
FUNCTIONING (PF): CKD patients with Heart Failure appear to have lesser physical 
functioning capacities when compared to CKD patients without Heart Failure; (2) ROLE-
PHYSICAL (RP): CKD patients with Heart Failure appear to perceive more limitations in their 
life roles (due to their poor physical health), as compared to CKD patients without Heart Failure; 
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(3) VITALITY (VT): CKD patients with Heart Failure appear to have less energy (and more 
fatigue) when compared to CKD patients without Heart Failure; (4) SOCIAL FUNCTIONING 
(SF): CKD patients with Heart Failure appear to have lesser social functioning abilities when 
compared to CKD patients without Heart Failure; (5) GENERAL HEALTH (GH): CKD patients 
with Heart Failure appear to perceive their overall health as being worse, in relation to CKD 
patients without Heart Failure; (6) PHYSICAL COMPONENT SUMMARY (PCS): CKD 
patients with Heart Failure appear to have worse physical health, overall when compared to CKD 
patients without Heart Failure. 
[See Appendix IX.5 for Table] 
Mann-Whitney U Test (Grouping Variable – Angina) 
TABLE IX.17: Significance of each Outcome variable (i.e. each SF-36 score)    
 PF RP VT SF RE MH BP GH Recoded 
SF-2 
Question 
PCS MCS 
Mann-
Whitney 
U 
19162.5 25127.5 20139.5 27226.5 26052.0 26539.5 9866.5 10050.5 11187.5 9291.5 12280.0 
Wilcoxon 
W 
20488.5 26453.5 21465.5 28552.5 27378.0 605965.0 11192.5 11376.5 12513.5 10617.5 13606.0 
Z -3.650 -1.059 -3.221 -.096 -.717 -.397 -3.124 -2.947 -2.065 -3.610 -.976 
Asymp. 
Sig. (2-
tailed) 
.000 .290 .001 .923 .473 .692 .002 .003 .039 .000 .329 
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Notes: (1) The Levene’s Non-parametric Test results proved the Homogeneity of Variance, with 
regards to this analysis; (2) For reasons already discussed, comparisons of the BP Domain 
score, the GH Domain score, the Recoded SF-2 Question score, and the PCS score during this 
analysis could only be performed across a smaller sample (utilizing only 23% of the total 
number of Hemodialysis patients from the whole dataset). 
Observations: The significantly different SF-36 scores are those that pertain to - (1) PHYSICAL 
FUNCTIONING (PF): CKD patients with Angina appear to have lesser physical functioning 
capacities when compared to CKD patients without Angina; (2) VITALITY (VT): CKD patients 
with Angina appear to have less energy (and more fatigue) when compared to CKD patients 
without Angina; (3) BODILY PAIN (BP): CKD patients with Angina appear to experience more 
pain when compared to CKD patients without Angina; (4) GENERAL HEALTH (GH): CKD 
patients with Angina appear to perceive their overall health as being worse, in relation to CKD 
patients without Angina; (5) RECODED SF-2 QUESTION: In relation to health status at one 
year ago, CKD patients with Angina appear to rate their current health status as being marginally 
worse when compared to CKD patients without Angina; (6) PHYSICAL COMPONENT 
SUMMARY (PCS): CKD patients with Angina appear to have worse physical health, overall 
when compared to CKD patients without Angina. 
[See Appendix IX.6 for Table] 
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Mann-Whitney U Test (Grouping Variable – Peripheral Vascular Disease) 
TABLE IX.18: Significance of each Outcome variable (i.e. each SF-36 score)    
 PF RP VT SF RE MH BP GH Recoded 
SF-2 
Question 
PCS MCS 
Mann-
Whitney 
U 
15834.0 17686.0 18528.0 20875.0 20048.5 19235.0 18982.5 16818.5 19398.0 16271.0 20647.0 
Wilcoxon 
W 
19404.0 21256.0 22098.0 24445.0 23618.5 22805.0 22552.5 20388.5 22968.0 19841.0 144898.0 
Z -3.570 -2.373 -1.679 -.030 -.767 -1.184 -1.365 -2.881 -1.135 -3.258 -.189 
Asymp. 
Sig. (2-
tailed) 
.000 .018 .093 .976 .443 .237 .172 .004 .257 .001 .850 
 
Notes: (1) The Levene’s Non-parametric Test results proved the Homogeneity of Variance, with 
regards to this analysis; (2) For reasons already discussed, comparisons of the GH Domain 
score and the PCS score during this analysis could only be performed across a smaller sample 
(utilizing only 23% of the total number of Hemodialysis patients from the whole dataset). 
Observations: The significantly different SF-36 scores are those that pertain to - (1) PHYSICAL 
FUNCTIONING (PF): CKD patients with Peripheral Vascular Disease appear to have lesser 
physical functioning capacities when compared to CKD patients without Peripheral Vascular 
Disease; (2) ROLE-PHYSICAL (RP): CKD patients with Peripheral Vascular Disease appear to 
perceive much more limitations in their life roles (due to their poor physical health), as compared 
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to CKD patients without Peripheral Vascular Disease; (3) GENERAL HEALTH (GH): CKD 
patients with Peripheral Vascular Disease appear to perceive their overall health as being worse, 
in relation to CKD patients without Peripheral Vascular Disease; (4) PHYSICAL COMPONENT 
SUMMARY (PCS): CKD patients with Peripheral Vascular Disease appear to have worse 
physical health, overall when compared to CKD patients without Peripheral Vascular Disease. 
[See Appendix IX.7 for Table] 
 
Mann-Whitney U Test (Grouping Variable – Stroke) 
TABLE IX.19: Significance of each Outcome variable (i.e. each SF-36 score) 
  
 PF RP VT SF RE MH BP GH Recoded 
SF-2 
Question 
PCS MCS 
Mann-
Whitney 
U 
5804.0 6688.0 5814.5 6663.5 7392.5 7347.5 6960.0 6298.0 7596.0 5994.5 7554.5 
Wilcoxon 
W 
6210.0 7094.0 6220.5 7069.5 157818.5 7753.5 7366.0 6704.0 158022.0 6400.5 157980.5 
Z -2.178 -1.199 -2.168 -1.234 -.410 -.379 -.835 -1.603 -.094 -1.953 -.137 
Asymp. 
Sig. (2-
tailed) 
.029 .231 .030 .217 .682 .705 .404 .109 .925 .051 .891 
   
Notes: (1) The Levene’s Non-parametric Test results proved the Homogeneity of Variance, with 
regards to this analysis; (2) For reasons already discussed, comparisons of the PCS score during 
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this analysis could only be performed across a smaller sample (utilizing only 23% of the total 
number of Hemodialysis patients from the whole dataset). 
Observations: The significantly different SF-36 scores are those that pertain to - (1) PHYSICAL 
FUNCTIONING (PF): CKD patients with a history of Stroke appear to have lesser physical 
functioning capacities when compared to CKD patients without a history of Stroke; (2) 
VITALITY (VT): CKD patients with a history of Stroke appear to have less energy (and more 
fatigue) when compared to CKD patients without a history of Stroke; (3) PHYSICAL 
COMPONENT SUMMARY (PCS): CKD patients with a history of Stroke appear to have worse 
physical health, overall when compared to CKD patients without a history of Stroke. 
[See Appendix IX.8 for Table] 
 
IX.4 MULTIPLE LINEAR REGRESSION MODELS 
Prior to the Multiple Linear Regression modelling, it should be noted that a higher score for any 
of the SF-36 Domains/Summary measures (as well as for the Recoded SF-2 Question) indicates a 
superior QoL with respect to that particular Domain/Summary measure (or Recoded SF-2 
Question); therefore, a higher score on the Physical Functioning Domain indicates a greater 
physical functioning capacity, a higher score on the Role-Physical Domain indicates a lower 
level of limitation due to poor physical health, a higher score on the Bodily Pain Domain 
indicates less pain being experienced, and so on. 
The respective Multiple Linear Regression models led to the following observations - 
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TABLE IX.20: Significant predictors of the Physical Functioning Domain score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 96.841 3.745  25.856 .000 89.492 104.190 
Age in Years -.486 .055 -.272 -8.836 .000 -.594 -.378 
Stage of CKD -11.518 1.682 -.209 -6.846 .000 -14.819 -8.217 
Gender 9.644 1.491 .181 6.467 .000 6.718 12.571 
Diabetes -7.017 1.747 -.114 -4.018 .000 -10.444 -3.590 
Heart Disease -10.400 2.194 -.137 -4.740 .000 -14.705 -6.095 
 
Notes: (1) The overall significance of the model is proven (as per the ANOVA Test); (2) Only 
15% of the Variability in the PF Domain score can be explained by Age In Years, Gender, Stage 
Of CKD, Diabetes, and Heart Disease (as per the R
2 
Value); (3) There is no significant 
correlation between residuals (as per the Durbin-Watson Test Value, which is = 1.997); (4) 
Tolerance values are all >0.1 by a large degree, which means that none of the predictors in the 
model are redundant; (5) All values for Cook’s Distance are <1, which indicates that there is no 
undue influence on the model by any leverage point, while <5% of cases have Standardized 
Residuals >2, which indicates that the data fits the model well; (6) Residuals are normally 
distributed (as per the histogram and P-P plots). 
Observations: The significant predictors of the Physical Functioning (PF) Domain score are - 
(1) AGE: As the age of CKD patients increases by one year, the PF score decreases by a factor of 
0.5; (2) GENDER: Male CKD patients have higher PF scores than female CKD patients by a 
factor of 9.6; (3) STAGE OF CKD: Kidney Failure (i.e. Stage 5 CKD) patients have lower PF 
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scores than Non-Kidney Failure CKD patients by a factor of 11.5; (4) DIABETES: CKD patients 
with Diabetes have lower PF scores than CKD patients without Diabetes by a factor of 7; (5) 
HEART DISEASE: CKD patients with Heart Disease have lower PF scores than CKD patients 
without Heart Disease by a factor of 10.4. 
 
TABLE IX.21: Significant predictors of the Role-Physical Domain score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 66.810 2.186  30.563 .000 62.521 71.099 
Stage of CKD -17.201 2.587 -.198 -6.650 .000 -22.276 -12.126 
Heart Disease -11.812 3.531 -.099 -3.345 .001 -18.740 -4.884 
 
Notes: (1) The overall significance of the model is proven (as per the ANOVA Test); (2) Only 4% 
of the Variability in the RP Domain score can be explained by Stage Of CKD and Heart Disease 
(as per the R
2 
Value); (3) There is no significant correlation between residuals (as per the 
Durbin-Watson Test Value, which is = 1.928); (4) Tolerance values are all >0.1 by a large 
degree, which means that none of the predictors in the model are redundant; (5) All values for 
Cook’s Distance are <1, which indicates that there is no undue influence on the model by any 
leverage point, while no cases have Standardized Residuals >2, which indicates that the data fits 
the model well; (6) Residuals are not normally distributed (as per the histogram and P-P plots); 
this means that an assumption has been violated. 
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Observations: The significant predictors of the Role-Physical (RP) Domain score are - (1) 
STAGE OF CKD: Kidney Failure (i.e. Stage 5 CKD) patients have lower RP scores than Non-
Kidney Failure CKD patients by a factor of 17.2; (2) HEART DISEASE: CKD patients with 
Heart Disease have lower RP scores than CKD patients without Heart Disease by a factor of 
11.8. 
(Caveat: Due to the violation of an assumption, as well as due to the low R
2
 value, the results of 
this particular Multiple Linear Regression model are likely to comprise a high degree of 
inaccuracy; therefore, more weight should be give to the results of the non-parametric 
comparisons of medians/mean ranks, with regards to the relationship between (i) the RP Domain 
score and the Stage of CKD, and (ii) the RP Domain score and Heart Disease in CKD patients). 
 
TABLE IX.22: Significant predictors of the Vitality Domain score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 58.364 1.349  43.280 .000 55.718 61.010 
Stage of CKD -5.513 1.393 -.119 -3.958 .000 -8.246 -2.780 
Gender 5.467 1.318 .122 4.148 .000 2.881 8.053 
Diabetes -4.243 1.533 -.083 -2.767 .006 -7.251 -1.234 
Heart Disease -9.406 1.906 -.149 -4.935 .000 -13.145 -5.666 
 
Notes: (1) The overall significance of the model is proven (as per the ANOVA Test); (2) Only 5% 
of the Variability in the VT Domain score can be explained by Gender, Stage Of CKD, Diabetes, 
and Heart Disease (as per the R
2 
Value); (3) There is no significant correlation between residuals 
160 
(as per the Durbin-Watson Test Value, which is = 1.932); (4) Tolerance values are all >0.1 by a 
large degree, which means that none of the predictors in the model are redundant; (5) All values 
for Cook’s Distance are <1, which indicates that there is no undue influence on the model by any 
leverage point, while <5% of cases have Standardized Residuals >2, which indicates that the 
data fits the model well; (6) Residuals are normally distributed (as per the histogram and P-P 
plots). 
Observations: The significant predictors of the Vitality (VT) Domain score are - (1) GENDER: 
Male CKD patients have higher VT scores than female CKD patients by a factor of 5.5; (2) 
STAGE OF CKD: Kidney Failure (i.e. Stage 5 CKD) patients have lower VT scores than Non-
Kidney Failure CKD patients by a factor of 5.5; (3) DIABETES: CKD patients with Diabetes 
have lower VT scores than CKD patients without Diabetes by a factor of 4.2; (4) HEART 
DISEASE: CKD patients with Heart Disease have lower VT scores than CKD patients without 
Heart Disease by a factor of 9.4. 
TABLE IX.23: Significant predictors of the Social Functioning Domain score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 83.215 1.433  58.066 .000 80.403 86.027 
Gender 3.814 1.456 .076 2.619 .009 .957 6.671 
Stage of CKD -12.957 1.535 -.251 -8.440 .000 -15.969 -9.945 
Heart Disease -6.882 2.082 -.097 -3.306 .001 -10.967 -2.798 
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Notes: (1) The overall significance of the model is proven (as per the ANOVA Test); (2) Only 6% 
of the Variability in the SF Domain score can be explained by Gender, Stage Of CKD, and Heart 
Disease (as per the R
2 
Value); (3) There is no significant correlation between residuals (as per 
the Durbin-Watson Test Value, which is = 2.006); (4) Tolerance values are all >0.1 by a large 
degree, which means that none of the predictors in the model are redundant; (5) All values for 
Cook’s Distance are <1, which indicates that there is no undue influence on the model by any 
leverage point, while <5% of cases have Standardized Residuals >2, which indicates that the 
data fits the model well; (6) Residuals are normally distributed (as per the histogram and P-P 
plots). 
Observations: The significant predictors of the Social Functioning (SF) Domain score are - (1) 
GENDER: Male CKD patients have higher SF scores than female CKD patients by a factor of 
3.8; (2) STAGE OF CKD: Kidney Failure (i.e. Stage 5 CKD) patients have lower SF scores than 
Non-Kidney Failure CKD patients by a factor of 13; (3) HEART DISEASE: CKD patients with 
Heart Disease have lower SF scores than CKD patients without Heart Disease by a factor of 6.9. 
 
TABLE IX.24: Significant predictor of the Role-Emotional Domain score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 82.697 1.840  44.944 .000 79.087 86.307 
Stage of CKD -12.539 2.317 -.159 -5.412 .000 -17.084 -7.993 
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Notes: (1) The overall significance of the model is proven (as per the ANOVA Test); (2) Only 3% 
of the Variability in the RE Domain score can be explained by the Stage Of CKD (as per the R
2 
Value); (3) There is no significant correlation between residuals (as per the Durbin-Watson Test 
Value, which is = 1.979); (4) Tolerance values are all >0.1 by a large degree, which means that 
the predictor in the model is not redundant; (5) All values for Cook’s Distance are <1, which 
indicates that there is no undue influence on the model by any leverage point, while <5% of 
cases have Standardized Residuals >2, which indicates that the data fits the model well; (6) 
Residuals are not normally distributed (as per the histogram and P-P plots); this means that an 
assumption has been violated. 
Observations: The only significant predictor of the Role-Emotional (RE) Domain score is - 
STAGE OF CKD: Kidney Failure (i.e. Stage 5 CKD) patients have lower RE scores than Non-
Kidney Failure CKD patients by a factor of 12.5. 
(Caveat: Due to the violation of an assumption, as well as due to the low R
2
 value, the results of 
this particular Multiple Linear Regression model are likely to comprise a high degree of 
inaccuracy; therefore, more weight should be give to the results of the non-parametric 
comparisons of medians/mean ranks, with regards to the relationship between the RE Domain 
score and the Stage of CKD). 
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TABLE IX.25: Significant predictors of the Mental Health Domain score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 70.691 2.864  24.685 .000 65.072 76.310 
Age in Years .085 .041 .066 2.077 .038 .005 .166 
Stage of CKD -6.291 1.277 -.157 -4.928 .000 -8.796 -3.786 
Gender 3.797 1.140 .098 3.332 .001 1.561 6.033 
 
Notes: (1) The overall significance of the model is proven (as per the ANOVA Test); (2) Only 4% 
of the Variability in the MH Domain score can be explained by Age In Years, Gender, and Stage 
Of CKD (as per the R
2 
Value); (3) There is no significant correlation between residuals (as per 
the Durbin-Watson Test Value, which is = 1.911); (4) Tolerance values are all >0.1 by a large 
degree, which means that none of the predictors in the model are redundant; (5) All values for 
Cook’s Distance are <1, which indicates that there is no undue influence on the model by any 
leverage point, while <5% of cases have Standardized Residuals >2, which indicates that the 
data fits the model well; (6) Residuals are normally distributed (as per the histogram and P-P 
plots). 
Observations: The significant predictors of the Mental Health (MH) Domain score are - (1) 
AGE: As the age of CKD patients increases by one year, the MH score increases by a factor of 
0.09 (however, this increase is an all-encompassing average, and greater weight should be given 
to the results of the Kruskal-Wallis Test, which suggest that the relationship between the MH 
score and Age is not quite so monotonic); (2) GENDER: Male CKD patients have higher MH 
scores than female CKD patients by a factor of 3.8; (3) STAGE OF CKD: Kidney Failure (i.e. 
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Stage 5 CKD) patients have lower MH scores than Non-Kidney Failure CKD patients by a factor 
of 6.3. 
 
TABLE IX.26: Significant predictors of the Bodily Pain Domain score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 64.943 1.617  40.173 .000 61.768 68.118 
Gender 8.529 2.194 .161 3.887 .000 4.219 12.839 
Heart Disease -7.472 2.431 -.127 -3.074 .002 -12.247 -2.697 
 
Notes: (1) This model had to exclude the 551 subjects from the EPO-INTERNATIONAL dataset 
for whom scores for this particular Domain were unavailable; (2) The overall significance of the 
model is proven (as per the ANOVA Test); (3) Only 4% of the Variability in the BP Domain score 
can be explained by Gender and Heart Disease (as per the R
2 
Value); (4) There is no significant 
correlation between residuals (as per the Durbin-Watson Test Value, which is = 1.885); (5) 
Tolerance values are all >0.1 by a large degree, which means that none of the predictors in the 
model are redundant; (6) All values for Cook’s Distance are <1, which indicates that there is no 
undue influence on the model by any leverage point, while <5% of cases have Standardized 
Residuals >2, which indicates that the data fits the model well; (7) Residuals are not normally 
distributed (as per the histogram and P-P plots); this means that an assumption has been 
violated. 
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Observations: The significant predictors of the Bodily Pain (BP) Domain score are - (1) 
GENDER: Male CKD patients have higher BP scores than female CKD patients by a factor of 
8.5; (2) HEART DISEASE: CKD patients with Heart Disease have lower BP scores than CKD 
patients without Heart Disease by a factor of 7.5. 
(Caveat: Due to the violation of an assumption, as well as due to the low R
2
 value, the results of 
this particular Multiple Linear Regression model are likely to comprise a high degree of 
inaccuracy; therefore, more weight should be give to the results of the non-parametric 
comparisons of medians/mean ranks, with regards to the relationship between (i) the BP Domain 
score and Gender, and (ii) the BP Domain score and Heart Disease in CKD patients). 
TABLE IX.27: Significant predictors of the General Health Domain score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 36.218 5.280  6.859 .000 25.847 46.589 
Age in Years .401 .080 .198 4.984 .000 .243 .559 
Stage of CKD -9.374 1.918 -.195 -4.888 .000 -13.140 -5.607 
Diabetes -6.103 1.801 -.132 -3.389 .001 -9.640 -2.566 
Heart Disease -9.893 1.936 -.205 -5.110 .000 -13.695 -6.091 
 
Notes: (1) This model had to exclude the 551 subjects from the EPO-INTERNATIONAL dataset 
for whom scores for this particular Domain were unavailable; (2) The overall significance of the 
model is proven (as per the ANOVA Test); (3) Only 16% of the Variability in the GH Domain 
score can be explained by Age In Years, Stage Of CKD, Diabetes, and Heart Disease (as per the 
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R
2 
Value); (4) There is no significant correlation between residuals (as per the Durbin-Watson 
Test Value, which is = 1.968); (5) Tolerance values are all >0.1 by a large degree, which means 
that none of the predictors in the model are redundant; (6) All values for Cook’s Distance are <1, 
which indicates that there is no undue influence on the model by any leverage point, while <5% 
of cases have Standardized Residuals >2, which indicates that the data fits the model well; (7) 
Residuals are normally distributed (as per the histogram and P-P plots). 
Observations: The significant predictors of the General Health (GH) Domain score are - (1) 
AGE: As the age of CKD patients increases by one year, the GH score increases by a factor of 
0.4; (2) STAGE OF CKD.: Kidney Failure (i.e. Stage 5 CKD) patients have lower GH scores 
than Non-Kidney Failure CKD patients by a factor of 9.4; (3) DIABETES: CKD patients with 
Diabetes have lower GH scores than CKD patients without Diabetes by a factor of 6.1; (4) 
HEART DISEASE: CKD patients with Heart Disease have lower GH scores than CKD patients 
without Heart Disease by a factor of 9.9. 
TABLE IX.28: Significant predictor of the Recoded SF-2 Question score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 53.520 1.232 
 
43.439 .000 51.100 55.940 
Stage of CKD 11.480 2.318 .201 4.953 .000 6.927 16.032 
 
Notes: (1) This model had to exclude the 551 subjects from the EPO-INTERNATIONAL dataset 
for whom scores for this particular Question were unavailable; (2) The overall significance of 
the model is proven (as per the ANOVA Test); (3) Only 4% of the Variability in the Recoded SF-2 
Question score can be explained by Stage Of CKD (as per the R
2 
Value); (4) There is no 
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significant correlation between residuals (as per the Durbin-Watson Test Value, which is = 
2.163); (5) Tolerance values are all >0.1 by a large degree, which means that the predictor in the 
model is not redundant; (6) All values for Cook’s Distance are <1, which indicates that there is 
no undue influence on the model by any leverage point, while <5% of cases have Standardized 
Residuals >2, which indicates that the data fits the model well; (7) Residuals are normally 
distributed (as per the histogram and P-P plots). 
Observations: The only significant predictor of the Recoded SF-2 Question score is - STAGE 
OF CKD: When compared to Non-Kidney Failure CKD patients, Kidney Failure (i.e. Stage 5 
CKD) patients are more likely (by a factor of 11.5) to rate their current overall health as being 
better than their overall health at one year ago; this could possibly be due to perceived success of 
their Hemodialysis therapy (along with adequate adjustments of their lives around said therapy). 
 
TABLE IX.29: Significant predictors of the Physical Component Summary score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 47.124 3.119 
 15.11
0 
.000 40.998 53.249 
Age in Years -.102 .047 -.088 -2.158 .031 -.196 -.009 
Gender 3.541 .990 .142 3.576 .000 1.596 5.486 
Stage of CKD -5.113 1.125 -.185 -4.545 .000 -7.323 -2.903 
Diabetes -4.106 1.056 -.155 -3.888 .000 -6.181 -2.032 
Heart Disease -4.959 1.134 -.180 -4.373 .000 -7.187 -2.731 
168 
Notes: (1) This model had to exclude the 551 subjects from the EPO-INTERNATIONAL dataset 
for whom scores for this particular measure were incalculable; (2) The overall significance of 
the model is proven (as per the ANOVA Test); (3) Only 12% of the Variability in the PCS score 
can be explained by Age In Years, Gender, Stage Of CKD, Diabetes, and Heart Disease (as per 
the R
2 
Value); (4) There is no significant correlation between residuals (as per the Durbin-
Watson Test Value, which is = 1.969); (5) Tolerance values are all >0.1 by a large degree, which 
means that none of the predictors in the model are redundant; (6) All values for Cook’s Distance 
are <1, which indicates that there is no undue influence on the model by any leverage point, 
while <5% of cases have Standardized Residuals >2, which indicates that the data fits the model 
well; (7) Residuals are normally distributed (as per the histogram and P-P plots). 
Observations: The significant predictors of the Physical Component Summary (PCS) score are - 
(1) AGE: As the age of CKD patients increases by one year, the PCS score decreases by a factor 
of 0.1; (2) GENDER: Male CKD patients have higher PCS scores than female CKD patients by a 
factor of 3.5; (3) STAGE OF CKD: Kidney Failure (i.e. Stage 5 CKD) patients have lower PCS 
scores than Non-Kidney Failure CKD patients by a factor of 5.1; (4) DIABETES: CKD patients 
with Diabetes have lower PCS scores than CKD patients without Diabetes by a factor of 4.1; (5) 
HEART DISEASE: CKD patients with Heart Disease have lower PCS scores than CKD patients 
without Heart Disease by a factor of 5. 
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TABLE IX.30: Significant predictors of the Mental Component Summary score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95% Confidence Interval for B 
B Std. Error Beta Lower Bound Upper Bound 
 
(Constant) 39.508 2.854  13.843 .000 33.902 45.113 
Age in Years .193 .043 .184 4.465 .000 .108 .278 
Stage of CKD -2.129 1.027 -.085 -2.073 .039 -4.146 -.112 
 
Notes: (1) This model had to exclude the 551 subjects from the EPO-INTERNATIONAL dataset 
for whom scores for this particular measure were incalculable; (2) The overall significance of 
the model is proven (as per the ANOVA Test); (3) Only 4% of the Variability in the MCS score 
can be explained by Age In Years and Stage Of CKD (as per the R
2 
Value); (4) There is no 
significant correlation between residuals (as per the Durbin-Watson Test Value, which is = 
1.907); (5) Tolerance values are all >0.1 by a large degree, which means that none of the 
predictors in the model are redundant; (6) All values for Cook’s Distance are <1, which indicates 
that there is no undue influence on the model by any leverage point, but 6% of cases have 
Standardized Residuals >2, which indicates that the data may not perfectly fit the model 
(however, the value of 6% is only marginally above the ideal value of something <5%); (7) 
Residuals are normally distributed (as per the histogram and P-P plots). 
Observations: The significant predictors of the Mental Component Summary (MCS) score are - 
(1) AGE: As the age of CKD patients increases by one year, the MCS score increases by a factor 
of 0.2 (however, this increase is an all-encompassing average, and greater weight should be 
given to the results of the Kruskal-Wallis Test, which suggest that the relationship between the 
MCS score and Age is not quite so monotonic); (2) STAGE OF CKD: Kidney Failure (i.e. Stage 
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5 CKD) patients have lower MCS scores than Non-Kidney Failure CKD patients by a factor of 
2.1.  
 
Footnote to Chapter IX:  
 Appendix V – Histograms for the respective Outcome variables in the analyses. 
 Appendix VI – Means of each Demographic Factor across each of the other Grouping 
variables of interest. 
 Appendix VII - General relationships between mean SF-36 scores and the Grouping 
variables of (i) Age Category, (ii) Gender, (iii) Diabetes, and (iv) Heart Disease. 
 Appendix VIII – Tests of Normality (Kolmogorov-Smirnov and Shapiro-Wilk), prior to 
comparisons of mean ranks/medians. 
 Appendix IX – Comparisons of SF-36 mean rank/median scores across the Grouping 
variables of (i) Age Category, (ii) Gender, (iii) Diabetes, (iv) Heart Disease, (v) Heart 
Failure, (vi) Angina, (vii) Peripheral Vascular Disease, and (viii) Stroke. 
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X. DISCUSSION 
X.1 SAMPLE CHARACTERISTICS 
With regards to the general characteristics of the sample used for this Study, the following 
important points should be appreciated - 
 The mean age of the Study sample (57 years) was lower than the average age of CKD 
patients in general,
78
 and the mean age of Stage 5 CKD patients in the Study sample (53 
years) was lower than the average age of Stage 5 CKD patients in general.
78
 Although 
CKD can occur at any age, the risk for CKD increases with age; CKD is predominantly 
seen in those who are 60 years and over
78
, and the average age of CKD patients generally 
increases, as the stage of the disease worsens (note - as life expectancy has increased, 
approximately 25% of individuals aged >60 years in the U.S. are now affected by CKD, 
while CKD rates among those <40 years of age has remained virtually unchanged during 
the past two decades
78
). However, the relatively lower mean age of the Study sample 
could be explained by the exclusion of Heart Disease patients from the EPO-
INTERNATIONAL Study, which provided 48.6% of the patients for this particular Study 
(note - CKD patients with one or more co-morbidities are generally older than CKD 
patients without a co-morbidity
79
). It may be emphasized that the mean age of non-Stage 
5 CKD patients in the Study sample was in line with general trends. 
 As per trends among CKD patients in Canada and elsewhere80, the mean age of males in 
the Study sample was marginally lower than the mean age of females in the Study sample 
(with 57 years being the approximate mean age of each of the gender-based groups). 
172 
 As per trends among CKD patients in Canada and elsewhere80, patients with Diabetes 
and/or Heart Disease were older when compared to patients without either one of those 
co-morbidities (in the Study sample). 
 There were more males than females (by approximately 7.5%) in the Study sample, 
which is dissimilar to the general gender-based prevalence of CKD; in various historical 
studies, CKD has been reported to be more common in females by between 2 and 7%.
81
 
However, the fact that Stage 5 CKD patients outnumbered Stage 2-4 CKD patients 
(63.1% to 36.9%) within the Study sample could explain the greater number of males in 
said sample (note – while CKD is more prevalent among females in general, the 
proportion of males increases at more advanced stages
82
, and males have been reported to 
constitute a majority of the patients on Dialysis
83
). It may be emphasized that (just as in 
general trends) the majority of non-Stage 5 CKD patients in the Study sample were 
female. 
 As per trends in Canada and elsewhere among patients with Diabetes and/or Heart 
Disease
84,85
, males constituted a majority among patients having one or both of those 
conditions (in the Study sample). Therefore (based on these variables, at least), the 
sample analyzed during this Study is similar to most populations with CKD, with the 
exception of the many patients on Dialysis who were free of Heart Disease. 
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X.2 RESULTS 
It was determined that performing non-parametric comparisons of medians/mean ranks, and then 
verifying/substantiating the results of those comparisons via Multiple Linear Regression analyses 
would be most prudent. 
Comparisons of medians/mean ranks: The non-parametric tests (Kruskal-Wallis or Mann-
Whitney U) were the primary statistical tests performed, and they resulted in observations that 
should be dissected, as follows - 
 Similar to the results from most of the studies that were summarized in Chapter VI, Stage 
5 CKD patients had (i) significantly more role limitations due to poor physical health, (ii) 
significantly lower perceptions of their general health, and (iii) significantly lower PCS 
scores, as compared to patients with the preceding stages of CKD. While Stage 5 CKD 
patients also exhibited significantly greater negative impacts on their social functioning 
abilities and mental health (as compared to patients with Stage 2-4 CKD), these 
observations are not consistent with the results of most similar studies from the past; 
however, a noteworthy exception is the previously-summarized Swedish Study by Pagels 
et al. in 2012, which did indeed lead to such results (i.e. significant negative impacts on 
aspects of mental health-related QoL). The GH and SF Domain scores, as well as the 
PCS score were (i) significantly lower for Stage 4 CKD patients when compared to Stage 
3 CKD patients, and (ii) significantly lower for Stage 5 CKD patients when compared to 
Stage 4 CKD patients; even though the total number of Stage 4 CKD patients in the Study 
sample was very small, the stage-wise decrease in physical health-related QoL is 
consistent with the results of most of the studies that were summarized in Chapter VI. 
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While CKD is generally associated with fatigue (and, therefore, loss of energy), the fact 
that the VT Domain score was not significantly impacted by the stage of the disease 
suggests that the degree of fatigue does not differ greatly across the various stages of 
CKD. Another interesting observation was that when current health status was compared 
with health status at a year ago, Stage 5 CKD patients rated their current health status as 
being better to a greater extent than Stage 2-4 CKD patients did (note - Stage 2-4 CKD 
patients provided a significantly lower rating on this matter); this could be because the 
vast majority of Stage 5 CKD patients in the Study sample had already been on 
Hemodialysis therapy for more than 3 months, thereby having had sufficient time to get 
accustomed to a beneficial therapy (in addition – unlike patients with the preceding 
stages of CKD, Stage 5 CKD patients may value the stability that comes with the natural 
end of disease progression).  
 As observed during similar studies from the past, the co-morbidities of Diabetes and 
Heart Disease were both associated with further (significant) reductions in physical 
health-related QoL (with the PF, GH, and VT Domains, as well as the PCS measure being 
negatively impacted by Diabetes and Heart Disease, respectively); it ought to be 
remembered that the GH and VT Domains each comprise aspects of both physical health 
and mental health, which means that the impacts of the co-morbidities on these Domains 
is not unexpected. Perceptions of pain were significantly higher in those CKD patients 
with Heart Disease, which is explained by the fact that a majority (64%) of the Heart 
Disease patients in the Study sample had been diagnosed with pain-associated IHD (i.e. 
Angina and/or Myocardial Infarction), prior to their baseline QoL measurement. As 
would be expected, CKD patients with any one of the analysable components of 
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Cardiovascular Disease (i.e. Heart Failure, Angina, PVD and Stroke) had significantly 
worse physical health-related QoL than CKD patients who did not have the respective 
component of Cardiovascular Disease; it may also be mentioned that Angina, as 
expected, was the only one of the four named conditions to be significantly associated 
with increased perceptions of pain (note – while PVD is also often associated with pain, it 
is possible that an impressive number of patients in the CANPREVENT dataset who had 
a diagnosis of PVD in their histories did not have active symptoms of PVD at the time of 
baseline QoL measurement; however, there was no way to verify this supposition). 
 The demographic factor of Age appeared to significantly impact the QoL of CKD patients 
in ways that are not totally consistent with the results of past studies on the topic. Mental 
health-related QoL (including social functions) was observed to be progressively worse in 
every succeeding group of older patients within the <50 years of age subset, but mental 
health-related QoL (including social functions) was then seen to be progressively better 
in every succeeding group of older patients within the >50 years of age subset; this could 
be due to patients discovering better coping mechanisms (to deal with CKD-associated 
discomforts/disabilities) as time passes, after struggling to cope during their early years 
with the disease. On the other hand, physical functions (as per the PF Domain score) 
were observed to be progressively worse in absolutely every succeeding group of older 
patients; this is consistent with logical expectations because increasing age is naturally 
associated with decreasing physical capabilities, but even this observation is not totally 
consistent with the existing literature on CKD patients. While patients >60 years of age 
seemed to perceive their general health as being better when compared to patients <60 
years of age, this appears to be due to a correlation with the mental health-related QoL 
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trends within the Study sample (note – the GH Domain score reflects perceptions of both 
physical health and mental health). A caveat worth bearing in mind is that the EPO-
INTERNATIONAL dataset contained individuals who were relatively younger and 
relatively healthier (at least, in terms of co-morbidities); this fact could have led to the 
results of this Study being rather different from the results of prior studies that looked 
into age-based effects on CKD patients’ QoL. 
 Male CKD patients appeared to experience a significantly better QoL, across the board 
when compared to female CKD patients (with the difference in physical health-related 
QoL being slightly greater than the difference in mental health-related QoL). This 
observation is consistent with not only the existing literature that pertains to QoL in CKD 
patients, but also that which pertains to QoL in patients with other chronic diseases (the 
previously-summarized publication by Hopman et al. from 2009 is one such piece of 
evidence). 
Regression analyses: Multiple Linear Regression models were principally built to strengthen the 
results of the non-parametric comparisons of medians/mean ranks, although any additional 
pertinent information was looked for in the models, as well. Prior to discussing the results of the 
Multiple Linear Regression analyses, it is worth emphasizing that for five Outcome variables 
(i.e. BP Domain score, GH Domain score, PCS score, MCS score, and Recoded SF-2 Question 
score), the 551 subjects from the EPO-INTERNATIONAL Study could not be part of the 
analyses; in addition, SF-36 Domain scores (especially those for RP, BP, SF and RE) and the 
Recoded SF-2 Question score have ordinal characteristics, which impede truly accurate results 
coming out of those Multiple Linear Regression models. In any case, the results of the Multiple 
Linear Regression analyses should be dissected, as follows - 
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 Stage of CKD was a significant predictor for all of the SF-36 Domain scores (except the 
BP score), as well as for both of the Summary scores, and the Recoded SF-2 Question 
score. Each of the significantly predicted SF-36 scores worsened along with the 
worsening of the Stage of CKD, except for the Recoded SF-36 Question score (which did 
the reverse, thus being consistent with the previously-explained results of the Kruskal-
Wallis Test). It may be noted that pain is not usually associated with CKD unless there is 
an associated pain-inducing co-morbidity; therefore, it is not surprising that perceptions 
of pain are not significantly impacted in CKD patients (whatever the stage of the disease 
might be). Overall, these results corroborate the results of the non-parametric 
comparisons of medians/mean ranks where Stage of CKD was the variable (out of all of 
the Grouping variables) that led to significantly different scores for the greatest number 
of Outcome variables. 
 Similar to the results of the non-parametric comparisons of medians/mean ranks, co-
morbidities were generally associated with further worsening of physical health-related 
QoL among CKD patients (note - both Diabetes and Heart Disease were significantly 
predictors of the PF, VT, and GH Domain scores, plus the PCS score, while Heart 
Disease alone was a significant predictor of the RP and BP Domain scores). The fact that 
Heart Disease and not Diabetes was significantly associated with worse BP Domain 
scores is, once again, likely because IHD was the commonest form of Heart Disease in 
patients labelled as having Heart Disease (note - 64% of Heart Disease patients in the 
Study sample had had pain-associated IHD). In addition, the fact that Heart Disease 
(compared to Diabetes) was associated with greater negative impacts on QoL could be 
explained by (i) the comparatively more debilitating nature of the Heart Disease 
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symptomatology, and (ii) a large percentage (46.3%) of Diabetics in the Study sample not 
being on Dialysis therapy (note – Dialysis therapy is specifically purported to lead to 
severe impacts on the QoL of Diabetics
86
). 
 Consistent with the observations derived from the non-parametric comparisons of 
medians/mean ranks, increasing age among CKD patients was significantly associated 
with (i) a worsening of physical functions (i.e. the PF Domain score), and (ii) an 
improvement in some aspects of mental health (however, this improvement in mental 
health-related QoL shown by the Regression models is just an overall trend, and is less 
informative than the Kruskal-Wallis Test, which indicated one trend for those <50 years 
of age, and another trend for those >50 years of age). 
 Just as indicated by the non-parametric comparisons of medians/mean ranks, male CKD 
patients perceived their QoL to be significantly better than that of female CKD patients; 
this was observed across the board with a slightly greater difference between the genders 
being noted in aspects of physical health-related QoL. 
It should be noted that, as per each Regression model, the Variability in each of the SF-36 scores 
was due in relatively small part (range: 3-16%) to the significant predictor variables (i.e. one or 
more of - Age, Gender, Stage of CKD, Diabetes, and Heart Disease); this indicates that there are 
other factors, which affect CKD patients' QoL to a great degree (and, those factors are 
potentially stronger predictors of QoL than any of the five predictor variables used during these 
analyses). However, it should be emphasized that the Variability in three SF-36 scores (i.e. the 
PF Domain score, the GH Domain score, and the PCS score) was explained by the significant 
predictor variables to a much greater extent (i.e. 12-16%) when compared to each of the other 
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SF-36 scores, for which the Variability was explained by the significant predictor variables to a 
very small extent (i.e. 3-6%); this observation also helps one to infer that the stages of CKD and 
the main CKD-associated co-morbidities lead to greater impacts on physical health-related QoL, 
rather than mental health-related QoL. 
 
X.3 LIMITATIONS 
While interpreting the results of the various analyses performed during this particular Study, it is 
also important to consider the limitations of the Study, which include the following - 
 As a result of being based on historical data from three separate studies, the definitions of 
several variables of interest were not identical across the three original datasets; this 
limitation led to - (a) the possibility that Diabetics from the EPO-INTERNATIONAL 
Study were slightly under-represented, in the merged dataset, (b) the possibility that some 
patients with no symptoms of Heart Disease during baseline QoL measurement were 
labelled as symptomatic Heart Disease patients, in the merged dataset (note – the 
opposite form of this misclassification was also possible, but much less likely), (c) a 
disproportionately large number of patients in the merged dataset being free of Heart 
Disease (as a result of the exclusion criteria of the EPO-INTERNATIONAL Study), and 
(d) the SF-36 Domain scores for GH and BP being absent for 48.6% of the patients in the 
merged dataset due to the different scoring algorithm used during the EPO-
INTERNATIONAL Study. 
 Not only were the BP and GH Domain scores unavailable for 48.6% of patients in the 
merged dataset, the two Summary scores and the Recoded SF-2 Question score were also 
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unavailable for those same patients; this was due to both the lack of “raw” SF-36 scores 
from the EPO-INTERNATIONAL Study, as well as the different SF-36 scoring algorithm 
used during that particular Study (note – the scoring algorithm used during both the 
PPHS and CANPREVENT studies is the recommended scoring algorithm, as per the 
relevant literature
56
). 
 Due to the small proportion of patients with Stage 2 CKD (0.09%) and Stage 4 CKD 
(1.6%) in the merged dataset, this Study was basically a comparison of QoL between 
Stage 3 CKD patients and Stage 5 CKD patients; in addition, the Stage 5 CKD patients in 
this Study were all on Hemodialysis therapy, which means that that particular stage of 
CKD was not as well represented as it could have been (note – in general, Stage 5 CKD 
patients would also include those who are on other forms of Renal Replacement Therapy, 
as well as those who are yet to be started on a form of Renal Replacement Therapy). 
 The mean age of the Study sample was lower than the mean age of CKD patients in 
general; this difference was accentuated, with regards to Stage 5 CKD patients in the 
sample. 
 There was a majority of males in the Study sample, which is different from the gender-
based distribution among CKD patients in the general population. 
 The disparate settings in which data had been collected during the original studies may 
have impacted subjective evaluations of health differently, thus leading to widely 
different QoL scores, even among patients with similar symptoms (note – each of the 
three original studies, in turn, involved data collection from several different locations). 
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 In the merged dataset, only 12% of the total number of patients on Hemodialysis (i.e. 
those with Stage 5 CKD) had been started on Hemodialysis therapy >18 months prior to 
their baseline QoL measurement; this meant that a meaningful comparison of QoL 
between incident and prevalent Hemodialysis patients was untenable. 
 The usual disadvantages of a cross-sectional study (such as - not being able to make 
inferences about cause, not being able to track QoL along with the course of illness, etc.) 
were present, as well. 
 Any analysis that is based on a QoL-measuring instrument involves certain inherent 
limitations (such as – “ceiling” and “floor” effects of the instrument, subjective 
evaluations that are based on each patient's surroundings and/or beliefs, perceptions of 
health that derive only from the diagnosis that the patient is labelled with, patients' 
differing adaptations to similar symptoms, etc.); these issues mean that caution should be 
applied when interpreting the results. 
 The QoL data was all based on a generic QoL-measuring instrument (i.e. the SF-36), 
which meant that many specific dimensions of health (e.g. Sleep, Cognitive Functions, 
Sexual Functioning, etc.) could not be assessed, even though they also contribute to a 
patient's QoL; in addition, variables that often influence mental health-related QoL (e.g. 
self-management, psycho-social supports, etc.) could not be part of the Study. 
 The SF-36 Domain scores are not purely continuous variables because they contain 
ordinal characteristics, too; therefore, caution is required while interpreting the results of 
the Multiple Linear Regression analyses that were performed to predict each SF-36 
Domain score (note - Discriminant Function tests for those semi-ordinal variables could 
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be performed, later, but said tests would be superfluous in this case because the results of 
the non-parametric comparisons of medians/mean ranks take precedence over and carry 
more weight than the results of the Regression analyses). 
 
X.4 STRENGTHS 
The obvious strengths of this particular Study must also be stated, and they are - 
 The total sample size of 1135 subjects was large, especially in comparison with previous 
studies that have specifically compared QoL among CKD patients (note – even excluding 
the subjects from the EPO-INTERNATIONAL Study for whom some of the SF-36 scores 
were unavailable, the remaining sample size of 584 is still relatively large). 
 The fact that the data were collected via three different studies (which were each 
conducted in vastly different settings) can also be called a strength because the resultant 
final sample will potentially consist of a more diverse population than would otherwise 
be the case. 
 A Study that compares QoL between predominantly Stage 3 and Stage 5 CKD patients 
(with very few Stage 2 and Stage 4 CKD patients included in the Study) is still clinically 
important, considering that the majority of reported CKD cases (i.e. 5-6% of the general 
population) have stages 3-5 CKD.
82
 
 A look into how the co-morbidities of Diabetes and Heart Disease impact the QoL of 
CKD patients has not been performed in such an elaborate manner, to date; this objective 
is clinically important because of the extra risk of disability/death that is involved with 
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the co-morbidities (note - Heart Disease is the leading cause of mortality in CKD 
patients, and for CKD patients, the risk of dying from Heart Disease is greater than the 
risk of ever requiring Renal Replacement Therapy
82
). 
 The use of more than one form of statistical analyses to relate QoL dimensions to CKD 
(with/without co-morbidities) provides an extra layer of validation to the final results. 
 
X.5 INCIDENTAL OBSERVATIONS 
Even though this particular Study was never intended to compare the QoL of CKD patients with 
the QoL of a non-diseased population sample (and, even though the two Summary scores could 
not be calculated for 48.6% of the patients in the Study sample due to already-stated reasons), it 
is still worth pointing out the following incidental observations - 
 The mean PCS score for the sample used during this Study was 38.2, while the mean 
MCS score for the sample was 51.2; this suggests that CKD patients generally have a 
much lower physical health-related QoL than the Canadian “norm” population, while the 
same CKD patients apparently have a mental health-related QoL that is mildly but not 
significantly higher than that of the Canadian “norm” population (note – as per the 
Canadian Norm-Based Scores that were utilized for computations during this Study, 50 
indicates the Canadian “norm” population's mean score for the PCS and MCS measures, 
respectively). These observations are also consistent with findings listed in the 
previously-summarized Study by Hopman et al. (published in 2009). 
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 Taking the afore-mentioned observation a bit further, it should also be stated that the 
mean PCS scores were well below 50, across all of the stages of CKD; on the other hand, 
the mean MCS score for Stage 5 CKD patients was slightly <50 while the mean MCS 
scores for patients with the preceding stages of CKD was slightly >50 (and, this could 
indicate a mild negative impact of Dialysis therapy on mental health-related QoL). 
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XI. CONCLUSIONS 
As a result of the observations obtained via this particular Study, the following points may be 
inferred - 
 Stage 5 CKD is associated with a significantly worse physical health-related QoL, as 
compared to Stage 3 CKD (and, there is also a suggestion that progression of CKD from 
stage to stage is directly associated with worsening of physical health-related QoL). 
 The co-morbidities of Diabetes and Heart Disease are associated with further decrements 
of physical health-related QoL in CKD patients (and, Heart Disease is associated with 
slightly greater negative impacts on QoL, as compared to Diabetes). 
 Female CKD patients are associated with significantly worse physical and mental health-
related QoL, as compared to male CKD patients (when the gender-based comparison 
groups are similar, in terms of age-range and prevalent co-morbidities). 
 CKD patients over 50 years of age are associated with mildly better mental health-related 
QoL, as compared to CKD patients below 50 years of age. 
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XII. RECOMMENDATIONS 
With the conclusions of this Study in mind, the following recommendations may be put forward - 
 From the perspective of a clinician, it is clear that substantive efforts must be made to 
prevent the progression of CKD towards Stage 5, and great efforts must also be made to 
prevent/control the co-morbidities of Diabetes and Heart Disease; when this approach is 
successful, not only would the QoL of affected patients be negatively impacted to a lesser 
degree, but the burden and cost of care would also come down because more 
advanced/complicated disease entails more time and effort on the part of healthcare 
workers. 
 From the perspective of a present or future CKD patient, more information can and 
should be accessed by him/her, with regards to how CKD during each of its stages will 
potentially affect his/her QoL (and therefore, his/her physical abilities, family life, work 
situation, employment prospects, etc.). 
 From the perspective of a health policy-maker, investing more to prevent the progression 
of CKD towards Stage 5 would be wise because (i) the poor QoL of Stage 5 CKD 
patients greatly reduces their productivity in the community, and (ii) the cost involved 
with Renal Replacement Therapy (which is the usual treatment for Stage 5 CKD patients) 
is far higher than the costs involved with other treatments for kidney ailments; 
considering the relatively long life expectancies and the relatively large ageing 
populations in countries like Canada, this approach should be emphasized because the 
financial burden placed on the healthcare system by all forms of Renal Replacement 
Therapy (i.e. Dialysis and Kidney Transplantation) is immense.
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 From the perspective of a researcher, it would be advisable to answer this Study's 
fundamental question by carrying out a Prospective Longitudinal Observational Study 
using a single large cohort of CKD patients who would answer to a kidney-specific health 
survey, such as - the KDQOL (the timings and settings for each survey administration 
would have to be based on the characteristics of the available sample, of course); this 
approach would naturally (i) include more specific dimensions of health, (ii) indicate the 
perceptions of patients, as time passes, (iii) indicate the perceptions of patients, as 
symptomatology changes, (iv) circumvent many of the shortcomings that are associated 
with cross-sectional studies, and (v) circumvent many of the shortcomings that are 
associated with the use of historical datasets. 
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APPENDIX 
 
I. RAND SF-36 Questionnaire (Version 1; 4-week recall) 
[courtesy of the Workplace Safety & Insurance Board, Ontario (wsib.on.ca)] 
 
1. In general, would you say your health is: 
Excellent = 1 
Very good = 2 
Good = 3 
Fair = 4 
Poor = 5 
 
2. Compared to one year ago, how would your rate your health in general now? 
Much better now than one year ago = 1 
Somewhat better now than one year ago = 2 
About the same = 3 
Somewhat worse now than one year ago = 4 
Much worse now than one year ago = 5 
 
The following items are about activities you might do during a typical day. Does your health now limit you in 
these activities? If so, how much? 
3. Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports 
4. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf 
5. Lifting or carrying groceries 
6. Climbing several flights of stairs 
7. Climbing one flight of stairs 
8. Bending, kneeling, or stooping 
9. Walking more than a mile 
10. Walking several blocks 
11. Walking one block 
12. Bathing or dressing myself 
(For Questions 3-12: Yes, limited a lot = 1; Yes, limited a little = 2; No, not limited at all = 3). 
 XI 
 
During the past 4 weeks, have you had any of the following problems with your work or other regular daily 
activities as a result of your physical health? 
13. Cut down the amount of time you spent on work or other activities 
14. Accomplished less than you would like 
15. Were limited in the kind of work or other activities 
16. Had difficulty performing the work or other activities (for example, it took extra effort) 
(For Questions 13-16: Yes = 1; No = 2). 
 
During the past 4 weeks, have you had any of the following problems with your work or other regular daily 
activities as a result of any emotional problems (such as feeling depressed or anxious)? 
17. Cut down the amount of time you spent on work or other activities 
18. Accomplished less than you would like 
19. Didn’t do work or other activities as carefully as usual 
(For Questions 17-19: Yes = 1; No = 2). 
 
20. During the past 4 weeks, to what extent has your physical health or emotional problems interfered with 
your normal social activities with family, friends, neighbours, or groups? 
Not at all = 1  
Slightly = 2  
Moderately = 3  
Quite a bit = 4  
Extremely = 5 
 
21. How much bodily pain have you had during the past 4 weeks? 
None = 1  
Very mild = 2  
Mild = 3  
Moderate = 4  
Severe = 5  
Very severe = 6 
22. During the past 4 weeks, how much did pain interfere with your normal work (including both work 
outside the home and housework)? 
Not at all = 1 
A little bit = 2 
 XII 
 
Moderately = 3 
Quite a bit = 4  
Extremely = 5 
 
These questions are about how you feel and how things have been with you during the past 4 weeks. For each 
question, please give the one answer that comes closest to the way you have been feeling. How much of the 
time during the past 4 weeks . . .  
 
23. Did you feel full of pep? 
24. Have you been a very nervous person? 
25. Have you felt so down in the dumps that nothing could cheer you up? 
26. Have you felt calm and peaceful? 
27. Did you have a lot of energy? 
28. Have you felt downhearted and blue? 
29. Did you feel worn out? 
30. Have you been a happy person? 
31. Did you feel tired? 
(For Questions 23-31: All of the time = 1; Most of the time = 2; A good bit of the time = 3; Some of the time = 4; A 
little of the time = 5; None of the time = 6). 
 
32. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered 
with your social activities (like visiting with friends, relatives, etc.)? 
All of the time = 1  
Most of the time = 2  
Some of the time = 3  
A little of the time = 4  
None of the time = 5 
 
How TRUE or FALSE is each of the following statements for you? 
33. I seem to get sick a little easier than other people 
34. I am as healthy as anybody I know 
35. I expect my health to get worse 
36. My health is excellent 
(For Questions 33-36: Definitely true = 1; Mostly true = 2; Don’t know = 3; Mostly false = 4; Definitely false = 5). 
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II. Scoring Instructions for the RAND SF-36 Questionnaire 
[courtesy of the Workplace Safety & Insurance Board, Ontario (wsib.on.ca)] 
 
Step 1: Recoding Items (i.e. Questions) 
 
For Questions 1, 2, 20, 22, 34, 36: 1 = 100; 2 = 75; 3 = 50; 4 = 25; 5 = 0 
For Questions 3-12: 1 = 0; 2 = 50; 3 = 100 
For Questions 13-19: 1 = 0; 2 = 100 
For Questions 21, 23, 26, 27, 30: 1 = 100; 2 = 80; 3 = 60; 4 = 40; 5 = 20; 6 = 0 
For Questions 24, 25, 28, 29, 31: 1 = 0; 2 = 20; 3 = 40; 4 = 60; 5 = 80; 6 = 100 
For Questions 32, 33, 35: 1 = 0; 2 = 25; 3 = 50; 4 = 75; 5 = 100 
 
Step 2: Averaging Items (i.e. Questions) To Form Subscales (i.e. Domains) 
 
Physical Functioning (PF): After recoding the answers, average these 10 Items (i.e. Questions) – Questions 3-12. 
Role limitations due to Physical health (RP): After recoding the answers, average these 4 Items (i.e. Questions) – 
Questions 13-16. 
Bodily Pain (BP): After recoding the answers, average these 2 Items (i.e. Questions) – 21-22. 
General Health (GH): After recoding the answers, average these 5 Items (i.e. Questions) – 1, 33, 34, 35, 36. 
Vitality (VT): After recoding the answers, average these 4 Items (i.e. Questions) – 23, 27, 29, 31. 
Social Functioning (SF): After recoding the answers, average these 2 Items (i.e. Questions) – 20, 32. 
Role limitations due to Emotional problems (RE): After recoding the answers, average these 3 Items (i.e. 
Questions) – 17-19. 
Mental Health (MH): After recoding the answers, average these 5 Items (i.e. Questions) – 24, 25, 26, 28, 30. 
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III. Reliability, Central Tendency and Variability of the RAND SF-36 Domains 
[courtesy of the Workplace Safety & Insurance Board, Ontario (wsib.on.ca)] 
 
Domains Questions Alpha Mean Standard Deviation 
PF 10 0.93 70.61 27.42 
RP 4 0.84 52.97 40.78 
BP 2 0.78 70.77 25.48 
GH 5 0.78 56.99 21.11 
VT 4 0.86 52.15 22.39 
SF 2 0.85 78.77 25.43 
RE 3 0.83 65.78 40.71 
MH 5 0.90 70.38 21.97 
Health Change 1 - 59.14 23.12 
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IV. Summary of Information about the SF-36 Domains and Summary measures 
[courtesy of Ware, Kosinski & Keller (1994)] 
 
Scales 
Correlations 
with PCS 
Correlations 
with MCS 
Number 
of Items 
Levels Mean SD Reliability 
95% 
C.I. 
Lowest Possible Score 
(Floor) 
Highest Possible Score (Ceiling) 
Physical 
Functioning 
(PF) 
0.85 0.12 10 21 84.2 23.3 0.93 12.3 
Very limited in 
performing all physical 
activities, including 
bathing or dressing 
(0.8%) 
Performs all types of physical 
activities including the most 
vigorous without limitations due 
to health (38.8%) 
Role-Physical 
(RP) 
0.81 0.27 4 5 80.9 34.0 0.89 22.6 
Problems with work or 
other daily activities as a 
result of physical health 
(10.3%) 
No problems with work or other 
daily activities (70.9%) 
Bodily Pain 
(BP) 
0.76 0.28 2 11 75.2 23.7 0.90 15.0 
Very severe and 
extremely limiting pain 
(0.6%) 
No pain or limitations due to 
pain (31.9%) 
General 
Health (GH) 
0.69 0.37 5 21 71.9 20.3 0.81 17.6 
Evaluates personal 
health as poor and 
believes it is likely to get 
worse (0.0%) 
Evaluates personal health as 
excellent (7.4%) 
Vitality 
(VT) 
0.47 0.65 4 21 60.9 20.9 0.86 15.6 
Feels tired and worn out 
all of the time (0.5%) 
Feels full of pep and energy all 
of the time (1.5%) 
Social 
Functioning 
(SF) 
0.42 0.67 2 9 83.3 22.7 0.68 25.7 
Extreme and frequent 
interference with normal 
social activities due to 
physical and emotional 
problems (0.6%) 
Performs normal social activities 
without interference due to 
physical or emotional problems 
(52.3%) 
Role-
Emotional 
(RE) 
0.16 0.78 3 4 81.3 33.0 0.82 28.0 
Problems with work or 
other daily activities as a 
result of emotional 
problems (9.6%) 
No problems with work or other 
daily activities (71.0%) 
Mental Health 
(MH) 
0.17 0.87 5 26 74.7 18.1 0.84 14.0 
Feelings of nervousness 
and depression all of the 
time (0.0%) 
Feels peaceful, happy, and calm 
all of the time (0.2%) 
Physical 
Component 
Summary 
  
35 567 50.0 10.0 0.92 5.7 
Limitations in self-care, 
physical, social, and role 
activities, severe bodily 
pain, frequent tiredness, 
health rated "poor" 
(0.0%) 
No physical limitations, 
disabilities, or decrements in 
well-being, high energy level, 
health rated "excellent" (0.0%) 
Mental 
Component 
Summary 
  
35 493 50.0 10.0 0.88 6.3 
Frequent psychological 
distress, social and role 
disability due to 
emotional problems, 
health rated "poor" 
(0.0%) 
Frequent positive affect, absence 
of psychological distress and 
limitations in usual social/role 
activities due to emotional 
problems, health rated 
"excellent" (0.0%) 
 
[Notes: (1) The percentages of observed “floor” and “ceiling” scores are from the general U.S. 
population sample (n = 2474); (2) Scores for the eight Domains are the percentage of the total possible 
score achieved for each of these Domains; scores for PCS and MCS are T-scores]. 
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V. Histograms for respective Outcome variables in the analyses 
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VI. Means of each Demographic Factor across each of the other main Grouping variables 
 
VI.1: Age across Gender 
         
 
         
Gender Mean Age N Std. Deviation 
Female 57.99 523 14.140 
Male 56.82 609 15.420 
Total 57.36 1132 14.847 
 
 
VI.2: Age across Stage of Chronic Kidney Disease 
         
 
         
Stage of Chronic Kidney Disease Mean Age N Std. Deviation 
CKD Stage 2 62.00 1 . 
CKD Stage 3 64.74 400 7.605 
CKD Stage 4 68.61 18 5.962 
CKD Stage 5 52.89 714 16.243 
Total 57.33 1133 14.866 
 
 
VI.3: Age across Diabetes 
         
 
         
Diabetes Mean Age N Std. Deviation 
No 55.84 853 15.554 
Yes 61.88 280 11.417 
Total 57.33 1133 14.866 
 
 
VI.4: Age across Heart Disease 
         
 
         
Heart Disease Mean Age N Std. Deviation 
No 55.78 963 15.004 
Yes 66.44 162 10.424 
Total 57.31 1125 14.908 
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VI.5: Gender across Age Categories          
 
         
 
Age Categories Total 
30 and under 31-40 41-50 51-60 61-70 71 and above 
Gender 
Female 27 40 71 114 173 98 523 
Male 42 68 77 124 169 129 609 
Total 69 108 148 238 342 227 1132 
 
 
 
VI.6: Gender across Stage of Chronic Kidney Disease 
         
 
         
 
Stage of Chronic Kidney Disease Total 
CKD Stage 2 CKD Stage 3 CKD Stage 4 CKD Stage 5 
Gender 
Female 0 221 11 292 524 
Male 1 179 7 422 609 
Total 1 400 18 714 1133 
 
 
VI.7: Gender across Diabetes 
         
 
         
 
Diabetes Total 
No Yes 
Gender 
Female 407 117 524 
Male 445 164 609 
Total 852 281 1133 
 
 
VI.8: Gender across Heart Disease 
         
 
         
 
Heart Disease Total 
No Yes 
Gender 
Female 446 71 517 
Male 516 92 608 
Total 962 163 1125 
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VII. General relationships between mean SF-36 scores and the main Grouping variables 
(except - Stage of CKD) 
 
 
VII.1: Means (across each stated Age Category) for the scores that are common to all datasets 
         
AGE CATEGORIES PF RP VT SF RE MH 
30 AND 
UNDER 
Mean 75.89 57.50 56.83 74.64 77.62 74.20 
Std. Dev. 21.85 40.01 21.19 23.50 37.09 16.70 
31-40 
Mean 70.82 54.40 53.75 71.07 72.53 69.82 
Std. Dev. 23.94 40.56 22.66 26.23 39.95 21.16 
41-50 
Mean 70.43 49.55 54.21 70.52 67.79 68.81 
Std. Dev. 22.97 43.37 23.29 25.59 41.22 20.10 
51-60 
Mean 65.54 54.73 53.56 76.16 72.83 71.24 
Std. Dev. 25.78 41.23 23.63 25.31 39.44 20.21 
61-70 
Mean 61.63 56.82 57.43 79.39 77.68 76.21 
Std. Dev. 26.11 42.19 21.71 23.23 36.45 18.46 
71 AND 
ABOVE 
Mean 53.43 52.64 55.55 77.48 77.46 77.36 
Std. Dev. 28.86 42.18 21.15 25.19 35.92 17.70 
TOTAL 
Mean 63.71 54.41 55.43 76.08 74.83 73.70 
Std. Dev. 26.56 41.84 22.29 24.85 38.09 19.31 
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VII.2: Means (across each stated Age Category) for the scores that are common to only two 
datasets 
         
AGE CATEGORIES BP GH Recoded SF-2 
Question 
PCS MCS 
30 AND 
UNDER 
Mean 73.57 39.29 53.57 40.84 47.33 
Std. Dev. 32.34 10.18 39.34 12.51 12.93 
31-40 
Mean 65.16 38.13 70.31 36.72 44.12 
Std. Dev. 24.62 20.07 33.19 12.29 13.90 
41-50 
Mean 72.37 48.46 55.13 42.09 44.68 
Std. Dev. 20.95 20.33 29.35 10.65 12.28 
51-60 
Mean 66.28 49.72 51.58 38.26 49.59 
Std. Dev. 24.82 22.52 23.66 12.33 12.87 
61-70 
Mean 66.75 56.84 57.44 38.50 52.40 
Std. Dev. 26.20 21.70 24.56 12.46 10.08 
71 AND 
ABOVE 
Mean 66.47 57.73 58.23 36.76 52.95 
Std. Dev. 29.09 20.50 25.95 12.67 10.12 
TOTAL 
Mean 66.99 54.45 56.70 38.17 51.22 
Std. Dev. 26.48 21.73 25.70 12.40 11.21 
 
VII.3: Means (across each Gender) for the scores that are common to all datasets 
         
GENDER PF RP VT SF RE MH 
FEMALE 
Mean 59.46 55.71 53.06 75.05 74.43 72.19 
Std. Deviation 27.64 42.04 22.54 25.52 38.28 20.00 
MALE 
Mean 67.38 53.12 57.43 76.95 75.18 74.99 
Std. Deviation 25.05 41.69 21.87 24.23 37.96 18.62 
TOTAL 
Mean 63.71 54.32 55.41 76.07 74.83 73.69 
Std. Deviation 26.56 41.85 22.28 24.84 38.09 19.31 
 XXIV 
 
VII.4: Means (across each Gender) for the scores that are common to only two datasets          
GENDER BP GH Recoded SF-2 Question PCS MCS 
FEMALE 
Mean 63.52 54.18 57.27 37.26 50.48 
Std. Deviation 26.17 21.48 26.36 12.45 11.61 
MALE 
Mean 70.88 54.88 56.07 39.18 52.01 
Std. Deviation 26.36 22.00 24.99 12.30 10.69 
TOTAL 
Mean 67.01 54.51 56.70 38.17 51.21 
Std. Deviation 26.50 21.71 25.70 12.41 11.20 
 
 
VII.5: Means (across presence/absence of Diabetes) for the scores that are common to all 
datasets 
         
DIABETES PF RP VT SF RE MH 
NO 
Mean 64.63 61.49 55.92 80.05 81.06 76.30 
Std. Deviation 27.65 41.15 21.44 24.58 34.26 17.16 
YES 
Mean 54.93 52.93 51.54 78.46 80.59 78.22 
Std. Deviation 27.79 40.94 23.40 24.07 33.64 17.29 
TOTAL 
Mean 61.51 58.73 54.51 79.54 80.91 76.92 
Std. Deviation 28.04 41.24 22.16 24.41 34.03 17.21 
 
 
VII.6: Means (across presence/absence of Diabetes) for the scores that are common to only two 
datasets 
DIABETES BP GH Recoded SF-2 Question PCS MCS 
NO 
Mean 68.02 57.05 56.50 39.69 50.79 
Std. Deviation 25.99 21.05 25.35 12.13 11.17 
YES 
Mean 65.19 49.27 57.31 34.92 52.17 
Std. Deviation 27.53 22.40 26.55 12.34 11.26 
TOTAL 
Mean 67.11 54.55 56.76 38.15 51.23 
Std. Deviation 26.50 21.78 25.72 12.39 11.21 
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VII.7: Means (across presence/absence of Heart Disease) for the scores that are common to all 
datasets 
HEART DISEASE PF RP VT SF RE MH 
NO 
Mean 65.59 55.24 56.69 76.57 74.35 73.30 
Std. Deviation 25.99 41.80 22.00 24.43 38.52 19.57 
YES 
Mean 51.51 47.87 48.04 73.17 76.73 75.99 
Std. Deviation 27.20 41.94 22.44 27.11 36.30 17.60 
TOTAL 
Mean 63.55 54.16 55.43 76.08 74.70 73.69 
Std. Deviation 26.63 41.89 22.27 24.86 38.20 19.31 
 
 
VII.8: Means (across presence/absence of Heart Disease) for the scores that are common to only two 
datasets 
HEART DISEASE BP GH Recoded SF-2 
Question 
PCS MCS 
NO 
Mean 68.79 57.46 56.80 39.89 51.57 
Std. Deviation 26.12 20.95 24.65 12.29 11.12 
YES 
Mean 62.52 46.89 56.86 33.48 50.47 
Std. Deviation 27.25 22.05 28.42 11.50 11.39 
TOTAL 
Mean 67.0052 54.4531 56.8142 38.063 51.253 
Std. Deviation 26.58 21.78 25.75 12.41 11.20 
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VIII. Tests of Normality (prior to comparisons of mean ranks/medians) 
VIII.1 Outcome variable - Physical Functioning Domain score 
Grouping variable - Age Categories 
 Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
PHYSICAL FUNCTIONING 
30 AND UNDER .378 6 .007 .751 6 .020 
31-40 .203 16 .076 .876 16 .034 
41-50 .174 38 .005 .883 38 .001 
51-60 .158 108 .000 .926 108 .000 
61-70 .134 238 .000 .943 238 .000 
71 AND OVER .089 167 .003 .951 167 .000 
 
Grouping variable - Gender 
 
Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
PHYSICAL FUNCTIONING 
FEMALE .103 298 .000 .948 298 .000 
MALE .141 275 .000 .919 275 .000 
 
Grouping variable - Stage of CKD 
 
Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
PHYSICAL 
FUNCTIONING 
STAGE 2-3 CKD .120 393 .000 .932 393 .000 
STAGE 4 CKD .189 18 .088 .908 18 .078 
STAGE 5 CKD .125 162 .000 .941 162 .000 
 
Grouping variable - Diabetes 
 Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
PHYSICAL FUNCTIONING 
NO .121 386 .000 .923 386 .000 
YES .116 187 .000 .956 187 .000 
 
Grouping variable - Heart Disease 
 
Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
 PHYSICAL 
FUNCTIONING 
NO .142 411 .000 .918 411 .000 
YES .095 162 .001 .968 162 .001 
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VIII.2 Outcome variable – Role-Physical Domain score 
Grouping variable - Age Categories 
 
Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
ROLE-PHYSICAL 
30 AND UNDER .315 6 .063 .753 6 .021 
31-40 .201 16 .083 .828 16 .007 
41-50 .253 38 .000 .808 38 .000 
51-60 .245 108 .000 .804 108 .000 
61-70 .260 238 .000 .785 238 .000 
71 AND OVER .250 167 .000 .796 167 .000 
 
Grouping variable - Gender 
 Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
ROLE-PHYSICAL 
FEMALE .244 298 .000 .798 298 .000 
MALE .261 275 .000 .790 275 .000 
 
Grouping variable - Stage of CKD 
 Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
ROLE-PHYSICAL 
STAGE 2-3 CKD .285 393 .000 .772 393 .000 
STAGE 4 CKD .218 18 .024 .838 18 .005 
STAGE 5 CKD .203 162 .000 .814 162 .000 
 
Grouping variable - Diabetes 
 Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
ROLE-PHYSICAL 
NO .267 386 .000 .779 386 .000 
YES .222 187 .000 .819 187 .000 
 
Grouping variable - Heart Disease 
 Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
 ROLE-PHYSICAL 
NO .271 411 .000 .783 411 .000 
YES .206 162 .000 .808 162 .000 
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VIII.3 Outcome variable – Vitality Domain score 
Grouping variable - Age Categories 
 
Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
VITALITY 
30 AND UNDER .184 6 .200 .925 6 .543 
31-40 .130 16 .200 .970 16 .840 
41-50 .088 38 .200 .976 38 .572 
51-60 .092 108 .026 .977 108 .053 
61-70 .103 238 .000 .975 238 .000 
71 AND OVER .084 167 .006 .979 167 .011 
 
Grouping variable - Gender 
 Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
VITALITY 
FEMALE .082 298 .000 .982 298 .001 
MALE .091 275 .000 .973 275 .000 
 
Grouping variable - Stage of CKD 
 Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
VITALITY 
STAGE 2-3 CKD .085 393 .000 .976 393 .000 
STAGE 4 CKD .161 18 .200 .973 18 .847 
STAGE 5 CKD .072 162 .040 .983 162 .039 
 
Grouping variable - Diabetes 
 
Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
VITALITY 
NO .094 386 .000 .974 386 .000 
YES .115 187 .000 .980 187 .010 
 
Grouping variable - Heart Disease 
 
Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
VITALITY 
NO .086 411 .000 .976 411 .000 
YES .087 162 .005 .981 162 .027 
 XXIX 
 
VIII.4 Outcome variable – Social Functioning Domain score 
Grouping variable - Age Categories 
 
Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
SOCIAL FUNCTIONING 
30 AND UNDER .172 6 .200 .912 6 .452 
31-40 .205 16 .071 .868 16 .025 
41-50 .186 38 .002 .888 38 .001 
51-60 .279 108 .000 .778 108 .000 
61-70 .266 238 .000 .804 238 .000 
71 AND OVER .236 167 .000 .790 167 .000 
 
Grouping variable - Gender 
 
Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
SOCIAL FUNCTIONING 
FEMALE .225 298 .000 .833 298 .000 
MALE .263 275 .000 .784 275 .000 
 
Grouping variable - Stage of CKD 
 Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
SOCIAL 
FUNCTIONING 
STAGE 2-3 CKD .286 393 .000 .777 393 .000 
STAGE 4 CKD .238 18 .008 .827 18 .004 
STAGE 5 CKD .181 162 .000 .883 162 .000 
 
Grouping variable - Diabetes 
 Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
 SOCIAL FUNCTIONING 
NO .249 386 .000 .798 386 .000 
YES .232 187 .000 .836 187 .000 
 
Grouping variable - Heart Disease 
 Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
SOCIAL FUNCTIONING 
NO .270 411 .000 .786 411 .000 
YES .183 162 .000 .869 162 .000 
 XXX 
 
VIII.5 Outcome variable – Role-Emotional Domain score 
Grouping variable - Age Categories 
 Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
ROLE-EMOTIONAL 
30 AND UNDER .401 6 .003 .702 6 .007 
31-40 .405 16 .000 .631 16 .000 
41-50 .364 38 .000 .695 38 .000 
51-60 .430 108 .000 .590 108 .000 
61-70 .450 238 .000 .563 238 .000 
71 AND OVER .417 167 .000 .614 167 .000 
 
Grouping variable - Gender 
 Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
ROLE-EMOTIONAL 
FEMALE .417 298 .000 .618 298 .000 
MALE .443 275 .000 .572 275 .000 
 
Grouping variable - Stage of CKD 
 Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
ROLE-EMOTIONAL 
STAGE 2-3 CKD .435 393 .000 .588 393 .000 
STAGE 4 CKD .454 18 .000 .540 18 .000 
STAGE 5 CKD .415 162 .000 .621 162 .000 
 
Grouping variable - Diabetes 
 
Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
ROLE-EMOTIONAL 
NO .435 386 .000 .587 386 .000 
YES .419 187 .000 .616 187 .000 
 
Grouping variable - Heart Disease 
 
Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
ROLE-EMOTIONAL 
NO .442 411 .000 .571 411 .000 
YES .399 162 .000 .654 162 .000 
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VIII.6 Outcome variable – Mental Health Domain score 
Grouping variable - Age Categories 
 Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL HEALTH 
30 AND UNDER .156 6 .200 .965 6 .860 
31-40 .135 16 .200 .911 16 .121 
41-50 .131 38 .099 .972 38 .459 
51-60 .139 108 .000 .909 108 .000 
61-70 .125 238 .000 .921 238 .000 
71 AND OVER .152 167 .000 .907 167 .000 
 
Grouping variable - Gender 
 
Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL HEALTH 
FEMALE .113 298 .000 .928 298 .000 
MALE .147 275 .000 .914 275 .000 
 
Grouping variable - Stage of CKD 
 
Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL 
HEALTH 
STAGE 2-3 CKD .140 393 .000 .916 393 .000 
STAGE 4 CKD .199 18 .057 .877 18 .023 
STAGE 5 CKD .133 162 .000 .932 162 .000 
 
Grouping variable - Diabetes 
 
Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL HEALTH 
NO .139 386 .000 .924 386 .000 
YES .136 187 .000 .908 187 .000 
 
Grouping variable - Heart Disease 
 
Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL HEALTH 
NO .132 411 .000 .908 411 .000 
YES .147 162 .000 .934 162 .000 
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VIII.7 Outcome variable – Bodily Pain Domain score 
Grouping variable - Age Categories 
 Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
BODILY PAIN 
30 AND UNDER .271 6 .190 .814 6 .079 
31-40 .140 16 .200 .940 16 .354 
41-50 .167 38 .009 .933 38 .025 
51-60 .123 108 .000 .940 108 .000 
61-70 .135 238 .000 .933 238 .000 
71 AND OVER .162 167 .000 .905 167 .000 
 
Grouping variable - Gender 
 Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
BODILY PAIN 
FEMALE .130 298 .000 .939 298 .000 
MALE .154 275 .000 .903 275 .000 
 
Grouping variable - Stage of CKD 
 Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
BODILY PAIN 
STAGE 2-3 CKD .132 393 .000 .935 393 .000 
STAGE 4 CKD .226 18 .016 .931 18 .204 
STAGE 5 CKD .172 162 .000 .896 162 .000 
 
Grouping variable - Diabetes 
 Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
BODILY PAIN 
NO .150 386 .000 .922 386 .000 
YES .123 187 .000 .932 187 .000 
 
Grouping variable - Heart Disease 
 Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
BODILY PAIN 
NO .159 411 .000 .918 411 .000 
YES .118 162 .000 .941 162 .000 
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VIII.8 Outcome variable – General Health Domain score 
Grouping variable - Age Categories 
 Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
GENERAL HEALTH 
30 AND UNDER .366 6 .012 .822 6 .092 
31-40 .275 16 .002 .860 16 .019 
41-50 .100 38 .200* .977 38 .605 
51-60 .129 108 .000 .955 108 .001 
61-70 .082 238 .001 .984 238 .009 
71 AND OVER .091 167 .002 .980 167 .015 
 
Grouping variable - Gender 
 Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
GENERAL HEALTH 
FEMALE .082 298 .000 .981 298 .001 
MALE .082 275 .000 .981 275 .001 
 
Grouping variable - Stage of CKD 
 Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
GENERAL 
HEALTH 
STAGE 2-3 CKD .086 393 .000 .981 393 .000 
STAGE 4 CKD .164 18 .200 .983 18 .973 
STAGE 5 CKD .143 162 .000 .959 162 .000 
 
Grouping variable - Diabetes 
 Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
GENERAL HEALTH 
NO .094 386 .000 .978 386 .000 
YES .092 187 .001 .979 187 .006 
 
Grouping variable - Heart Disease 
 Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
GENERAL HEALTH 
NO .087 411 .000 .980 411 .000 
YES .110 162 .000 .978 162 .011 
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VIII.9 Outcome variable – Recoded SF-2 Question score 
Grouping variable - Age Categories 
 Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
RECODED SF-2 QUESTION 
30 AND UNDER .251 6 .200 .869 6 .223 
31-40 .244 16 .012 .808 16 .003 
41-50 .212 38 .000 .879 38 .001 
51-60 .286 108 .000 .870 108 .000 
61-70 .298 238 .000 .858 238 .000 
71 AND OVER .271 167 .000 .877 167 .000 
 
Grouping variable - Gender 
 Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
RECODED SF-2 QUESTION 
FEMALE .249 298 .000 .890 298 .000 
MALE .300 275 .000 .858 275 .000 
 
Grouping variable - Stage of CKD 
 Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
RECODED SF-2 
QUESTION 
STAGE 2-3 CKD .319 393 .000 .837 393 .000 
STAGE 4 CKD .265 18 .002 .902 18 .062 
STAGE 5 CKD .216 162 .000 .861 162 .000 
 
Grouping variable - Diabetes 
 Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
RECODED SF-2 QUESTION 
NO .277 386 .000 .875 386 .000 
YES .267 187 .000 .880 187 .000 
 
Grouping variable - Heart Disease 
 Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
RECODED SF-2 QUESTION 
NO .300 411 .000 .857 411 .000 
YES .210 162 .000 .904 162 .000 
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VIII.10 Outcome variable – Physical Component Summary score 
Grouping variable - Age Categories 
 Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
PHYSICAL COMPONENT 
SUMMARY 
30 AND 
UNDER 
.214 6 .200 .902 6 .386 
31-40 .136 16 .200 .958 16 .620 
41-50 .095 38 .200 .968 38 .341 
51-60 .092 108 .025 .965 108 .006 
61-70 .085 238 .000 .964 238 .000 
71 AND OVER .093 167 .001 .969 167 .001 
 
Grouping variable - Gender 
 
Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
PHYSICAL COMPONENT SUMMARY 
FEMALE .091 298 .000 .970 298 .000 
MALE .072 275 .002 .967 275 .000 
 
Grouping variable - Stage of CKD 
 
Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
PHYSICAL COMPONENT 
SUMMARY 
STAGE 2-3 CKD .098 393 .000 .959 393 .000 
STAGE 4 CKD .143 18 .200 .955 18 .512 
STAGE 5 CKD .052 162 .200 .984 162 .057 
 
Grouping variable - Diabetes 
 
Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
PHYSICAL COMPONENT 
SUMMARY 
NO .098 386 .000 .960 386 .000 
YES .051 187 .200 .983 187 .020 
 
Grouping variable - Heart Disease 
 
Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
PHYSICAL COMPONENT 
SUMMARY 
NO .098 411 .000 .957 411 .000 
YES .054 162 .200 .988 162 .185 
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VIII.11 Outcome variable – Mental Component Summary score 
Grouping variable - Age Categories 
 Age Categories Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL COMPONENT 
SUMMARY 
30 AND UNDER .279 6 .159 .795 6 .053 
31-40 .270 16 .003 .882 16 .042 
41-50 .110 38 .200 .948 38 .078 
51-60 .171 108 .000 .889 108 .000 
61-70 .114 238 .000 .915 238 .000 
71 AND OVER .121 167 .000 .913 167 .000 
 
Grouping variable - Gender 
 Gender Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL COMPONENT SUMMARY 
FEMALE .131 298 .000 .920 298 .000 
MALE .135 275 .000 .901 275 .000 
 
Grouping variable - Stage of CKD 
 Stage of Chronic Kidney Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL COMPONENT 
SUMMARY 
STAGE 2-3 CKD .127 393 .000 .908 393 .000 
STAGE 4 CKD .155 18 .200 .944 18 .337 
STAGE 5 CKD .138 162 .000 .921 162 .000 
 
Grouping variable - Diabetes 
 Diabetes Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL COMPONENT 
SUMMARY 
NO .131 386 .000 .905 386 .000 
YES .129 187 .000 .915 187 .000 
 
Grouping variable - Heart Disease 
 Heart Disease Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic DF Sig. Statistic DF Sig. 
MENTAL COMPONENT 
SUMMARY 
NO .135 411 .000 .901 411 .000 
YES .132 162 .000 .924 162 .000 
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IX. Comparisons of SF-36 scores across Grouping variables (except - Stage of CKD) 
IX.1: Significantly different Mean Ranks and Medians (Grouping variable – Age Category) 
 
         
 Age Categories N Mean Rank Median 
PHYSICAL FUNCTIONING 
30 & UNDER 70 723.01 82.5 
31-40 108 654.14 75 
41-50 148 644.05 75 
51-60 238 587.60 70 
61-70 342 537.32 65 
71 & OVER 227 450.32 55 
SOCIAL FUNCTIONING 
30 & UNDER 70 537.14 75 
31-40 108 504.04 75 
41-50 148 492.38 75 
51-60 238 570.51 81.25 
61-70 342 608.88 87.5 
71 & OVER 227 588.04 87.5 
MENTAL HEALTH 
30 & UNDER 70 558.27 76 
31-40 108 507.83 74 
41-50 148 479.89 72 
51-60 238 527.58 76 
61-70 342 610.55 80 
71 & OVER 227 630.36 84 
GENERAL HEALTH 
30 & UNDER 7 162.36 40 
31-40 16 164.63 35 
41-50 39 246.88 45 
51-60 111 254.09 45 
61-70 242 310.30 57.5 
71 & OVER 167 317.11 60 
RECODED SF-2 QUESTION 
30 & UNDER 7 271.71 50 
31-40 16 385.44 75 
41-50 39 275.95 50 
51-60 111 260.88 50 
61-70 242 295.49 50 
71 & OVER 167 301.54 50 
MENTAL COMPONENT SUMMARY 
30 & UNDER 7 218.64 50.3 
31-40 16 187.84 48.75 
41-50 39 194.88 45.9 
51-60 111 277.40 53.7 
61-70 242 305.56 54.7 
71 & OVER 167 316.04 55.4 
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IX.2: Significantly different Mean Ranks and Medians (Grouping variable – Gender)  
         
 Gender N Mean Rank Sum of Ranks Median 
PHYSICAL FUNCTIONING 
FEMALE 524 516.30 270541.50 65 
MALE 609 610.62 371869.50 70 
VITALITY (ENERGY/FATIGUE) 
FEMALE 524 533.22 279408.50 54.17 
MALE 609 596.06 363002.50 60 
MENTAL HEALTH 
FEMALE 524 543.21 284642.00 76 
MALE 609 587.47 357769.00 80 
BODILY PAIN 
FEMALE 306 267.71 81920.50 67.5 
MALE 276 317.87 87732.50 77.5 
PHYSICAL COMPONENT SUMMARY 
FEMALE 306 279.02 85380.50 38.2 
MALE 276 305.34 84272.50 40.6 
  
IX.3: Significantly different Mean Ranks and Medians (Grouping variable – Diabetes) 
 
         
 Diabetes N Mean Rank Sum of Ranks Median 
PHYSICAL FUNCTIONING 
NO 854 596.82 509686.00 70 
YES 281 480.41 134994.00 60 
VITALITY (ENERGY/FATIGUE) 
NO 854 584.64 499280.50 60 
YES 281 517.44 145399.50 50 
GENERAL HEALTH 
NO 396 312.24 123646.00 60 
YES 188 250.93 47174.00 50 
PHYSICAL COMPONENT SUMMARY 
NO 396 313.89 124299.50 41.35 
YES 188 247.45 46520.50 35 
 
 IX.4: Significantly different Mean Ranks and Medians (Grouping variable – Heart Disease) 
 
         
 
Heart Disease N Mean Rank Sum of 
Ranks 
Median 
PHYSICAL FUNCTIONING 
NO 963 588.40 566632.50 70 
YES 164 420.70 68995.50 50 
ROLE-PHYSICAL 
NO 963 571.85 550696.00 50 
YES 164 517.88 84932.00 50 
VITALITY (ENERGY/FATIGUE) 
NO 963 581.66 560143.00 60 
YES 164 460.27 75485.00 50 
BODILY PAIN 
NO 412 299.42 123363.00 70 
YES 164 261.05 42813.00 66.25 
GENERAL HEALTH 
NO 412 311.32 128265.50 60 
YES 164 231.16 37910.50 45 
PHYSICAL COMPONENT SUMMARY 
NO 412 313.87 129313.50 41.85 
YES 164 224.77 36862.50 32.75 
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IX.5: Significantly different Mean Ranks and Medians (Grouping variable – Heart Failure)  
 
Heart 
Failure 
N Mean Rank Sum of Ranks Median 
PHYSICAL FUNCTIONING 
NO 1060 579.51 614280.50 70 
YES 67 318.62 21347.50 40 
ROLE-PHYSICAL 
NO 1060 572.00 606319.00 50 
YES 67 437.45 29309.00 25 
VITALITY (ENERGY/FATIGUE) 
NO 1060 575.11 609613.00 55 
YES 67 388.28 26015.00 45 
SOCIAL FUNCTIONING 
NO 1060 570.92 605180.00 87.5 
YES 67 454.45 30448.00 75 
GENERAL HEALTH 
NO 509 300.99 153205.50 55 
YES 67 193.59 12970.50 40 
PHYSICAL COMPONENT SUMMARY 
NO 509 302.83 154142.50 40.6 
YES 67 179.60 12033.50 27.7 
 
 
 
IX.6: Significantly different Mean Ranks and Medians (Grouping variable – Angina) 
 
 
Angina N Mean Rank Sum of 
Ranks 
Median 
PHYSICAL FUNCTIONING 
NO 1076 571.69 615139.50 70 
YES 51 401.74 20488.50 50 
VITALITY (ENERGY/FATIGUE) 
NO 1076 570.78 614162.50 55 
YES 51 420.89 21465.50 50 
BODILY PAIN 
NO 525 295.21 154983.50 70 
YES 51 219.46 11192.50 45 
GENERAL HEALTH 
NO 525 294.86 154799.50 55 
YES 51 223.07 11376.50 43.75 
RECODED SF-2 QUESTION 
NO 525 292.69 153662.50 50 
YES 51 245.36 12513.50 50 
PHYSICAL COMPONENT SUMMARY 
NO 525 296.30 155558.50 39.9 
YES 51 208.19 10617.50 32.5 
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IX.7: Significantly different Mean Ranks and Medians (Grouping variable – Peripheral Vascular Disease) 
 
Peripheral 
Vascular Disease 
N Mean Rank Sum of Ranks Median 
PHYSICAL FUNCTIONING 
NO 498 301.70 150249.00 70 
YES 84 231.00 19404.00 50 
ROLE-PHYSICAL 
 
NO 
 
498 
 
297.99 
 
148397.00 
 
75 
YES 84 253.05 21256.00 25 
GENERAL HEALTH 
 
NO 
 
498 
 
299.73 
 
149264.50 
 
55 
YES 84 242.72 20388.50 47.5 
PHYSICAL COMPONENT SUMMARY 
 
NO 
 
498 
 
300.83 
 
149812.00 
 
40.2 
YES 84 236.20 19841.00 33.25 
 
 
 
IX.8: Significantly different Mean Ranks and Medians (Grouping variable – Stroke) 
 
 
Stroke N Mean 
Rank 
Sum of Ranks Median 
PHYSICAL FUNCTIONING 
NO 548 291.91 159966.00 65 
YES 28 221.79 6210.00 50 
VITALITY (ENERGY/FATIGUE) 
NO 548 291.89 159955.50 55 
YES 28 222.16 6220.50 50 
PHYSICAL COMPONENT SUMMARY 
NO 548 291.56 159775.50 39.35 
YES 28 228.59 6400.50 36 
 
